US20230139745A1 - Non-peptidic polymeric linker compound, conjugate comprising same linker compound, and methods for preparing same linker compound and conjugate - Google Patents
Non-peptidic polymeric linker compound, conjugate comprising same linker compound, and methods for preparing same linker compound and conjugate Download PDFInfo
- Publication number
- US20230139745A1 US20230139745A1 US16/484,290 US201816484290A US2023139745A1 US 20230139745 A1 US20230139745 A1 US 20230139745A1 US 201816484290 A US201816484290 A US 201816484290A US 2023139745 A1 US2023139745 A1 US 2023139745A1
- Authority
- US
- United States
- Prior art keywords
- physiologically active
- active polypeptide
- compound
- peptide
- immunoglobulin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 30
- -1 linker compound Chemical class 0.000 title claims description 177
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 203
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 189
- 229920001184 polypeptide Polymers 0.000 claims abstract description 178
- 150000001875 compounds Chemical class 0.000 claims abstract description 165
- 108060003951 Immunoglobulin Proteins 0.000 claims abstract description 121
- 102000018358 immunoglobulin Human genes 0.000 claims abstract description 121
- 125000000524 functional group Chemical group 0.000 claims abstract description 65
- 229920000642 polymer Polymers 0.000 claims abstract description 38
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 80
- 150000001413 amino acids Chemical class 0.000 claims description 60
- 229920001223 polyethylene glycol Polymers 0.000 claims description 57
- 229910052757 nitrogen Inorganic materials 0.000 claims description 40
- 125000001151 peptidyl group Chemical group 0.000 claims description 39
- TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 claims description 37
- 101800000221 Glucagon-like peptide 2 Proteins 0.000 claims description 27
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims description 26
- 235000018102 proteins Nutrition 0.000 claims description 25
- 102000004169 proteins and genes Human genes 0.000 claims description 25
- 108090000623 proteins and genes Proteins 0.000 claims description 25
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 claims description 23
- 125000003277 amino group Chemical group 0.000 claims description 20
- ZPWOOKQUDFIEIX-UHFFFAOYSA-N cyclooctyne Chemical class C1CCCC#CCC1 ZPWOOKQUDFIEIX-UHFFFAOYSA-N 0.000 claims description 20
- 102000051325 Glucagon Human genes 0.000 claims description 18
- 229960004666 glucagon Drugs 0.000 claims description 18
- 229910052760 oxygen Inorganic materials 0.000 claims description 18
- 229910052717 sulfur Inorganic materials 0.000 claims description 18
- 229910052799 carbon Inorganic materials 0.000 claims description 17
- 125000004432 carbon atom Chemical group C* 0.000 claims description 17
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 16
- 108060003199 Glucagon Proteins 0.000 claims description 16
- 125000001931 aliphatic group Chemical group 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 16
- 150000001299 aldehydes Chemical class 0.000 claims description 14
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 12
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 12
- 150000003573 thiols Chemical class 0.000 claims description 12
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 claims description 11
- 239000002202 Polyethylene glycol Substances 0.000 claims description 11
- 150000003869 acetamides Chemical class 0.000 claims description 11
- ACBQROXDOHKANW-UHFFFAOYSA-N bis(4-nitrophenyl) carbonate Chemical compound C1=CC([N+](=O)[O-])=CC=C1OC(=O)OC1=CC=C([N+]([O-])=O)C=C1 ACBQROXDOHKANW-UHFFFAOYSA-N 0.000 claims description 11
- AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical compound C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 claims description 11
- 125000005842 heteroatom Chemical group 0.000 claims description 11
- 229960002317 succinimide Drugs 0.000 claims description 11
- 150000003852 triazoles Chemical class 0.000 claims description 11
- 125000000304 alkynyl group Chemical group 0.000 claims description 10
- 125000006835 (C6-C20) arylene group Chemical group 0.000 claims description 8
- ZJJAWGLRWHRNGC-UHFFFAOYSA-N 1,2-dimethoxy-1-azacyclooct-7-yne Chemical compound COC1CCCCC#CN1OC ZJJAWGLRWHRNGC-UHFFFAOYSA-N 0.000 claims description 8
- GKSFVIWCGXWBRG-UHFFFAOYSA-N 2-(5,6-didehydro-7,8,9,10-tetrahydrobenzo[8]annulen-1-yl)acetic acid Chemical compound C1#CCCCCC2=C1C=CC=C2CC(=O)O GKSFVIWCGXWBRG-UHFFFAOYSA-N 0.000 claims description 8
- YGWKNEANLXWJDM-UHFFFAOYSA-N 4,5-didehydro-6,7,8,9-tetrahydro-1H-cycloocta[b]pyrrole Chemical compound N1C=CC2=C1CCCCC#C2 YGWKNEANLXWJDM-UHFFFAOYSA-N 0.000 claims description 8
- ZUHQCDZJPTXVCU-UHFFFAOYSA-N C1#CCCC2=CC=CC=C2C2=CC=CC=C21 Chemical compound C1#CCCC2=CC=CC=C2C2=CC=CC=C21 ZUHQCDZJPTXVCU-UHFFFAOYSA-N 0.000 claims description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 8
- SBTXYHVTBXDKLE-UHFFFAOYSA-N bicyclo[6.1.0]non-6-yne Chemical compound C1CCCC#CC2CC21 SBTXYHVTBXDKLE-UHFFFAOYSA-N 0.000 claims description 8
- 210000004369 blood Anatomy 0.000 claims description 8
- 239000008280 blood Substances 0.000 claims description 8
- 150000004676 glycans Chemical class 0.000 claims description 8
- 229920001282 polysaccharide Polymers 0.000 claims description 8
- 239000005017 polysaccharide Substances 0.000 claims description 8
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 7
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 7
- 125000003172 aldehyde group Chemical group 0.000 claims description 7
- 125000000539 amino acid group Chemical group 0.000 claims description 7
- 239000003102 growth factor Substances 0.000 claims description 7
- 101800001288 Atrial natriuretic factor Proteins 0.000 claims description 6
- 102100025841 Cholecystokinin Human genes 0.000 claims description 6
- 101800001982 Cholecystokinin Proteins 0.000 claims description 6
- 239000000427 antigen Substances 0.000 claims description 6
- 102000036639 antigens Human genes 0.000 claims description 6
- 108091007433 antigens Proteins 0.000 claims description 6
- NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 claims description 6
- 229940107137 cholecystokinin Drugs 0.000 claims description 6
- 239000012634 fragment Substances 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- 150000002367 halogens Chemical class 0.000 claims description 6
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 6
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 claims description 6
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 5
- 102000004190 Enzymes Human genes 0.000 claims description 5
- 108090000790 Enzymes Proteins 0.000 claims description 5
- 125000003118 aryl group Chemical group 0.000 claims description 5
- 229940088598 enzyme Drugs 0.000 claims description 5
- 102000005962 receptors Human genes 0.000 claims description 5
- 108020003175 receptors Proteins 0.000 claims description 5
- 239000012453 solvate Substances 0.000 claims description 5
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 4
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims description 4
- DNUQYCIIJUCMFI-UHFFFAOYSA-N 3,3,6,6-tetramethyl-1lambda4-thiacyclohept-7-yne Chemical compound CC1(C)CCC(C)(C)C#SC1 DNUQYCIIJUCMFI-UHFFFAOYSA-N 0.000 claims description 4
- 102400001282 Atrial natriuretic peptide Human genes 0.000 claims description 4
- 101800001890 Atrial natriuretic peptide Proteins 0.000 claims description 4
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 claims description 4
- 102000012421 C-Type Natriuretic Peptide Human genes 0.000 claims description 4
- 101800000060 C-type natriuretic peptide Proteins 0.000 claims description 4
- 229920002101 Chitin Polymers 0.000 claims description 4
- 102400000739 Corticotropin Human genes 0.000 claims description 4
- 101800000414 Corticotropin Proteins 0.000 claims description 4
- 229920002307 Dextran Polymers 0.000 claims description 4
- 102000003951 Erythropoietin Human genes 0.000 claims description 4
- 108090000394 Erythropoietin Proteins 0.000 claims description 4
- 108010004460 Gastric Inhibitory Polypeptide Proteins 0.000 claims description 4
- 102100039994 Gastric inhibitory polypeptide Human genes 0.000 claims description 4
- 102400000921 Gastrin Human genes 0.000 claims description 4
- 108010052343 Gastrins Proteins 0.000 claims description 4
- 102000002265 Human Growth Hormone Human genes 0.000 claims description 4
- 108010000521 Human Growth Hormone Proteins 0.000 claims description 4
- 239000000854 Human Growth Hormone Substances 0.000 claims description 4
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 4
- 102000014150 Interferons Human genes 0.000 claims description 4
- 108010050904 Interferons Proteins 0.000 claims description 4
- 102000015696 Interleukins Human genes 0.000 claims description 4
- 108010063738 Interleukins Proteins 0.000 claims description 4
- 102000009151 Luteinizing Hormone Human genes 0.000 claims description 4
- 108010073521 Luteinizing Hormone Proteins 0.000 claims description 4
- 108090000189 Neuropeptides Proteins 0.000 claims description 4
- 102400000319 Oxyntomodulin Human genes 0.000 claims description 4
- 101800001388 Oxyntomodulin Proteins 0.000 claims description 4
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 4
- 102000013275 Somatomedins Human genes 0.000 claims description 4
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims description 4
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims description 4
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 claims description 4
- 102400000015 Vasoactive intestinal peptide Human genes 0.000 claims description 4
- 125000004429 atom Chemical group 0.000 claims description 4
- 229960000182 blood factors Drugs 0.000 claims description 4
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 claims description 4
- 229920001577 copolymer Polymers 0.000 claims description 4
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 claims description 4
- 229960000258 corticotropin Drugs 0.000 claims description 4
- 229940105423 erythropoietin Drugs 0.000 claims description 4
- 229920002674 hyaluronan Polymers 0.000 claims description 4
- 229960003160 hyaluronic acid Drugs 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 4
- 150000002632 lipids Chemical class 0.000 claims description 4
- PXZWGQLGAKCNKD-DPNMSELWSA-N molport-023-276-326 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 PXZWGQLGAKCNKD-DPNMSELWSA-N 0.000 claims description 4
- 125000004043 oxo group Chemical group O=* 0.000 claims description 4
- 229920001583 poly(oxyethylated polyols) Polymers 0.000 claims description 4
- 239000004626 polylactic acid Substances 0.000 claims description 4
- 229920001451 polypropylene glycol Polymers 0.000 claims description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 4
- 125000006413 ring segment Chemical group 0.000 claims description 4
- 229920006395 saturated elastomer Polymers 0.000 claims description 4
- 229960005356 urokinase Drugs 0.000 claims description 4
- 229960005486 vaccine Drugs 0.000 claims description 4
- 229920002554 vinyl polymer Polymers 0.000 claims description 4
- 102000014914 Carrier Proteins Human genes 0.000 claims description 3
- 108091008324 binding proteins Proteins 0.000 claims description 3
- 210000004027 cell Anatomy 0.000 claims description 3
- 239000003112 inhibitor Substances 0.000 claims description 3
- VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 claims description 3
- 230000001105 regulatory effect Effects 0.000 claims description 3
- RWBLWXCGQLZKLK-USVTTYPOSA-N (2s)-2-[(2-aminoacetyl)amino]-n-[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[2-[[(2s)-1-[[(2s)-1-[[(2s)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxob Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(N)=O)NC(=O)CN)C(C)C)C1=CN=CN1 RWBLWXCGQLZKLK-USVTTYPOSA-N 0.000 claims description 2
- LIFNDDBLJFPEAN-BPSSIEEOSA-N (2s)-4-amino-2-[[(2s)-2-[[2-[[2-[[(2s)-5-amino-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2s)-5-oxopyrrolidine-2-carbonyl]amino]propanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@@H]1CCC(=O)N1 LIFNDDBLJFPEAN-BPSSIEEOSA-N 0.000 claims description 2
- SDAFHXYVWUEZIJ-LRHNFOCQSA-N (2s)-n-[(2s)-1-[[(2s)-1-[[(2s)-1-[[2-[[(2s)-1-[[2-[[(2s)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminom Chemical group C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)CNC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)N)C1=CC=CC=C1 SDAFHXYVWUEZIJ-LRHNFOCQSA-N 0.000 claims description 2
- LVRVABPNVHYXRT-BQWXUCBYSA-N 52906-92-0 Chemical compound C([C@H](N)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)C(C)C)C1=CC=CC=C1 LVRVABPNVHYXRT-BQWXUCBYSA-N 0.000 claims description 2
- 102000014777 Adipokines Human genes 0.000 claims description 2
- 108010078606 Adipokines Proteins 0.000 claims description 2
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 claims description 2
- 102000009027 Albumins Human genes 0.000 claims description 2
- 108010088751 Albumins Proteins 0.000 claims description 2
- 108010090849 Amyloid beta-Peptides Chemical group 0.000 claims description 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims description 2
- 102000009840 Angiopoietins Human genes 0.000 claims description 2
- 108010009906 Angiopoietins Proteins 0.000 claims description 2
- 102400000068 Angiostatin Human genes 0.000 claims description 2
- 108010079709 Angiostatins Proteins 0.000 claims description 2
- 102000015427 Angiotensins Human genes 0.000 claims description 2
- 108010064733 Angiotensins Proteins 0.000 claims description 2
- 101800000068 Antioxidant peptide Proteins 0.000 claims description 2
- 102100029470 Apolipoprotein E Human genes 0.000 claims description 2
- 101710095339 Apolipoprotein E Proteins 0.000 claims description 2
- 102100033367 Appetite-regulating hormone Human genes 0.000 claims description 2
- 102000002723 Atrial Natriuretic Factor Human genes 0.000 claims description 2
- 102100023995 Beta-nerve growth factor Human genes 0.000 claims description 2
- 102000013585 Bombesin Human genes 0.000 claims description 2
- 108010051479 Bombesin Proteins 0.000 claims description 2
- 102400000967 Bradykinin Human genes 0.000 claims description 2
- 101800004538 Bradykinin Proteins 0.000 claims description 2
- 108010074051 C-Reactive Protein Proteins 0.000 claims description 2
- 102100032752 C-reactive protein Human genes 0.000 claims description 2
- 102000055006 Calcitonin Human genes 0.000 claims description 2
- 108060001064 Calcitonin Proteins 0.000 claims description 2
- 102000000584 Calmodulin Human genes 0.000 claims description 2
- 108010041952 Calmodulin Proteins 0.000 claims description 2
- 108010003422 Circulating Thymic Factor Proteins 0.000 claims description 2
- 108010022152 Corticotropin-Releasing Hormone Proteins 0.000 claims description 2
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 claims description 2
- 102000012289 Corticotropin-Releasing Hormone Human genes 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 101800002242 Dermorphin Proteins 0.000 claims description 2
- FHZPGIUBXYVUOY-VWGYHWLBSA-N Dermorphin Chemical compound C([C@H](N)C(=O)N[C@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)C1=CC=C(O)C=C1 FHZPGIUBXYVUOY-VWGYHWLBSA-N 0.000 claims description 2
- 108010065372 Dynorphins Proteins 0.000 claims description 2
- 108010024212 E-Selectin Proteins 0.000 claims description 2
- 102100023471 E-selectin Human genes 0.000 claims description 2
- 102100021977 Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 Human genes 0.000 claims description 2
- 108050004000 Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 Proteins 0.000 claims description 2
- 108010051021 Eledoisin Proteins 0.000 claims description 2
- 108010049140 Endorphins Proteins 0.000 claims description 2
- 102000009025 Endorphins Human genes 0.000 claims description 2
- 108050009340 Endothelin Proteins 0.000 claims description 2
- 102000002045 Endothelin Human genes 0.000 claims description 2
- 108010032976 Enfuvirtide Proteins 0.000 claims description 2
- 108010011459 Exenatide Proteins 0.000 claims description 2
- 102000009123 Fibrin Human genes 0.000 claims description 2
- 108010073385 Fibrin Proteins 0.000 claims description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims description 2
- 102100037362 Fibronectin Human genes 0.000 claims description 2
- 108010067306 Fibronectins Proteins 0.000 claims description 2
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 claims description 2
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 claims description 2
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 claims description 2
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 claims description 2
- 102400001370 Galanin Human genes 0.000 claims description 2
- 101800002068 Galanin Proteins 0.000 claims description 2
- 102000004862 Gastrin releasing peptide Human genes 0.000 claims description 2
- 108090001053 Gastrin releasing peptide Proteins 0.000 claims description 2
- 101800001586 Ghrelin Proteins 0.000 claims description 2
- 102400000442 Ghrelin-28 Human genes 0.000 claims description 2
- 108010088406 Glucagon-Like Peptides Proteins 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 102000003886 Glycoproteins Human genes 0.000 claims description 2
- 108090000288 Glycoproteins Proteins 0.000 claims description 2
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 claims description 2
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 claims description 2
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 claims description 2
- 102000001554 Hemoglobins Human genes 0.000 claims description 2
- 108010054147 Hemoglobins Proteins 0.000 claims description 2
- 102000007625 Hirudins Human genes 0.000 claims description 2
- 108010007267 Hirudins Proteins 0.000 claims description 2
- 206010020751 Hypersensitivity Diseases 0.000 claims description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 2
- 102000002746 Inhibins Human genes 0.000 claims description 2
- 108010004250 Inhibins Proteins 0.000 claims description 2
- 102000004877 Insulin Human genes 0.000 claims description 2
- 108090001061 Insulin Proteins 0.000 claims description 2
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims description 2
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims description 2
- 102000001617 Interferon Receptors Human genes 0.000 claims description 2
- 108010054267 Interferon Receptors Proteins 0.000 claims description 2
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 claims description 2
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 claims description 2
- 102000004407 Lactalbumin Human genes 0.000 claims description 2
- 108090000942 Lactalbumin Proteins 0.000 claims description 2
- 108010063045 Lactoferrin Proteins 0.000 claims description 2
- 102000010445 Lactoferrin Human genes 0.000 claims description 2
- 101710163560 Lamina-associated polypeptide 2, isoform alpha Proteins 0.000 claims description 2
- 101710189385 Lamina-associated polypeptide 2, isoforms beta/gamma Proteins 0.000 claims description 2
- 102000007547 Laminin Human genes 0.000 claims description 2
- 108010085895 Laminin Proteins 0.000 claims description 2
- 102000004083 Lymphotoxin-alpha Human genes 0.000 claims description 2
- 108090000542 Lymphotoxin-alpha Proteins 0.000 claims description 2
- 206010027476 Metastases Diseases 0.000 claims description 2
- 102000002419 Motilin Human genes 0.000 claims description 2
- 101800002372 Motilin Proteins 0.000 claims description 2
- 108010056852 Myostatin Proteins 0.000 claims description 2
- 108020001621 Natriuretic Peptide Proteins 0.000 claims description 2
- 102000004571 Natriuretic peptide Human genes 0.000 claims description 2
- 206010028851 Necrosis Diseases 0.000 claims description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 claims description 2
- 102400000097 Neurokinin A Human genes 0.000 claims description 2
- HEAUFJZALFKPBA-YRVBCFNBSA-N Neurokinin A Chemical compound C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)O)C1=CC=CC=C1 HEAUFJZALFKPBA-YRVBCFNBSA-N 0.000 claims description 2
- 101800000399 Neurokinin A Proteins 0.000 claims description 2
- 102000002512 Orexin Human genes 0.000 claims description 2
- 108090000573 Osteocalcin Proteins 0.000 claims description 2
- 102000004067 Osteocalcin Human genes 0.000 claims description 2
- 102400000050 Oxytocin Human genes 0.000 claims description 2
- 101800000989 Oxytocin Proteins 0.000 claims description 2
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 claims description 2
- 102400000203 Pancreastatin Human genes 0.000 claims description 2
- 101800005322 Pancreastatin Proteins 0.000 claims description 2
- 102000018886 Pancreatic Polypeptide Human genes 0.000 claims description 2
- 108090000445 Parathyroid hormone Proteins 0.000 claims description 2
- 102000003982 Parathyroid hormone Human genes 0.000 claims description 2
- 102100024622 Proenkephalin-B Human genes 0.000 claims description 2
- 108010087786 Prolactin-Releasing Hormone Proteins 0.000 claims description 2
- 102100028850 Prolactin-releasing peptide Human genes 0.000 claims description 2
- 101800004937 Protein C Proteins 0.000 claims description 2
- 102000003743 Relaxin Human genes 0.000 claims description 2
- 108090000103 Relaxin Proteins 0.000 claims description 2
- 108090000783 Renin Proteins 0.000 claims description 2
- 102100028255 Renin Human genes 0.000 claims description 2
- 102400000827 Saposin-D Human genes 0.000 claims description 2
- 101800001700 Saposin-D Proteins 0.000 claims description 2
- 101710205037 Sarafotoxin Proteins 0.000 claims description 2
- 102100037505 Secretin Human genes 0.000 claims description 2
- 108010086019 Secretin Proteins 0.000 claims description 2
- 108010056088 Somatostatin Proteins 0.000 claims description 2
- 102000005157 Somatostatin Human genes 0.000 claims description 2
- 108010023197 Streptokinase Proteins 0.000 claims description 2
- 101710172711 Structural protein Proteins 0.000 claims description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 claims description 2
- 108010012715 Superoxide dismutase Proteins 0.000 claims description 2
- 101000983124 Sus scrofa Pancreatic prohormone precursor Proteins 0.000 claims description 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 2
- 102000000479 TCF Transcription Factors Human genes 0.000 claims description 2
- 108010016283 TCF Transcription Factors Proteins 0.000 claims description 2
- 108090000190 Thrombin Proteins 0.000 claims description 2
- 102000003790 Thrombin receptors Human genes 0.000 claims description 2
- 102000012607 Thrombomodulin Human genes 0.000 claims description 2
- 108010079274 Thrombomodulin Proteins 0.000 claims description 2
- 102400000160 Thymopentin Human genes 0.000 claims description 2
- 101800001703 Thymopentin Proteins 0.000 claims description 2
- 102400000159 Thymopoietin Human genes 0.000 claims description 2
- 239000000898 Thymopoietin Substances 0.000 claims description 2
- 102000011923 Thyrotropin Human genes 0.000 claims description 2
- 108010061174 Thyrotropin Proteins 0.000 claims description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims description 2
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 claims description 2
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 claims description 2
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 claims description 2
- 108010004977 Vasopressins Proteins 0.000 claims description 2
- 102000002852 Vasopressins Human genes 0.000 claims description 2
- 241000700605 Viruses Species 0.000 claims description 2
- 102400000752 Xenin Human genes 0.000 claims description 2
- 239000000478 adipokine Substances 0.000 claims description 2
- 239000003470 adrenal cortex hormone Substances 0.000 claims description 2
- 108010055455 allatostatin Proteins 0.000 claims description 2
- 208000026935 allergic disease Diseases 0.000 claims description 2
- 230000007815 allergy Effects 0.000 claims description 2
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 claims description 2
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 claims description 2
- 229940024142 alpha 1-antitrypsin Drugs 0.000 claims description 2
- 230000003579 anti-obesity Effects 0.000 claims description 2
- 230000000840 anti-viral effect Effects 0.000 claims description 2
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 claims description 2
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 claims description 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 2
- 230000037396 body weight Effects 0.000 claims description 2
- DNDCVAGJPBKION-DOPDSADYSA-N bombesin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC2=CC=CC=C2C=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DNDCVAGJPBKION-DOPDSADYSA-N 0.000 claims description 2
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 claims description 2
- 229960004015 calcitonin Drugs 0.000 claims description 2
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims description 2
- 229950008486 carperitide Drugs 0.000 claims description 2
- 210000000845 cartilage Anatomy 0.000 claims description 2
- 230000010261 cell growth Effects 0.000 claims description 2
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 claims description 2
- DDPFHDCZUJFNAT-PZPWKVFESA-N chembl2104402 Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CCCCCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 DDPFHDCZUJFNAT-PZPWKVFESA-N 0.000 claims description 2
- 108700032673 cocaine- and amphetamine-regulated transcript Proteins 0.000 claims description 2
- 239000002442 collagenase inhibitor Substances 0.000 claims description 2
- 102000026898 cytokine binding proteins Human genes 0.000 claims description 2
- 108091008470 cytokine binding proteins Proteins 0.000 claims description 2
- 108700032313 elcatonin Proteins 0.000 claims description 2
- 229960000756 elcatonin Drugs 0.000 claims description 2
- AYLPVIWBPZMVSH-FCKMLYJASA-N eledoisin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1NC(=O)CC1)C1=CC=CC=C1 AYLPVIWBPZMVSH-FCKMLYJASA-N 0.000 claims description 2
- 229950011049 eledoisin Drugs 0.000 claims description 2
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 claims description 2
- PEASPLKKXBYDKL-FXEVSJAOSA-N enfuvirtide Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(C)=O)[C@@H](C)O)[C@@H](C)CC)C1=CN=CN1 PEASPLKKXBYDKL-FXEVSJAOSA-N 0.000 claims description 2
- 210000002919 epithelial cell Anatomy 0.000 claims description 2
- 229960001519 exenatide Drugs 0.000 claims description 2
- 229950003499 fibrin Drugs 0.000 claims description 2
- 229940126864 fibroblast growth factor Drugs 0.000 claims description 2
- 229940028334 follicle stimulating hormone Drugs 0.000 claims description 2
- 229940099052 fuzeon Drugs 0.000 claims description 2
- BGHSOEHUOOAYMY-JTZMCQEISA-N ghrelin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)CN)C1=CC=CC=C1 BGHSOEHUOOAYMY-JTZMCQEISA-N 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 claims description 2
- 229940006607 hirudin Drugs 0.000 claims description 2
- 229940088597 hormone Drugs 0.000 claims description 2
- 239000005556 hormone Substances 0.000 claims description 2
- 239000000960 hypophysis hormone Substances 0.000 claims description 2
- 230000002637 immunotoxin Effects 0.000 claims description 2
- 229940051026 immunotoxin Drugs 0.000 claims description 2
- 239000002596 immunotoxin Substances 0.000 claims description 2
- 231100000608 immunotoxin Toxicity 0.000 claims description 2
- 239000000859 incretin Substances 0.000 claims description 2
- 239000000893 inhibin Substances 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 claims description 2
- 229940125396 insulin Drugs 0.000 claims description 2
- 230000002473 insulinotropic effect Effects 0.000 claims description 2
- 102000002467 interleukin receptors Human genes 0.000 claims description 2
- 108010093036 interleukin receptors Proteins 0.000 claims description 2
- 210000000936 intestine Anatomy 0.000 claims description 2
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims description 2
- 229940078795 lactoferrin Drugs 0.000 claims description 2
- 235000021242 lactoferrin Nutrition 0.000 claims description 2
- 239000003446 ligand Substances 0.000 claims description 2
- 229940040129 luteinizing hormone Drugs 0.000 claims description 2
- 230000001294 luteotrophic effect Effects 0.000 claims description 2
- 210000002540 macrophage Anatomy 0.000 claims description 2
- 230000009401 metastasis Effects 0.000 claims description 2
- SLZIZIJTGAYEKK-CIJSCKBQSA-N molport-023-220-247 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)[C@@H](C)O)C1=CNC=N1 SLZIZIJTGAYEKK-CIJSCKBQSA-N 0.000 claims description 2
- 210000003205 muscle Anatomy 0.000 claims description 2
- 239000000692 natriuretic peptide Substances 0.000 claims description 2
- 230000017074 necrotic cell death Effects 0.000 claims description 2
- 229940053128 nerve growth factor Drugs 0.000 claims description 2
- BPGXUIVWLQTVLZ-OFGSCBOVSA-N neuropeptide y(npy) Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 BPGXUIVWLQTVLZ-OFGSCBOVSA-N 0.000 claims description 2
- 108060005714 orexin Proteins 0.000 claims description 2
- 230000002188 osteogenic effect Effects 0.000 claims description 2
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 claims description 2
- 229960001723 oxytocin Drugs 0.000 claims description 2
- RYZUEKXRBSXBRH-CTXORKPYSA-N pancreastatin Chemical compound C([C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)C1=CN=CN1 RYZUEKXRBSXBRH-CTXORKPYSA-N 0.000 claims description 2
- 239000000199 parathyroid hormone Substances 0.000 claims description 2
- 229960001319 parathyroid hormone Drugs 0.000 claims description 2
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 claims description 2
- 229960000856 protein c Drugs 0.000 claims description 2
- 239000002461 renin inhibitor Substances 0.000 claims description 2
- 229940086526 renin-inhibitors Drugs 0.000 claims description 2
- 229960002101 secretin Drugs 0.000 claims description 2
- OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 claims description 2
- WGWPRVFKDLAUQJ-MITYVQBRSA-N sermorelin Chemical compound C([C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)C1=CC=C(O)C=C1 WGWPRVFKDLAUQJ-MITYVQBRSA-N 0.000 claims description 2
- 229960002758 sermorelin Drugs 0.000 claims description 2
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims description 2
- 229960000553 somatostatin Drugs 0.000 claims description 2
- 210000002784 stomach Anatomy 0.000 claims description 2
- 229960005202 streptokinase Drugs 0.000 claims description 2
- 229960004072 thrombin Drugs 0.000 claims description 2
- PSWFFKRAVBDQEG-YGQNSOCVSA-N thymopentin Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 PSWFFKRAVBDQEG-YGQNSOCVSA-N 0.000 claims description 2
- 229960004517 thymopentin Drugs 0.000 claims description 2
- 210000001685 thyroid gland Anatomy 0.000 claims description 2
- 102000003390 tumor necrosis factor Human genes 0.000 claims description 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims description 2
- 230000001875 tumorinhibitory effect Effects 0.000 claims description 2
- 229960003726 vasopressin Drugs 0.000 claims description 2
- IDHVLSACPFUBDY-QCDLPZBNSA-N xenin Chemical compound C([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CN=CN1 IDHVLSACPFUBDY-QCDLPZBNSA-N 0.000 claims description 2
- 108010006643 xenin 25 Proteins 0.000 claims description 2
- 235000021241 α-lactalbumin Nutrition 0.000 claims description 2
- 102400000326 Glucagon-like peptide 2 Human genes 0.000 claims 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims 2
- 102000003797 Neuropeptides Human genes 0.000 claims 2
- 229940079322 interferon Drugs 0.000 claims 2
- FHZSIZRTNHGLSX-FLMSMKGQSA-N (2s)-1-[(2s)-4-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-hydroxypropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-4-oxobutanoyl]pyrrolidine-2-carboxyl Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(N)=O)C(=O)N1[C@@H](CCC1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=CC=C1 FHZSIZRTNHGLSX-FLMSMKGQSA-N 0.000 claims 1
- HFDKKNHCYWNNNQ-YOGANYHLSA-N 75976-10-2 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)N)C(C)C)[C@@H](C)O)C1=CC=C(O)C=C1 HFDKKNHCYWNNNQ-YOGANYHLSA-N 0.000 claims 1
- 101000645291 Bos taurus Metalloproteinase inhibitor 2 Proteins 0.000 claims 1
- 229940122097 Collagenase inhibitor Drugs 0.000 claims 1
- 102400001368 Epidermal growth factor Human genes 0.000 claims 1
- 101800003838 Epidermal growth factor Proteins 0.000 claims 1
- 101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 claims 1
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 claims 1
- 101710160107 Outer membrane protein A Proteins 0.000 claims 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 claims 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 claims 1
- 102100030951 Tissue factor pathway inhibitor Human genes 0.000 claims 1
- 229940116977 epidermal growth factor Drugs 0.000 claims 1
- 108010077689 gamma-aminobutyryl-2-methyltryptophyl-2-methyltryptophyl-2-methyltryptophyl-lysinamide Proteins 0.000 claims 1
- PUBCCFNQJQKCNC-XKNFJVFFSA-N gastrin-releasingpeptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)C(C)C)[C@@H](C)O)C(C)C)[C@@H](C)O)C(C)C)C1=CNC=N1 PUBCCFNQJQKCNC-XKNFJVFFSA-N 0.000 claims 1
- 108010013555 lipoprotein-associated coagulation inhibitor Proteins 0.000 claims 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 claims 1
- 239000002877 prolactin releasing hormone Substances 0.000 claims 1
- 108010093640 thrombin receptor peptide SFLLRNP Proteins 0.000 claims 1
- 230000035897 transcription Effects 0.000 claims 1
- 238000013518 transcription Methods 0.000 claims 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims 1
- 229910052727 yttrium Inorganic materials 0.000 claims 1
- 238000012650 click reaction Methods 0.000 abstract description 31
- 102000006395 Globulins Human genes 0.000 abstract 1
- 108010044091 Globulins Proteins 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 255
- 238000006243 chemical reaction Methods 0.000 description 73
- 238000002360 preparation method Methods 0.000 description 65
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 60
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 60
- 235000001014 amino acid Nutrition 0.000 description 53
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 45
- 230000002829 reductive effect Effects 0.000 description 42
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 36
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 30
- 239000012141 concentrate Substances 0.000 description 30
- 239000013078 crystal Substances 0.000 description 30
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 30
- 235000019341 magnesium sulphate Nutrition 0.000 description 30
- 239000012044 organic layer Substances 0.000 description 30
- 238000003756 stirring Methods 0.000 description 30
- 102100040918 Pro-glucagon Human genes 0.000 description 27
- 238000005160 1H NMR spectroscopy Methods 0.000 description 24
- 238000001914 filtration Methods 0.000 description 21
- 239000000243 solution Substances 0.000 description 21
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 20
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 20
- 229940126214 compound 3 Drugs 0.000 description 20
- 238000000605 extraction Methods 0.000 description 20
- 239000010410 layer Substances 0.000 description 20
- 125000005647 linker group Chemical group 0.000 description 18
- 239000004472 Lysine Substances 0.000 description 16
- 239000007864 aqueous solution Substances 0.000 description 16
- 229940125782 compound 2 Drugs 0.000 description 16
- 238000004949 mass spectrometry Methods 0.000 description 16
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 15
- 150000001540 azides Chemical class 0.000 description 15
- 229940125898 compound 5 Drugs 0.000 description 14
- 239000003814 drug Substances 0.000 description 14
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 13
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 13
- 239000012153 distilled water Substances 0.000 description 13
- 229940079593 drug Drugs 0.000 description 13
- SQDFHQJTAWCFIB-UHFFFAOYSA-N n-methylidenehydroxylamine Chemical compound ON=C SQDFHQJTAWCFIB-UHFFFAOYSA-N 0.000 description 13
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 12
- 238000006352 cycloaddition reaction Methods 0.000 description 11
- 239000000706 filtrate Substances 0.000 description 11
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 11
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 10
- 238000005481 NMR spectroscopy Methods 0.000 description 10
- 238000004821 distillation Methods 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 235000017557 sodium bicarbonate Nutrition 0.000 description 10
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 125000005677 ethinylene group Chemical group [*:2]C#C[*:1] 0.000 description 8
- HTFFMYRVHHNNBE-YFKPBYRVSA-N (2s)-2-amino-6-azidohexanoic acid Chemical compound OC(=O)[C@@H](N)CCCCN=[N+]=[N-] HTFFMYRVHHNNBE-YFKPBYRVSA-N 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- 125000003412 L-alanyl group Chemical group [H]N([H])[C@@](C([H])([H])[H])(C(=O)[*])[H] 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 238000006268 reductive amination reaction Methods 0.000 description 6
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 6
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 5
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 5
- MEKOFIRRDATTAG-UHFFFAOYSA-N 2,2,5,8-tetramethyl-3,4-dihydrochromen-6-ol Chemical compound C1CC(C)(C)OC2=C1C(C)=C(O)C=C2C MEKOFIRRDATTAG-UHFFFAOYSA-N 0.000 description 5
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
- 239000004471 Glycine Substances 0.000 description 5
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 5
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 5
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 5
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 235000004279 alanine Nutrition 0.000 description 5
- 125000003275 alpha amino acid group Chemical group 0.000 description 5
- 235000019270 ammonium chloride Nutrition 0.000 description 5
- 229940125797 compound 12 Drugs 0.000 description 5
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 5
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 5
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 5
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 4
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 4
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 4
- 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 4
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N Butyraldehyde Chemical group CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 4
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- 238000010461 azide-alkyne cycloaddition reaction Methods 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 229940125904 compound 1 Drugs 0.000 description 4
- 229940126543 compound 14 Drugs 0.000 description 4
- 229940126142 compound 16 Drugs 0.000 description 4
- 229910052802 copper Inorganic materials 0.000 description 4
- 239000010949 copper Substances 0.000 description 4
- 235000018417 cysteine Nutrition 0.000 description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 125000003396 thiol group Chemical group [H]S* 0.000 description 4
- 239000013559 triple agonist Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 125000000570 L-alpha-aspartyl group Chemical group [H]OC(=O)C([H])([H])[C@]([H])(N([H])[H])C(*)=O 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical group CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 3
- 125000003342 alkenyl group Chemical group 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 3
- 239000003638 chemical reducing agent Substances 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 3
- 150000002527 isonitriles Chemical class 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 239000012046 mixed solvent Substances 0.000 description 3
- 230000006320 pegylation Effects 0.000 description 3
- 229910000160 potassium phosphate Inorganic materials 0.000 description 3
- 235000011009 potassium phosphates Nutrition 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 3
- OIGKWPIMJCPGGD-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-[2-[2-[2-(2-azidoethoxy)ethoxy]ethoxy]ethoxy]propanoate Chemical compound [N-]=[N+]=NCCOCCOCCOCCOCCC(=O)ON1C(=O)CCC1=O OIGKWPIMJCPGGD-UHFFFAOYSA-N 0.000 description 2
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical compound C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 2
- OXBLVCZKDOZZOJ-UHFFFAOYSA-N 2,3-Dihydrothiophene Chemical compound C1CC=CS1 OXBLVCZKDOZZOJ-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- YNXLOPYTAAFMTN-SBUIBGKBSA-N C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)C1=CC=C(O)C=C1 Chemical compound C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)C1=CC=C(O)C=C1 YNXLOPYTAAFMTN-SBUIBGKBSA-N 0.000 description 2
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 108010063919 Glucagon Receptors Proteins 0.000 description 2
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 2
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 125000003440 L-leucyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C(C([H])([H])[H])([H])C([H])([H])[H] 0.000 description 2
- 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 108010088847 Peptide YY Proteins 0.000 description 2
- 102100029909 Peptide YY Human genes 0.000 description 2
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- WDECIBYCCFPHNR-UHFFFAOYSA-N chrysene Chemical compound C1=CC=CC2=CC=C3C4=CC=CC=C4C=CC3=C21 WDECIBYCCFPHNR-UHFFFAOYSA-N 0.000 description 2
- TXCDCPKCNAJMEE-UHFFFAOYSA-N dibenzofuran Chemical compound C1=CC=C2C3=CC=CC=C3OC2=C1 TXCDCPKCNAJMEE-UHFFFAOYSA-N 0.000 description 2
- IYYZUPMFVPLQIF-UHFFFAOYSA-N dibenzothiophene Chemical compound C1=CC=C2C3=CC=CC=C3SC2=C1 IYYZUPMFVPLQIF-UHFFFAOYSA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 2
- 108010036598 gastric inhibitory polypeptide receptor Proteins 0.000 description 2
- 150000002334 glycols Chemical class 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 2
- RDOWQLZANAYVLL-UHFFFAOYSA-N phenanthridine Chemical compound C1=CC=C2C3=CC=CC=C3C=NC2=C1 RDOWQLZANAYVLL-UHFFFAOYSA-N 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 2
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 239000012064 sodium phosphate buffer Substances 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
- ZJIFDEVVTPEXDL-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) hydrogen carbonate Chemical compound OC(=O)ON1C(=O)CCC1=O ZJIFDEVVTPEXDL-UHFFFAOYSA-N 0.000 description 1
- AASBXERNXVFUEJ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) propanoate Chemical compound CCC(=O)ON1C(=O)CCC1=O AASBXERNXVFUEJ-UHFFFAOYSA-N 0.000 description 1
- DDYAPMZTJAYBOF-ZMYDTDHYSA-N (3S)-4-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-4-amino-1-[[(2S,3S)-1-[[(1S)-1-carboxyethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]amino]-5-oxopentanoyl]amino]-4-oxobutanoic acid Chemical class [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O DDYAPMZTJAYBOF-ZMYDTDHYSA-N 0.000 description 1
- ICPSWZFVWAPUKF-UHFFFAOYSA-N 1,1'-spirobi[fluorene] Chemical compound C1=CC=C2C=C3C4(C=5C(C6=CC=CC=C6C=5)=CC=C4)C=CC=C3C2=C1 ICPSWZFVWAPUKF-UHFFFAOYSA-N 0.000 description 1
- ZFXBERJDEUDDMX-UHFFFAOYSA-N 1,2,3,5-tetrazine Chemical compound C1=NC=NN=N1 ZFXBERJDEUDDMX-UHFFFAOYSA-N 0.000 description 1
- UGUHFDPGDQDVGX-UHFFFAOYSA-N 1,2,3-thiadiazole Chemical compound C1=CSN=N1 UGUHFDPGDQDVGX-UHFFFAOYSA-N 0.000 description 1
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
- HTJMXYRLEDBSLT-UHFFFAOYSA-N 1,2,4,5-tetrazine Chemical compound C1=NN=CN=N1 HTJMXYRLEDBSLT-UHFFFAOYSA-N 0.000 description 1
- BBVIDBNAYOIXOE-UHFFFAOYSA-N 1,2,4-oxadiazole Chemical compound C=1N=CON=1 BBVIDBNAYOIXOE-UHFFFAOYSA-N 0.000 description 1
- YGTAZGSLCXNBQL-UHFFFAOYSA-N 1,2,4-thiadiazole Chemical compound C=1N=CSN=1 YGTAZGSLCXNBQL-UHFFFAOYSA-N 0.000 description 1
- FYADHXFMURLYQI-UHFFFAOYSA-N 1,2,4-triazine Chemical compound C1=CN=NC=N1 FYADHXFMURLYQI-UHFFFAOYSA-N 0.000 description 1
- UDGKZGLPXCRRAM-UHFFFAOYSA-N 1,2,5-thiadiazole Chemical compound C=1C=NSN=1 UDGKZGLPXCRRAM-UHFFFAOYSA-N 0.000 description 1
- UUSUFQUCLACDTA-UHFFFAOYSA-N 1,2-dihydropyrene Chemical compound C1=CC=C2C=CC3=CCCC4=CC=C1C2=C43 UUSUFQUCLACDTA-UHFFFAOYSA-N 0.000 description 1
- CIISBYKBBMFLEZ-UHFFFAOYSA-N 1,2-oxazolidine Chemical compound C1CNOC1 CIISBYKBBMFLEZ-UHFFFAOYSA-N 0.000 description 1
- FKASFBLJDCHBNZ-UHFFFAOYSA-N 1,3,4-oxadiazole Chemical compound C1=NN=CO1 FKASFBLJDCHBNZ-UHFFFAOYSA-N 0.000 description 1
- MBIZXFATKUQOOA-UHFFFAOYSA-N 1,3,4-thiadiazole Chemical compound C1=NN=CS1 MBIZXFATKUQOOA-UHFFFAOYSA-N 0.000 description 1
- JIHQDMXYYFUGFV-UHFFFAOYSA-N 1,3,5-triazine Chemical compound C1=NC=NC=N1 JIHQDMXYYFUGFV-UHFFFAOYSA-N 0.000 description 1
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 1
- OHVLMTFVQDZYHP-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CN1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O OHVLMTFVQDZYHP-UHFFFAOYSA-N 0.000 description 1
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
- TZMSYXZUNZXBOL-UHFFFAOYSA-N 10H-phenoxazine Chemical compound C1=CC=C2NC3=CC=CC=C3OC2=C1 TZMSYXZUNZXBOL-UHFFFAOYSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- USYCQABRSUEURP-UHFFFAOYSA-N 1h-benzo[f]benzimidazole Chemical compound C1=CC=C2C=C(NC=N3)C3=CC2=C1 USYCQABRSUEURP-UHFFFAOYSA-N 0.000 description 1
- VEPOHXYIFQMVHW-XOZOLZJESA-N 2,3-dihydroxybutanedioic acid (2S,3S)-3,4-dimethyl-2-phenylmorpholine Chemical compound OC(C(O)C(O)=O)C(O)=O.C[C@H]1[C@@H](OCCN1C)c1ccccc1 VEPOHXYIFQMVHW-XOZOLZJESA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- UXGVMFHEKMGWMA-UHFFFAOYSA-N 2-benzofuran Chemical compound C1=CC=CC2=COC=C21 UXGVMFHEKMGWMA-UHFFFAOYSA-N 0.000 description 1
- LYTMVABTDYMBQK-UHFFFAOYSA-N 2-benzothiophene Chemical compound C1=CC=CC2=CSC=C21 LYTMVABTDYMBQK-UHFFFAOYSA-N 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 1
- BPMFPOGUJAAYHL-UHFFFAOYSA-N 9H-Pyrido[2,3-b]indole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=N1 BPMFPOGUJAAYHL-UHFFFAOYSA-N 0.000 description 1
- 102100031793 Adipolin Human genes 0.000 description 1
- 101710099074 Adipolin Proteins 0.000 description 1
- 102000011690 Adiponectin Human genes 0.000 description 1
- 108010076365 Adiponectin Proteins 0.000 description 1
- 102000018746 Apelin Human genes 0.000 description 1
- 108010052412 Apelin Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- FMMWHPNWAFZXNH-UHFFFAOYSA-N Benz[a]pyrene Chemical compound C1=C2C3=CC=CC=C3C=C(C=C3)C2=C2C3=CC=CC2=C1 FMMWHPNWAFZXNH-UHFFFAOYSA-N 0.000 description 1
- 239000012617 Butyl Sepharose™ 4 Fast Flow Substances 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 102100025890 Complement C1q tumor necrosis factor-related protein 3 Human genes 0.000 description 1
- 102100035784 Decorin Human genes 0.000 description 1
- 108090000738 Decorin Proteins 0.000 description 1
- 238000005698 Diels-Alder reaction Methods 0.000 description 1
- 108010066486 EGF Family of Proteins Proteins 0.000 description 1
- 102000018386 EGF Family of Proteins Human genes 0.000 description 1
- 102100030767 Erythroferrone Human genes 0.000 description 1
- 101710111526 Erythroferrone Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102000016970 Follistatin Human genes 0.000 description 1
- 108010014612 Follistatin Proteins 0.000 description 1
- 101710119601 Growth hormone-releasing peptides Proteins 0.000 description 1
- 101000933673 Homo sapiens Complement C1q tumor necrosis factor-related protein 3 Proteins 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 102400001216 Irisin Human genes 0.000 description 1
- 101800001026 Irisin Proteins 0.000 description 1
- 102000013599 Kisspeptins Human genes 0.000 description 1
- 108010012048 Kisspeptins Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 125000001176 L-lysyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C([H])([H])C(N([H])[H])([H])[H] 0.000 description 1
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 1
- 125000000769 L-threonyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](O[H])(C([H])([H])[H])[H] 0.000 description 1
- 125000003580 L-valyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(C([H])([H])[H])(C([H])([H])[H])[H] 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- YHBTXTFFTYXOFV-UHFFFAOYSA-N Liquid thiophthene Chemical compound C1=CSC2=C1C=CS2 YHBTXTFFTYXOFV-UHFFFAOYSA-N 0.000 description 1
- 102000007436 Macrophage-Activating Factors Human genes 0.000 description 1
- 108010086123 Macrophage-Activating Factors Proteins 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 102400001165 Nesfatin-1 Human genes 0.000 description 1
- 101800000396 Nesfatin-1 Proteins 0.000 description 1
- 102100040556 Osteocrin Human genes 0.000 description 1
- 101710089325 Osteocrin Proteins 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000006877 Pituitary Hormones Human genes 0.000 description 1
- 108010047386 Pituitary Hormones Proteins 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- XBDYBAVJXHJMNQ-UHFFFAOYSA-N Tetrahydroanthracene Natural products C1=CC=C2C=C(CCCC3)C3=CC2=C1 XBDYBAVJXHJMNQ-UHFFFAOYSA-N 0.000 description 1
- DPOPAJRDYZGTIR-UHFFFAOYSA-N Tetrazine Chemical compound C1=CN=NN=N1 DPOPAJRDYZGTIR-UHFFFAOYSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 108090000166 Thrombin receptors Proteins 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 102100030859 Tissue factor Human genes 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- SLGBZMMZGDRARJ-UHFFFAOYSA-N Triphenylene Natural products C1=CC=C2C3=CC=CC=C3C3=CC=CC=C3C2=C1 SLGBZMMZGDRARJ-UHFFFAOYSA-N 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 150000005325 alkali earth metal hydroxides Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Chemical class 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- BWVPHIKGXQBZPV-QKFDDRBGSA-N apelin Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N1[C@H](C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2NC=NC=2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=2NC=NC=2)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CCSC)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(O)=O)CCC1 BWVPHIKGXQBZPV-QKFDDRBGSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
- WMUIZUWOEIQJEH-UHFFFAOYSA-N benzo[e][1,3]benzoxazole Chemical compound C1=CC=C2C(N=CO3)=C3C=CC2=C1 WMUIZUWOEIQJEH-UHFFFAOYSA-N 0.000 description 1
- FZICDBOJOMQACG-UHFFFAOYSA-N benzo[h]isoquinoline Chemical compound C1=NC=C2C3=CC=CC=C3C=CC2=C1 FZICDBOJOMQACG-UHFFFAOYSA-N 0.000 description 1
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 1
- 239000012964 benzotriazole Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 125000002529 biphenylenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C12)* 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 125000003493 decenyl group Chemical group [H]C([*])=C([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005070 decynyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C#C* 0.000 description 1
- 230000022811 deglycosylation Effects 0.000 description 1
- 150000001993 dienes Chemical class 0.000 description 1
- RZCSPUKVPNZXPV-UHFFFAOYSA-N dithieno[3,2-a:2',3'-d]pyridine Chemical compound S1C=CC2=C1C=NC1=C2SC=C1 RZCSPUKVPNZXPV-UHFFFAOYSA-N 0.000 description 1
- HKNRNTYTYUWGLN-UHFFFAOYSA-N dithieno[3,2-a:2',3'-d]thiophene Chemical compound C1=CSC2=C1SC1=C2C=CS1 HKNRNTYTYUWGLN-UHFFFAOYSA-N 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000006126 farnesylation Effects 0.000 description 1
- GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthrene Natural products C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- JKFAIQOWCVVSKC-UHFFFAOYSA-N furazan Chemical compound C=1C=NON=1 JKFAIQOWCVVSKC-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 125000003827 glycol group Chemical group 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- PJULCNAVAGQLAT-UHFFFAOYSA-N indeno[2,1-a]fluorene Chemical compound C1=CC=C2C=C3C4=CC5=CC=CC=C5C4=CC=C3C2=C1 PJULCNAVAGQLAT-UHFFFAOYSA-N 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- HOBCFUWDNJPFHB-UHFFFAOYSA-N indolizine Chemical compound C1=CC=CN2C=CC=C21 HOBCFUWDNJPFHB-UHFFFAOYSA-N 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- LNQCUTNLHUQZLR-OZJWLQQPSA-N iridin Chemical compound OC1=C(OC)C(OC)=CC(C=2C(C3=C(O)C(OC)=C(O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)C=C3OC=2)=O)=C1 LNQCUTNLHUQZLR-OZJWLQQPSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- KAHDONZOCXSKII-NJVVDGNHSA-N kisspeptin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)O)C1=CN=CN1 KAHDONZOCXSKII-NJVVDGNHSA-N 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 125000004370 n-butenyl group Chemical group [H]\C([H])=C(/[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- SLIUAWYAILUBJU-UHFFFAOYSA-N pentacene Chemical compound C1=CC=CC2=CC3=CC4=CC5=CC=CC=C5C=C4C=C3C=C21 SLIUAWYAILUBJU-UHFFFAOYSA-N 0.000 description 1
- HGBOYTHUEUWSSQ-UHFFFAOYSA-N pentanal Chemical compound CCCCC=O HGBOYTHUEUWSSQ-UHFFFAOYSA-N 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 125000002080 perylenyl group Chemical group C1(=CC=C2C=CC=C3C4=CC=CC5=CC=CC(C1=C23)=C45)* 0.000 description 1
- CSHWQDPOILHKBI-UHFFFAOYSA-N peryrene Natural products C1=CC(C2=CC=CC=3C2=C2C=CC=3)=C3C2=CC=CC3=C1 CSHWQDPOILHKBI-UHFFFAOYSA-N 0.000 description 1
- 229950000688 phenothiazine Drugs 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 210000004896 polypeptide structure Anatomy 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 102000037983 regulatory factors Human genes 0.000 description 1
- 108091008025 regulatory factors Proteins 0.000 description 1
- 239000011369 resultant mixture Substances 0.000 description 1
- MABNMNVCOAICNO-UHFFFAOYSA-N selenophene Chemical compound C=1C=C[se]C=1 MABNMNVCOAICNO-UHFFFAOYSA-N 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000019635 sulfation Effects 0.000 description 1
- 238000005670 sulfation reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- IFLREYGFSNHWGE-UHFFFAOYSA-N tetracene Chemical compound C1=CC=CC2=CC3=CC4=CC=CC=C4C=C3C=C21 IFLREYGFSNHWGE-UHFFFAOYSA-N 0.000 description 1
- 150000004905 tetrazines Chemical class 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- VJYJJHQEVLEOFL-UHFFFAOYSA-N thieno[3,2-b]thiophene Chemical compound S1C=CC2=C1C=CS2 VJYJJHQEVLEOFL-UHFFFAOYSA-N 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 125000005580 triphenylene group Chemical group 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
- C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D225/08—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with two six-membered rings
Definitions
- the present disclosure relates to a non-peptidyl polymeric compound, a conjugate including the compound, and a method of preparing the same. More specifically, the present disclosure relates to a non-peptidyl polymeric compound which may be used as a linker to increase half-life of a physiologically active polypeptide, a conjugate linked with the physiologically active polypeptide via the compound as a linker, and a method of preparing the same.
- Protein drugs have short blood half-lives when administered to the human body. Thus, protein drugs are inconvenient in that they are required to be frequently administered in order to maintain their efficacy. To solve this problem, pegylation which binds polyethylene glycol to a protein drug has been used to increase blood half-life of the protein drug. This pegylation not only increases the blood half-life of the protein drug, but also reduces antigenicity of the protein drug, and thus pegylation is widely employed in protein therapeutic agents.
- the polyethylene glycol has a form of a polyethylene glycol derivative that further includes a functional group binding to an immunoglobulin Fc region which is known to improve the half-life of the protein drug, in addition to a functional group binding to the protein drug. Therefore, the polyethylene glycol may be used as a linker that links the protein drug and the immunoglobulin Fc region. Further, as the linker compound for the protein drug and the immunoglobulin Fc region, various non-peptidyl polymers having biocompatibility have been proposed as a linker capable of forming a conjugate together with the protein drug, in addition to the polyethylene glycol derivative (Patent Document 1).
- the non-peptidyl polymer may have, each independently at both ends thereof, an aldehyde group, a propionaldehyde group, a butyraldehyde group, a maleimide group, a succinimide derivative (succinimidyl propionate, hydroxy succinimidyl, succinimidyl carboxymethyl, or succinimidyl carbonate), etc., as a functional group to bind with the protein drug and immunoglobulin Fc.
- the functional groups have a disadvantage in that a conjugate production yield is reduced due to the reason that the entire substances introduced into a reaction may not be converted into conjugates during the reaction targeting a specific amino acid site upon binding with protein drugs, and some reactive groups have reduced stability in the blood.
- Patent Document 1 Korean Patent Publication No. 2014-0018462
- An aspect of the present disclosure is to provide a non-peptidyl polymeric compound not only capable of stably binding with a physiologically active polypeptide to increase blood half-life of the physiologically active polypeptide but also capable of binding therewith in a high yield.
- Another aspect of the present disclosure is to provide a physiologically active polypeptide linkage, in which a physiologically active polypeptide is linked at one end of the non-peptidyl polymeric compound.
- Still another aspect of the present disclosure is to provide a physiologically active polypeptide conjugate, in which a physiologically active polypeptide and an immunoglobulin Fc region are linked to both ends of the non-peptidyl polymeric compound, respectively.
- Still another aspect of the present disclosure is to provide a method of preparing the non-peptidyl polymeric compound, the physiologically active polypeptide linkage, and the physiologically active polypeptide conjugate.
- An aspect of the present disclosure is to provide a compound, in which a functional group capable of binding with an immunoglobulin Fc region or a physiologically active polypeptide is introduced at one end of a non-peptidyl polymer and a functional group capable of undergoing a click reaction is introduced at the other end thereof.
- the compound may include a compound of the following Formula 1, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof:
- R1 is an aliphatic hydrocarbon group including a functional group selected from the group consisting of 2,5-dioxopyrrolidinyl, 2,5-dioxopyrrolyl, aldehyde, maleimide, C 6 -C 20 aryl disulfide, C 5 -C 20 heteroaryl disulfide, vinyl sulfone, thiol, halogenated acetamide, succinimide, p-nitrophenyl carbonate, and derivatives thereof;
- the non-peptidyl polymer is selected from the group consisting of polyethylene glycol, polypropylene glycol, a copolymer of ethylene glycol and propylene glycol, polyoxyethylated polyol, polyvinyl alcohol, polysaccharide, dextran, polyvinyl ethyl ether, polylactic acid (PLA), polylactic-glycolic acid (PLGA), lipid polymers, chitins, hyaluronic acid, and polysaccharides;
- X is —(CH 2 ) j NHCO— or —(CH 2 ) j NHCS—, wherein j is an integer of 0 to 6;
- R2 is —(R3) k -(Z) l —(R4) m -(CZ) p —Y—,
- R3 and R4 are each independently C 1 -C 6 alkylene, C 6 -C 20 arylene, or C 5 -C 20 heteroarylene having 1 to 3 heteroatoms selected from N, O, and S,
- Z is O or S
- Y is C 2 -C 6 alkynyl, cycloalkynyl, arylcycloalkynyl, diarylcycloalkynyl, heterocycloalkynyl, or diarylheterocycloalkynyl (wherein each cycloalkynyl has 3 to 8 carbon atoms, each aryl has 5 to 8 carbon atoms, and each heterocycloalkynyl is a saturated ring including 3 to 8 atoms and having heteroatoms selected from N, O, and S in 1 to 3 of ring atoms),
- k, l, m, and p are each independently an integer of 0 to 3, provided that all of them may not be 0 at the same time, and
- the alkynyl, cycloalkynyl, arylcycloalkynyl, diarylcycloalkynyl, heterocycloalkynyl, or diarylheterocycloalkynyl is substituted or unsubstituted with C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 alkoxycarbonyl, oxo, or halogen.
- Another aspect of the present disclosure is to provide a method of preparing the compound according to an aspect of the present disclosure, the method including:
- Still another aspect of the present disclosure is to provide a physiologically active polypeptide linkage in which a physiologically active polypeptide is linked to the functional group capable of undergoing a click reaction at one end of the compound according to an aspect.
- Still another aspect of the present disclosure is to provide an immunoglobulin Fc region linkage in which an immunoglobulin Fc region is linked to the functional group capable of undergoing a click reaction at one end of the compound according to an aspect.
- Still another aspect of the present disclosure is to provide a physiologically active polypeptide conjugate in which a physiologically active polypeptide and an immunoglobulin Fc region are linked to each other via the compound according to an aspect as a linker.
- a compound according to an aspect of the present disclosure may be stably linked to a target site of a physiologically active polypeptide and may form a conjugate with high production yield and stability, as compared with known linker compounds.
- FIG. 8 shows a result of mass spectrometry of a linker compound ALD-PEG 10K-DBCO
- FIG. 9 shows a result of mass spectrometry of a linker compound ALD-PEG 5K-DBCO
- FIG. 10 shows a result of mass spectrometry of a linker compound ALD-PEG 3.4K-DBCO
- FIG. 11 shows a result of mass spectrometry of a linker compound ALD-PEG 2K-DBCO
- FIG. 12 shows a result of mass spectrometry of a linker compound PeALD-PEG 10K-BCN;
- FIG. 13 shows a result of mass spectrometry of a linker compound PeALD-PEG 10K-DBCO
- FIG. 14 shows a result of mass spectrometry of a linker compound ALD-PEG 10K-BCN
- FIG. 15 shows a result of SDS-PAGE purity analysis of an HMT211-azido-PEG-immunoglobulin Fc conjugate, wherein M: Marker, 1: HMT211-azido peptide, 2: mono-PEGylated HMT211-azido-PEG, 3: immunoglobulin Fc, 4: HMT211-azido-PEG-immunoglobulin FC conjugate prepared by linking HMT211-azido with an immunoglobulin Fc via the ALD-PEG 10K-BCN linker;
- FIG. 16 shows a result of non-reducing SDS-PAGE purity analysis of a GLP-2 analog-azido-PEG-immunoglobulin Fc conjugate, wherein M: Marker, 1: GLP-2 analog, 2: mono-PEGylated GLP-2 analog, 3: immunoglobulin Fc, 4: GLP-2 analog-PEG-immunoglobulin Fc conjugate prepared by linking GLP-2 analog-azido with an immunoglobulin Fc via the ALD-PEG 10K-DBCO linker; and
- FIG. 17 shows a result of non-reducing SDS-PAGE purity analysis of a glucagon analog-azido-PEG-immunoglobulin Fc conjugate, wherein M: Marker, 1: glucagon analog, 2: mono-PEGylated glucagon analog, 3: immunoglobulin Fc, 4: glucagon analog-PEG-immunoglobulin Fc conjugate prepared by linking glucagon analog-azido with an immunoglobulin Fc via a PeAL-PEG 10K-BCN linker.
- the present inventors have studied to develop a linker compound which may bind with a physiologically active polypeptide to improve in vivo stability of the physiologically active polypeptide, thereby increasing half-life thereof, and as a result, they developed a linker compound capable of more stably binding with a physiologically active polypeptide.
- An aspect of the present disclosure provides a linker compound, in which a functional group capable of binding with an immunoglobulin Fc region or a physiologically active polypeptide is introduced at one end of a non-peptidyl polymer and a functional group capable of undergoing a click reaction is introduced at the other end thereof.
- the “functional group capable of binding with an immunoglobulin Fc region or a physiologically active polypeptide” refers to a functional group capable of binding with a functional group of an amino acid at any region of the immunoglobulin Fc region or the physiologically active polypeptide.
- the “functional group of an amino acid at any region of the immunoglobulin Fc region or the physiologically active polypeptide” may include, for example, an amino group (—NH 2 ) of lysine, an amine group (—NH—) of proline, a thiol group (—SH) of cysteine, etc.
- the functional group capable of binding with the immunoglobulin Fc region or the physiologically active polypeptide refers to a functional group capable of binding with a functional group (an amine group, an amino group, or a thiol group) of N-terminal amino acid, lysine, or cysteine.
- the functional group capable of binding with the immunoglobulin Fc region or the physiologically active polypeptide may be, for example, selected from the group consisting of 2,5-dioxopyrrolidinyl, 2,5-dioxopyrrolyl, aldehyde, maleimide, C 6 -C 20 aryl disulfide, C 5 -C 20 heteroaryl disulfide, vinyl sulfone, thiol, halogenated acetamide, succinimide, p-nitrophenyl carbonate, and derivatives thereof, but is not limited thereto.
- the term “functional group capable of undergoing a click reaction” refers to a functional group capable of undergoing a so-called click reaction in organic chemistry, and the click reaction may include alkyne-azide or alkyne-nitrone cycloaddition, thiol-ene click reaction (Hoyle, Charles E. et al., 2010, “Thiol-Ene Click Chemistry”. Angewandte Chemie International Edition.
- the alkyne-azide or alkyne-nitrone cycloaddition may include Copper(I)-Catalyzed Azide-Alkyne Cycloaddition (CuAAC), Strain-promoted Azide-Alkyne Cycloaddition (SPAAC), or Strain-promoted Alkyne-Nitrone Cycloaddition (SPANC).
- CuAAC Copper(I)-Catalyzed Azide-Alkyne Cycloaddition
- SPAAC Strain-promoted Azide-Alkyne Cycloaddition
- SPANC Strain-promoted Alkyne-Nitrone Cycloaddition
- the “functional group capable of undergoing a click reaction” may specifically include alkynyl, dienyl, isonitrile, etc., but is not limited thereto.
- the alkynyl may include linear or branched alkynyl, cycloalkynyl, arylcycloalkynyl, diarylcycloalkynyl, heterocycloalkynyl, arylheterocycloalkynyl, or diarylheterocycloalkynyl.
- the functional group capable of undergoing a click reaction which exists at one end of the compound may undergo the click reaction together with a functional group such as azide or nitrone which may be introduced to the physiologically active polypeptide or the immunoglobulin Fc region.
- the functional group is introduced means that any linkable atomic group containing the corresponding functional group is bound.
- non-peptidyl polymer refers to any polymer known in the art which may bind with a physiologically active polypeptide to increase the in vivo half-life of the physiologically active polypeptide while having no peptidyl structure.
- the non-peptidyl polymer may be, for example, selected from the group consisting of polyethylene glycol, polypropylene glycol, a copolymer of ethylene glycol and propylene glycol, polyoxyethylated polyol, polyvinyl alcohol, polysaccharide, dextran, polyvinyl ethyl ether, polylactic acid (PLA), polylactic-glycolic acid (PLGA), lipid polymers, chitins, hyaluronic acid, and polysaccharides, but is not limited thereto.
- halogen refers to fluoro, chloro, bromo, or iodo.
- the compound according to an aspect may include a compound selected from a compound of the following Formula 1, a stereoisomer thereof, a solvate thereof, and a pharmaceutically acceptable salt thereof:
- R1 is an aliphatic hydrocarbon group including a functional group selected from the group consisting of 2,5-dioxopyrrolidinyl, 2,5-dioxopyrrolyl, aldehyde, maleimide, C 6 -C 20 aryl disulfide, C 5 -C 20 heteroaryl disulfide, vinyl sulfone, thiol, halogenated acetamide, succinimide, p-nitrophenyl carbonate, and derivatives thereof;
- the non-peptidyl polymer is selected from the group consisting of polyethylene glycol, polypropylene glycol, a copolymer of ethylene glycol and propylene glycol, polyoxyethylated polyol, polyvinyl alcohol, polysaccharide, dextran, polyvinyl ethyl ether, polylactic acid (PLA), polylactic-glycolic acid (PLGA), lipid polymers, chitins, hyaluronic acid, and polysaccharides;
- X is —(CH 2 ) j NHCO— or —(CH 2 ) j NHCS—, wherein j is an integer of 0 to 6;
- R2 is —(R3) k -(Z) l —(R4) m -(CZ) p —Y—,
- R3 and R4 is each independently C 1 -C 6 alkylene, C 6 -C 20 arylene, or C 5 -C 20 heteroarylene having 1 to 3 heteroatoms selected from N, O, and S,
- Z is be O or S
- Y is C 2 -C 6 alkynyl, cycloalkynyl, bicycloalkynyl, arylcycloalkynyl, diarylcycloalkynyl, heterocycloalkynyl, or diarylheterocycloalkynyl (wherein each cycloalkynyl has 3 to 8 carbon atoms, each aryl has 5 to 8 carbon atoms, and each heterocycloalkynyl is a saturated ring including 3 to 8 atoms and having heteroatoms selected from N, O, and S in 1 to 3 of ring atoms), k, l, m, and p are each independently an integer of 0 to 3, provided that all of them may not be 0 at the same time, and
- alkynyl, cycloalkynyl, bicycloalkynyl, arylcycloalkynyl, diarylcycloalkynyl, heterocycloalkynyl, or diarylheterocycloalkynyl may be substituted or unsubstituted with C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 alkoxycarbonyl, oxo, or halogen.
- the aliphatic hydrocarbon group may include linear or branched alkyl having 1 to 20 carbon atoms, specifically, 1 to 12 carbon atoms, and more specifically 1 to 6 carbon atoms; linear or branched alkenyl containing one or more carbon-carbon double bonds and having 2 to 15 carbon atoms, specifically 2 to 12 carbon atoms, and more specifically 2 to 6 carbon atoms; linear or branched alkynyl containing one or more carbon-carbon triple bonds and having 2 to 15 carbon atoms, specifically 2 to 12 carbon atoms, and more specifically 2 to 6 carbon atoms.
- the alkyl may be, for example, selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, n-pentyl, heptyl, nonyl, and decyl.
- the alkenyl may be, for example, selected from the group consisting of ethenyl, propenyl, n-butenyl, 3-methylbut-2-enyl, n-pentenyl, octenyl, and decenyl.
- the alkynyl may be, for example, selected from the group consisting of ethynyl, propynyl, 2-butynyl, 3-methylbutynyl, n-pentynyl, and decynyl.
- the alkyl, alkenyl, alkynyl may be substituted or unsubstituted with a group selected from the group consisting of C 1 -C 6 alkyl and halogen.
- R1 may be a C 1 -C 6 aliphatic hydrocarbon group containing an aldehyde group.
- R1 is C 1 -C 6 alkyl (i.e., HC(O)—C 1-6 alkyl) containing an aldehyde group, for example, n-pentaldehyde, n-butyraldehyde, propionaldehyde, or acetaldehyde.
- Y may be selected from the group consisting of bicyclo[6.1.0]nonyne (BCN), dibenzocyclooctyne (DBCO), difluorinated cyclooctyne (DIFO), DIFO2, DIFO3, dibenzoannulated cyclooctyne (DIBO), biarylazacyclooctynone (BARAC), cyclooctyne (OCT), aryl-less cyclooctyne (ALO), monofluorinated cyclooctyne (MOFO), dimethoxyazacyclooctyne (DIMAC), 2,3,6,7-tetramethoxy-DIBO (TMDIBO), carboxymethylmonobenzocyclooctyne (COMBO), pyrrolocyclooctyne (PYRROC), dibenzo-aza-cyclooctyne (DIBAC), 3,3,6,6-
- non-peptidyl polymer in Formula 1 may have a structure of the following Formula 1a having a polyethylene glycol structure:
- n is an integer of 20 to 1000, specifically an integer of 20 to 500, and more specifically an integer of 20 to 250;
- j is an integer of 0 to 6, and specifically, an integer of 0 or 2;
- R1 is an aliphatic hydrocarbon group including a functional group selected from the group consisting of 2,5-dioxopyrrolidinyl, 2,5-dioxopyrrolyl, aldehyde, maleimide, C 6 -C 20 aryl disulfide, C 5 -C 20 heteroaryl disulfide, vinyl sulfone, thiol, halogenated acetamide, succinimide, p-nitrophenyl carbonate, and derivatives thereof;
- R2 is —(R3) k -(Z) l —(R4) m -(CZ) p —Y,
- R3 and R4 are each independently C 1 -C 6 alkylene, C 6 -C 20 arylene, or C 5 -C 20 heteroarylene having 1 to 3 heteroatoms selected from N, O, and S,
- Z is O or S
- Y is selected from the group consisting of bicyclo[6.1.0]nonyne (BCN), dibenzocyclooctyne (DBCO), difluorinated cyclooctyne (DIFO), DIFO2, DIFO3, dibenzoannulated cyclooctyne (DIBO), biarylazacyclooctynone (BARAC), cyclooctyne (OCT), aryl-less cyclooctyne (ALO), monofluorinated cyclooctyne (MOFO), dimethoxyazacyclooctyne (DIMAC), 2,3,6,7-tetramethoxy-DIBO (TMDIBO), carboxymethylmonobenzocyclooctyne (COMBO), pyrrolocyclooctyne (PYRROC), dibenzo-aza-cyclooctyne (DIBAC), 3,3,6,6-t
- k, l, m, and p are each independently an integer of 0 to 3, provided that all of them may not be 0 at the same time.
- C 6 -C 20 arylene may be, for example, a divalent form of an aromatic group such as benzene, biphenylene, triphenylene, naphthalene, anthracene, binaphthylene, phenanthrene, pyrene, dihydropyrene, chrysene, perylene, tetracene, pentacene, benzopyrene, fluorene, indene, indenofluorene, or spirobifluorene, and more specifically, a divalent form of benzene,
- C 5 -C 20 heteroarylene may be, for example, a divalent form of a heteroaromatic group such as a 5-membered ring (e.g., pyrrole, pyrazole, imidazole, 1,2,3-triazole, 1,2,4-triazole, tetrazole, furan, thiophene, selenophene, oxazole, isoxazole, 1,2-thiazole, 1,3-thiazole, 1,2,3-oxadiazole, 1,2,4-oxadiazole, 1,2,5-oxadiazole, 1,3,4-oxadiazole, 1,2,3-thiadiazole, 1,2,4-thiadiazole, 1,2,5-thiadiazole, and 1,3,4-thiadiazole); a 6-membered ring (e.g., pyridine, pyridazine, pyrimidine, pyrazine, 1,3,5-triazine, 1,2,4-triazine
- Formula 1 a may have any structure of the following Formulae 2a to 2n:
- n may be an integer of 20 to 1000, specifically an integer of 20 to 500, and more specifically an integer of 20 to 250;
- j may be an integer of 0 to 6, and specifically, an integer of 0 or 2;
- R1 may be a C 1 -C 6 aliphatic hydrocarbon group including an aldehyde group.
- the compound according to an aspect may exist in the form of a pharmaceutically acceptable salt.
- a pharmaceutically acceptable salt As the salt, an acid addition salt formed by a pharmaceutically acceptable free acid is useful.
- pharmaceutically acceptable salt refers to any organic or inorganic addition salt of the compound, whose concentration has effective action because it is relatively non-toxic and harmless to patients and whose side effects do not degrade the beneficial efficacy of the compound which is represented by Formula 1, 1a, or 2a to 2n.
- the acid addition salt may be prepared by a common method, for example, by dissolving the compound in excessive quantity of an aqueous solution of the acid followed by precipitation of the resultant salt using a water-miscible organic solvent, for example, methanol, ethanol, acetone, or acetonitrile.
- a water-miscible organic solvent for example, methanol, ethanol, acetone, or acetonitrile.
- the compound of the same molar amount and acid or alcohol in water e.g., glycol monomethyl ether
- the resultant mixture may be dried by evaporating, or precipitated salts may be filtered by suction.
- an alkali metal salt or an alkali earth metal salt may be obtained by dissolving the compound in excessive quantity of an alkali metal hydroxide or alkali earth metal hydroxide solution, filtering an undissolved compound salt, and drying the filtrate by evaporation.
- the present disclosure may include the compound of Formula 1, 1a, or 2a to 2n and a pharmaceutically acceptable salt thereof as well as a solvate which may be prepared therefrom.
- the compound of Formula 1, 1a, or 2a to 2n when the compound of Formula 1, 1a, or 2a to 2n has an asymmetric carbon center (chiral carbon) in its substituent, it may exist in the form of an enantiomer (R or S isomer), a racemate, a diastereomer, or a mixture thereof. Further, when the compound of Formula 1, 1a, or 2a to 2n includes a bridged ring, it may exist as an exo or endo isomer, and for example, the compound of Formula 2a may exist as an exo or endo isomer.
- the compound according to an aspect may have a molecular weight in the range of 0.1 kDa to 100 kDa, specifically 0.1 kDa to 50 kDa, and more specifically 0.3 kDa to 10 kDa, but is not limited thereto.
- Another aspect of the present disclosure provides a method of preparing the compound according to an aspect of the present disclosure, the method including:
- the preparation method may include 1) introducing an amino group (—NH 2 ) at one end of the non-peptidyl polymer, and then introducing R2 at one end of the non-peptidyl polymer by an amide bond with the amino group; and
- an aliphatic hydrocarbon group including a functional group selected from the group consisting of 2,5-dioxopyrrolidinyl, 2,5-dioxopyrrolyl, aldehyde, maleimide, C 6 -C 20 aryl disulfide, C 5 -C 20 heteroaryl disulfide, vinyl sulfone, thiol, halogenated acetamide, succinimide, p-nitrophenyl carbonate, and derivatives thereof at the other end of the non-peptidyl polymer to which R2 is introduced, wherein R2 is the same as defined in Formula 1 or 1a.
- a functional group selected from the group consisting of 2,5-dioxopyrrolidinyl, 2,5-dioxopyrrolyl, aldehyde, maleimide, C 6 -C 20 aryl disulfide, C 5 -C 20 heteroaryl disulfide, vinyl sulfone, thiol,
- the non-peptidyl polymer of 1) may be polyethylene glycol.
- the non-peptidyl polymer of 1) may have a molecular weight in the range of 0.1 kDa to 100 kDa, specifically 0.1 kDa to 50 kDa, and more specifically 0.3 kDa to 10 kDa, but is not limited thereto.
- 2) may be introducing a C 1 -C 6 aliphatic hydrocarbon group including an aldehyde group at the other end of the non-peptidyl polymer to which R2 is introduced.
- Specific reaction conditions for a method of introducing the functional group capable of undergoing a click reaction at one end of the non-peptidyl polymer and a method of introducing the functional group capable of binding with the immunoglobulin Fc region or physiologically active polypeptide at the other end of the non-peptidyl polymer may be appropriately determined by those skilled in the organic chemistry field using a known technology.
- the above preparation method is described only for illustrating a method of preparing the compound according to an aspect.
- the method of preparing the compound according to an aspect is not limited thereto and may be appropriately modified by using a technology known in the art.
- Still another aspect of the present disclosure provides a physiologically active polypeptide linkage in which a physiologically active polypeptide is linked to the functional group capable of undergoing a click reaction at one end of the compound according to an aspect.
- Still another aspect of the present disclosure provides an immunoglobulin Fc region linkage in which an immunoglobulin Fc region is linked to the functional group capable of undergoing a click reaction at one end of the compound according to an aspect.
- physiologically active polypeptide linkage refers to a construct in which the physiologically active polypeptide is linked to the compound according to an aspect
- immunoglobulin Fc region linkage refers to a construct in which the immunoglobulin Fc region is linked to the compound according to an aspect.
- the linkage may be a covalent bond, but is not limited thereto.
- physiologically active polypeptide linkage or the immunoglobulin Fc region linkage is also called “physiologically active polypeptide or immunoglobulin Fc region linkage”.
- the physiologically active polypeptide or immunoglobulin Fc region linkage may include a physiologically active polypeptide or immunoglobulin Fc region linkage in which the physiologically active polypeptide or immunoglobulin Fc region is linked to the compound of Formula 1 or 1a via the functional group Y of the compound of Formula 1 or 1a.
- the functional group capable of undergoing the click reaction is introduced to the physiologically active polypeptide, and then the linkage may be formed by the click reaction.
- the functional group capable of undergoing the click reaction which may be introduced to the physiologically active polypeptide or immunoglobulin Fc region may be, for example, azide, nitrone, etc.
- an amino acid bound with azide or nitrone may be linked to the physiologically active polypeptide or immunoglobulin Fc region by amide bonds between amino acids.
- the amino acid bound with azide or nitrone may be directly prepared or purchased from a commercially available source.
- azidolysine N 3 -lysine
- the azidolysine may be linked to the physiologically active polypeptide by amide bonds
- the azidolysine may be purchased from a commercially available source (Sigma Aldrich, Fmoc-azidolysine).
- azidolysine N 3 -lysine
- azide or nitrone may be directly linked to an amino acid in the physiologically active polypeptide or immunoglobulin Fc region without separate amino acids.
- a functional group which is linkable with an amino acid to be linked with azide or nitrone may be first linked to azide or nitrone.
- N-hydroxysuccinimidyl azide e.g., NHS-azide, NHS-PEG4-azide
- NHS-azide e.g., NHS-PEG4-azide
- an amino acid e.g., lysine, N-terminal amino acid
- azide or nitrone may be linked via an amino acid added or substituted to the physiologically active polypeptide or immunoglobulin Fc region.
- an amino acid to be linked with azide or nitrone may be added or substituted to the physiologically active polypeptide or immunoglobulin Fc region, and then a functional group linkable with the added or substituted amino acid may be linked to the azide or nitrone.
- lysine may be added or substituted to the physiologically active polypeptide or immunoglobulin Fc region, and N-hydroxysuccinimidyl azide (e.g., NHS-azide, NHS-PEG4-azide) may be linked via the added or substituted lysine.
- the physiologically active polypeptide or immunoglobulin Fc region to which azide or nitrone is introduced may be linked with the linker compound by forming triazole (reaction of azide and an ethynylene group —C ⁇ C— of Y) or isoxazolidine (reaction of nitrone and an ethynylene group —C ⁇ C— of Y) together with the functional group capable of undergoing click reaction at one end of the linker compound according to an aspect, for example, the functional group Y of the compound of Formula 1 or 1a by cycloaddition by a click reaction.
- Specific conditions for the preparation method may be appropriately determined by those skilled in the art using the common knowledge.
- the physiologically active polypeptide linkage may be a physiologically active polypeptide linkage, in which the azide group is introduced to the physiologically active polypeptide and then the azide group and the ethynylene group of the functional group Y of the compound of Formula 1 or 1a may be bound to each other by forming 1,2,3-triazole by cycloaddition through click reaction.
- physiologically active polypeptide linkage may have any one Formula of the following Formulae 3a to 3l:
- R1, R3, R4, Z, j, k, l, m, n, and p are the same as defined in Formula 1a;
- amino acid is any one of amino acids constituting the physiologically active polypeptide sequence of a natural form, or an added or substituted amino acid that does not belong thereto.
- [amino acid] of Formulae 3a to 3l is a moiety excluding an epsilon-amino group from a lysine residue of the natural sequence of the physiologically active polypeptide, and triazole nitrogen of Formulae 3a to 3l may be linked to epsilon carbon of the lysine side chain.
- [amino acid] of Formulae 3a to 3l is a moiety excluding the alpha-amino group from the N-terminal amino acid of the natural sequence of the physiologically active polypeptide, and triazole nitrogen of Formulae 3a to 3l may be linked to alpha carbon of the N-terminal amino acid.
- physiologically active polypeptide linkage may be a physiologically active polypeptide linkage having any one structural formula of the following Formulae 4a to 4n:
- R1, j, and n are the same as defined in Formula 1a, and
- amino acid is any one of amino acids constituting the physiologically active polypeptide sequence of the natural form, or an added or substituted amino acid that does not belong thereto.
- [amino acid] of Formulae 4a to 4n is a moiety excluding the epsilon-amino group from the lysine residue of the natural sequence of the physiologically active polypeptide, and triazole nitrogen of Formulae 4a to 4n may be linked to epsilon carbon of the lysine side chain.
- [amino acid] of Formulae 4a to 4n is a moiety excluding the alpha-amino group from the N-terminal amino acid of the natural sequence of the physiologically active polypeptide, and triazole nitrogen of Formulae 4a to 4n may be linked to alpha carbon of the N-terminal amino acid.
- Still another aspect of the present disclosure provides a physiologically active polypeptide linkage in which a physiologically active polypeptide is linked to the functional group R1 at one end of the compound according to an aspect.
- Still another aspect of the present disclosure provides an immunoglobulin Fc region linkage in which an immunoglobulin Fc region is linked to the functional group R1 at one end of the compound according to an aspect.
- any amino acid of the physiologically active polypeptide or the immunoglobulin Fc region may form a covalent bond with the functional group R1 of the compound of Formula 1 or 1a.
- R1 which is an aliphatic hydrocarbon group including a functional group selected from the group consisting of 2,5-dioxopyrrolidinyl, 2,5-dioxopyrrolyl, aldehyde, maleimide, C 6 -C 20 aryl disulfide, C 5 -C 20 heteroaryl disulfide, vinyl sulfone, thiol, halogenated acetamide, succinimide, p-nitrophenyl carbonate, and derivatives thereof may be covalently linked to a functional group (e.g., amino (—NH 2 ) of lysine, amine (—NH—) of proline, thiol (—SH) of cysteine, etc.) of any amino acid of the physiologically active polypeptide or the immunoglobulin Fc region,
- the N-terminus of the physiologically active polypeptide when it has an amine group or an amino group, it may form a covalent bond with R1 including the aldehyde functional group by reductive amination.
- reductive amination refers to a reaction in which an amine group or an amino group of one reactant reacts with aldehyde (i.e., a functional group capable of undergoing reductive amination) of another reactant to form an imine, and then an amine bond is formed by reduction, and the reductive amination is an organic synthetic reaction widely known in the art.
- Still another aspect of the present disclosure provides a physiologically active polypeptide conjugate in which a physiologically active polypeptide and an immunoglobulin Fc region are linked to each other via the compound according to an aspect as a linker.
- physiologically active polypeptide conjugate refers to a construct in which a physiologically active polypeptide and an immunoglobulin Fc region are linked to each other via the compound according to an aspect as a linker to form a single substance.
- the linkage may be a covalent bond, but is not limited thereto.
- the physiologically active polypeptide conjugate may include a physiologically active polypeptide conjugate in which the physiologically active polypeptide and the immunoglobulin Fc region are linked to each other via the compound of Formula 1 or 1a as a linker.
- the physiologically active polypeptide conjugate may be linked to any one end of both ends of the linker compound including the compound of Formula 1 or 1a and the immunoglobulin Fc region may be linked to the other end of the linker compound including the compound of Formula 1 or 1a.
- a method of linking the physiologically active polypeptide to any one end of the linker compound including the compound of Formula 1 or 1a may be performed as in the above description of the physiologically active polypeptide linkage formed via the functional group Y or R1 at one end of the compound according to an aspect.
- a method of linking the immunoglobulin Fc region to any one end of the linker compound including the compound of Formula 1 or 1a may be performed as in the above description of the immunoglobulin Fc region linkage formed via the functional group Y or R1 at one end of the compound according to an aspect.
- the physiologically active polypeptide conjugate may be a physiologically active polypeptide conjugate, in which an azide group is introduced to the physiologically active polypeptide and then the azide group and the ethynylene group of R2 of Formula 1 may be bound to each other by forming 1,2,3-triazole by cycloaddition through click reaction, and an amino acid of the immunoglobulin Fc region is linked to R1 of the compound of Formula 1 via a covalent bond.
- the physiologically active polypeptide conjugate may be a physiologically active polypeptide conjugate, in which an azide group is introduced to the physiologically active polypeptide and then the azide group and the ethynylene group of R2 of Formula 1 may be bound to each other by forming 1,2,3-triazole by cycloaddition through click reaction, and N-terminal proline of the immunoglobulin Fc region may form an amine bond with R1 of Formula 1 by reductive amination.
- physiologically active polypeptide conjugate may be a physiologically active polypeptide conjugate having any one structural formula of the following Formulae 5a to 5l:
- R3, R4, Z, j, k, l, m, n, and p are the same as defined in Formula 1a;
- amino acid is any one of amino acids constituting the physiologically active polypeptide sequence of the natural form, or an added or substituted amino acid that does not belong thereto;
- q is an integer of 1 to 6.
- [amino acid] of Formulae 5a to 5l is a moiety excluding the epsilon-amino group from the lysine residue of the natural sequence of the physiologically active polypeptide, and triazole nitrogen of Formulae 5a to 5l may be linked to epsilon carbon of the lysine side chain.
- [amino acid] of Formulae 5a to 5l is a moiety excluding an alpha-amino group from the N-terminal amino acid of the natural sequence of the physiologically active polypeptide, and triazole nitrogen of Formulae 5a to 5l may be linked to alpha carbon of the N-terminal amino acid.
- physiologically active polypeptide conjugate may be a physiologically active polypeptide conjugate having any one structural formula of the following Formulae 6a to 6n:
- amino acid is any one of amino acids constituting the physiologically active polypeptide sequence of the natural form, or an added or substituted amino acid that does not belong thereto;
- q is an integer of 1 to 6.
- [amino acid] of Formulae 6a to 6n is a moiety excluding the epsilon-amino group from the lysine residue of the natural sequence of the physiologically active polypeptide, and triazole nitrogen of Formulae 6a to 6n may be linked to epsilon carbon of the lysine side chain.
- [amino acid] of Formulae 6a to 6n is a moiety excluding the alpha-amino group from the N-terminal amino acid of the natural sequence of the physiologically active polypeptide, and triazole nitrogen of Formulae 6a to 6n may be linked to alpha carbon of the N-terminal amino acid.
- physiologically active polypeptide refers to any substance having a polypeptide structure exhibiting physiological activity in vivo, in particular, in the human body, and is a concept including precursors, analogs, derivatives, fragments, or variants of a polypeptide having the physiological activity of the corresponding polypeptide.
- the physiologically active polypeptide may be selected from the group consisting of hormones, cytokines, enzymes, antibodies, growth factors, transcription regulatory factors, blood factors, vaccines, insulinotropic peptides, neuropeptides, pituitary hormones, anti-obesity peptides, antiviral peptides, physiologically active non-natural peptide derivatives, structural proteins, and receptors, but is not limited thereto.
- the physiologically active polypeptide may be, for example, selected from the group consisting of glucagon, gastric inhibitory polypeptide (GIP), xenin, insulin, cholecystokinin (CCK), amylin, gastrin, ghrelin, incretins regulating blood glucose and body weight in stomach or intestine (e.g., peptide YY (PYY)), adipokines secreted by adipose (e.g., leptin, adiponectin, adipolin, apelin, cartonectin), neuropeptides (e.g., Kisspeptin, Nesfatin-1), peptides or proteins secreted by muscles (e.g., irisin, myonectin, decorin, follistatin, musclin), vasoactive intestinal peptides, natriuretic peptide, somatostatin, neuropeptide Y (NPY), glucagon-like
- osteogenic growth factors osteogenesis-promoting proteins, atriopeptin, cartilage-inducing factors, elcatonin, connective tissue-activating factors, tissue factor pathway inhibitors, nerve growth factor, relaxin, somatomedin, insulin-like growth factor, adrenocortical hormone, pancreatic polypeptides, gastrin-releasing peptides, corticotropin-releasing factor, thyroid-stimulating hormone, autotaxin, lactoferrin, myostatin, cell surface antigens, virus-derived vaccine antigens, monoclonal antibody, polyclonal antibody, antibody fragments, erythropoietin, leukopoietin, and analogs thereof, but is not limited thereto.
- the type of the physiologically active polypeptide is not limited, and may include, for example, a triple agonist having activities to all of glucagon, GLP-1, and GIP receptors disclosed in International Patent Publication No. WO 2017-116205 A1; glucagon analogs disclosed in International Patent Publication No. WO 2017-003191 A1, etc.
- the physiologically active polypeptide may include GLP-2 analogs.
- the GLP-2 analogs may include a GLP-2 analog in which a thiol group (e.g., cysteine) is introduced to the C-terminus of natural GLP-2, alanine which is the 2 nd amino acid is replaced with glycine, and alpha carbon of a histidine residue which is the 1 st amino acid from the N-terminus is removed; a GLP-2 analog in which an amine group (e.g., lysine) is introduced to the C-terminus of natural GLP-2, alanine which is the 2 nd amino acid is replaced with glycine, and alpha carbon of a histidine residue which is the 1 st amino acid from the N-terminus is removed; a GLP-2 analog in which an amine group (e.g., lysine) is introduced to the C-terminus of natural GLP-2, alanine which is the 2 nd amino acid
- immunoglobulin Fc region refers to a region having a constant sequence excluding a variable region that binds to an antigen and has many sequence variations in an immunoglobulin, and the corresponding portion is characterized to have effector functions such as activation of complement, ability to cross the placenta, or acting as a ligand for receptors of various immune cells.
- the immunoglobulin Fc region and “immunoglobulin constant region” may be used with the same meaning.
- the immunoglobulin Fc region refers to a protein that contains the heavy chain constant region 2 (CH2) and the heavy chain constant region 3 (CH3) of an immunoglobulin, excluding the heavy chain and light chain variable regions, the heavy chain constant region 1 (CH1) and the light chain constant region 1 (CL1) of an immunoglobulin.
- the immunoglobulin Fc region may further include a hinge region in the heavy chain constant region.
- the immunoglobulin Fc region may be an extended Fc region that contains a portion or the whole of the heavy chain constant region 1 (CH1) and/or the light chain constant region 1 (CL1), except for the heavy chain and light chain variable regions, as long as it has effects substantially equal to or better than the native form.
- the immunoglobulin Fc region may be a fragment having a deletion in a relatively long portion of the amino acid sequence of CH2 and/or CH3.
- the immunoglobulin Fc region may include 1) a CH1 domain, a CH2 domain, a CH3 domain, and a CH4 domain, 2) a CH1 domain and a CH2 domain, 3) a CH1 domain and a CH3 domain, 4) a CH2 domain and a CH3 domain, 5) a combination of one or two or more domains and an immunoglobulin hinge region (or a portion of the hinge region), or 6) a dimer of each domain of the heavy chain constant regions and the light chain constant region.
- the immunoglobulin Fc region may include not only a native amino acid sequence, but also a sequence derivative (mutant) thereof.
- amino acid sequence derivative refers to a sequence that is different from the native amino acid sequence due to a deletion, insertion, non-conservative or conservative substitution or combinations thereof of one or more amino acid residues.
- amino acid residues at positions 214 to 238, 297 to 299, 318 to 322, or 327 to 331, known to be important in binding may be used as a suitable target for modification.
- various derivatives of the immunoglobulin Fc region are also possible, including derivatives having a deletion of a region capable of forming a disulfide bond, a deletion of several amino acid residues at the N-terminus of a native Fc, or an addition of methionine residue to the N-terminus of a native Fc.
- a complement-binding site for example, a C1q-binding site, may be removed, and an antibody dependent cell mediated cytotoxicity (ADCC) site may also be removed.
- ADCC antibody dependent cell mediated cytotoxicity
- the immunoglobulin Fc region may also be modified by phosphorylation, sulfation, acrylation, glycosylation, methylation, farnesylation, acetylation, amidation, etc.
- the sequence derivatives of the immunoglobulin Fc region are derivatives that exhibit the same biological activity as that of the immunoglobulin Fc region, but have improved structural stability against heat, pH, etc.
- the Fc immunoglobulin region may be obtained from native forms isolated from humans and animals including cows, goats, pigs, mice, rabbits, hamsters, rats, guinea pigs, etc., or may be recombinant forms or derivatives thereof, obtained from transformed animal cells or microorganisms.
- a method of obtaining the Fc immunoglobulin region from a native form may be a method of isolating a whole immunoglobulin from the living body of humans or animals and then treating it with protease.
- the immunoglobulin Fc region may be a recombinant immunoglobulin Fc region obtained from a microorganism by using a human Fc region.
- the immunoglobulin Fc region may be in the form of having native sugar chains, increased sugar chains as compared with a native form, or decreased sugar chains as compared with the native form, or may be in a deglycosylated form.
- the increase, decrease, or removal of sugar chains of the immunoglobulin Fc region may be performed using common methods, such as a chemical method, an enzymatic method, and a genetic engineering method using a microorganism.
- the deglycosylated immunoglobulin Fc region may exhibit a sharp decrease in binding affinity for the complement (c1q) and a decrease or loss in antibody-dependent cell-mediated cytotoxicity or complement-dependent cytotoxicity, and thus does not induce unnecessary immune responses in vivo.
- an immunoglobulin Fc region in a deglycosylated or aglycosylated form may be more suitable for use as a drug carrier.
- deglycosylation means an immunoglobulin Fc region from which sugar moieties are removed using an enzyme
- amino acid sequence means an unglycosylated immunoglobulin Fc region that is produced in a prokaryote, specifically E. coli.
- the immunoglobulin Fc region may originate from humans or animals such as cattle, goats, pigs, mice, rabbits, hamsters, rats, guinea pigs, etc. Specifically, it is of human origin.
- the immunoglobulin Fc region may be an Fc region that is derived from IgG, IgA, IgD, IgE, IgM, or combinations thereof, or hybrids thereof. Specifically, it is derived from IgG or IgM, which is the most abundant proteins in the human blood, and most specifically, it is derived from IgG known to enhance the half-life of binding proteins.
- a dimer or multimer may be formed from two or more fragments selected from the group consisting of IgG Fc, IgA Fc, IgM Fc, IgD Fc and IgE Fc fragments.
- hybrid means that sequences encoding two or more immunoglobulin Fc fragments of different origins are present in a single-chain immunoglobulin Fc region.
- domain hybrids may be composed of one to four domains selected from the group consisting of CH1, CH2, CH3 and CH4 of IgG Fc, IgM Fc, IgA Fc, IgE Fc, and IgD Fc, and optionally, may include a hinge region.
- IgG may be divided into IgG1, IgG2, IgG3, and IgG4 subclasses, and combinations or hybrids thereof may be used as the immunoglobulin Fc region.
- the immunoglobulin Fc region is specifically IgG2 and IgG4 subclasses, and most specifically, the Fc fragment of IgG4 rarely having effector functions such as complement dependent cytotoxicity (CDC).
- the immunoglobulin Fc region may be a human IgG4-derived aglycosylated Fc region.
- the human-derived Fc region is suitable, as compared with a non-human Fc region which may act as an antigen in the human body and cause undesirable immune responses such as the production of a new antibody against the antigen.
- Still another aspect of the present disclosure provides a method of preparing the physiologically active polypeptide conjugate in which the physiologically active polypeptide and the immunoglobulin Fc region are linked to each other via the compound of Formula 1 as a linker, the method including:
- R1 is an aliphatic hydrocarbon group including a functional group selected from the group consisting of 2,5-dioxopyrrolidinyl, 2,5-dioxopyrrolyl, aldehyde, maleimide, C 6 -C 20 aryl disulfide, C 5 -C 20 heteroaryl disulfide, vinyl sulfone, thiol, halogenated acetamide, succinimide, p-nitrophenyl carbonate, and derivatives thereof;
- X is —(CH 2 ) j NHCO— or —(CH 2 ) j NHCS—, wherein j is an integer of 0 to 6;
- R2 is —(R3) k -(Z) l —(R4) m -(CZ) p —Y, wherein R3 and R4 are each independently C 1 -C 6 alkylene, C 6 -C 20 arylene, or C 5 -C 20 heteroarylene having 1 to 3 heteroatoms selected from N, O, and S, Z is O or S,
- Y is C 2 -C 6 alkynyl, cycloalkynyl, bicycloalkynyl, arylcycloalkynyl, diarylcycloalkynyl, heterocycloalkynyl, or diarylheterocycloalkynyl (wherein each cycloalkynyl has 3 to 8 carbon atoms, each aryl has 5 to 8 carbon atoms, and each heterocycloalkynyl is a saturated ring including 3 to 8 atoms and having heteroatoms selected from N, O, and S in 1 to 3 of ring atoms),
- k, l, m, and p are each independently an integer of 0 to 3, provided that all of them may not be 0 at the same time, and
- alkynyl, cycloalkynyl, bicycloalkynyl, arylcycloalkynyl, diarylcycloalkynyl, heterocycloalkynyl, or diarylheterocycloalkynyl may be substituted or unsubstituted with C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 alkoxycarbonyl, oxo, or halogen.
- physiologically active polypeptide conjugate according to an aspect of the present disclosure may be applied as it is to the preparation method.
- a method of introducing the azide group to the physiologically active polypeptide may be performed according to a method known in the organic chemistry field.
- the amino acid at the C-terminus of the physiologically active polypeptide may be replaced with lysine, and the azide group may be introduced to the replaced lysine position.
- azidolysine may be linked to the C-terminus of the physiologically active polypeptide.
- the cycloaddition through click reaction of the azide group and the ethynylene group of R2 of the compound of the following Formula 1 may be performed according to Copper(I)-Catalyzed Azide-Alkyne Cycloaddition (CuAAC) or Strain-promoted Azide-Alkyne Cycloaddition (SPAAC) widely known in the organic chemistry field, depending on the structure of R2.
- CuAAC Copper(I)-Catalyzed Azide-Alkyne Cycloaddition
- SPAAC Strain-promoted Azide-Alkyne Cycloaddition
- click reaction may be carried out according to CuAAC in the presence of a monovalent copper catalyst
- Y of R2 has a ring structure such as cycloalkynyl, arylcycloalkynyl, heterocycloalkynyl, arylheterocycloalkynyl, diarylcycloalkynyl, diarylheterocycloalkynyl, etc.
- cycloaddition may be performed according to SPAAC in the absence of a monovalent copper catalyst.
- a reaction molar ratio of the physiologically active polypeptide and the compound of Formula 1 may be selected from the range of 1:1 to 1:20, but is not limited thereto. In a specific embodiment, the reaction molar ratio of the physiologically active polypeptide and the compound of Formula 1 may be 1:2 to 1:20.
- R1 which is an aliphatic hydrocarbon group including a functional group selected from the group consisting of 2,5-dioxopyrrolidinyl, 2,5-dioxopyrrolyl, aldehyde, maleimide, C 6 -C 20 aryl disulfide, C 5 -C 20 heteroaryl disulfide, vinyl sulfone, thiol, halogenated acetamide, succinimide, p-nitrophenyl carbonate, and derivatives thereof may be covalently linked to a functional group such as an amine group, an amino group, or a thiol group of the N-terminal amino acid of the immunoglobulin Fc region.
- a functional group such as an amine group, an amino group, or a thiol group of the N-terminal amino acid of the immunoglobulin Fc region.
- the amine group or amino group of the amino acid of the immunoglobulin Fc region may be covalently linked to R1 including an aldehyde functional group by reductive amination.
- the N-terminal amino acid of the immunoglobulin Fc region may be covalently linked to R1 of the compound of Formula 1.
- a reaction molar ratio of the compound of Formula 1 linked with the physiologically active polypeptide and the immunoglobulin Fc may be selected from the range of 1:1 to 1:20, but is not limited thereto. In a specific embodiment, the reaction molar ratio of the compound of Formula 1 linked with the physiologically active polypeptide and the immunoglobulin Fc may be 1:2 to 1:20.
- Still another aspect of the present disclosure provides a method of using a compound selected from the compound of Formula 1, a stereoisomer thereof, a solvate thereof, and a pharmaceutically acceptable salt thereof in the preparation of the physiologically active polypeptide linkage.
- a compound selected from the compound of Formula 1, a stereoisomer thereof, a solvate thereof, and a pharmaceutically acceptable salt thereof in the preparation of the physiologically active polypeptide linkage.
- Still another aspect of the present disclosure provides a method of using a compound selected from the compound of Formula 1, a stereoisomer thereof, a solvate thereof, and a pharmaceutically acceptable salt thereof in the preparation of the physiologically active polypeptide conjugate.
- a compound selected from the compound of Formula 1, a stereoisomer thereof, a solvate thereof, and a pharmaceutically acceptable salt thereof in the preparation of the physiologically active polypeptide conjugate.
- FIG. 8 shows a result of mass spectrometry of the linker compound ALD-PEG 10K-DBCO.
- FIG. 9 shows a result of mass spectrometry of the linker compound ALD-PEG 5K-DBCO.
- FIG. 10 shows a result of mass spectrometry of the linker compound ALD-PEG 3.4K-DBCO.
- FIG. 11 shows a result of mass spectrometry of the linker compound ALD-PEG 2K-DBCO.
- FIG. 12 shows a result of mass spectrometry of the linker compound PeALD-PEG 10K-BCN.
- FIG. 13 shows a result of mass spectrometry of the linker compound PeALD-PEG 10K-DBCO.
- FIG. 14 shows a result of mass spectrometry of the linker compound ALD-PEG 10K-BCN.
- a physiologically active polypeptide linkage was prepared by linking a physiologically active polypeptide to the ALD-PEG 10K-BCN linker of Example 5.
- the physiologically active polypeptide was a triple agonist having activities to all of glucagon, GLP-1, and GIP receptors, disclosed as SEQ ID NO: 42 in WO 2017/116205 A1.
- the C-terminal amino acid of the triple agonist was replaced with lysine, to which an azide group was introduced, thereby preparing an azide-introduced triple agonist, which was designated as HMT211-azido.
- the prepared HMT211-azido powder was dissolved in 10% (v/v) 10 mM HCl, and then HMT211-azido was prepared at a final concentration of 5 mg/ml such that a molar ratio of the HMT211-azido and the ALD-PEG 10K-BCN linker of Example 5 was 1:5, and allowed to react at 4° C. for about 2 hours. At this time, the reaction was allowed in a mixed solvent of 50 mM sodium citrate buffer (pH 7.5) and 60% (v/v) isopropanol.
- the reaction solution was purified using a SP-HP (GE Healthcare) column with a concentration gradient of KCl in a buffer containing sodium citrate (pH 3.0) and 45% (v/v) EtOH. As a result, mono-PEGylated HMT211-azido-PEG was obtained.
- reaction solution was applied to a S.15Q (GE, USA) column using a concentration gradient of NaCl in Tris-HCl (pH 7.5) buffer, thereby purifying a HMT211-azido-PEG-immunoglobulin Fc conjugate.
- FIG. 15 shows a result of SDS-PAGE purity analysis of the HMT211-azido-PEG-immunoglobulin Fc conjugate.
- M Marker
- 1 HMT211-azido peptide
- 2 mono-PEGylated HMT211-azido-PEG
- 3 immunoglobulin Fc
- 4 HMT211-azido-PEG-immunoglobulin FC conjugate prepared by linking HMT211-azido with an immunoglobulin Fc via the ALD-PEG 10K-BCN linker.
- the linker compound according to Example 5 As shown in FIG. 15 , it was confirmed that when the linker compound according to Example 5 is used, the physiologically active polypeptide conjugate, of which both ends are linked with the physiologically active polypeptide and the immunoglobulin Fc, may be obtained in a high yield.
- a physiologically active polypeptide linkage was prepared by linking a physiologically active polypeptide to the ALD-PEG 10K-DBCO linker of Example 1.
- the physiologically active polypeptide was GLP-2 derivative-azido, in which azido-lysine was introduced to the C-terminus of GLP-2.
- GLP-2 derivative-azido in this Example was prepared by introducing azido-lysine to the C-terminus of natural GLP-2, substituting glycine for alanine which is the second amino acid, and removing alpha carbon of a histidine residue which is the first amino acid from the N-terminus.
- GLP-2 derivative-azido was prepared at a concentration of 5 mg/ml such that a molar ratio of GLP-2 derivative-azido powder:ALD-PEG 10K-DBCO was 1:5, and allowed to react at 4° C. for about 4 hours. At this time, the reaction was allowed in a mixed solvent of 50 mM sodium phosphate buffer (pH 7.5) and 60% (v/v) isopropanol.
- the reaction solution was purified by applying it to a Q Sepharose High Performance (GE Healthcare, USA) column using a concentration gradient of sodium chloride in Bis-Tris (pH 6.2). As a result, SDS-PAGE analysis confirmed that mono-PEGylated GLP-2 derivative-azido-PEG was purified ( FIG. 16 ).
- reaction solution was applied to a Butyl Sepharose 4 Fast Flow (GE Healthcare, USA) column using a concentration gradient of sodium chloride in Tris (pH 7.5) and isopropanol buffer, thereby purifying a GLP-2 analog-azido-PEG-immunoglobulin Fc conjugate.
- FIG. 16 shows a result of non-reducing SDS-PAGE purity analysis of the GLP-2 analog-azido-PEG-immunoglobulin Fc conjugate.
- M Marker
- 1 GLP-2 analog
- 2 mono-PEGylated GLP-2 analog
- 3 immunoglobulin Fc
- 4 GLP-2 analog-PEG-immunoglobulin Fc conjugate prepared by linking GLP-2 analog-azido with the immunoglobulin Fc via the ALD-PEG 10K-DBCO linker.
- the linker compound according to Example 1 As shown in FIG. 16 , it was confirmed that when the linker compound according to Example 1 is used, the physiologically active polypeptide conjugate, of which both ends are linked with the physiologically active polypeptide and the immunoglobulin Fc, may be obtained in a high yield.
- a physiologically active polypeptide linkage was prepared by linking a physiologically active polypeptide to the PeAL-PEG 10K-BCN linker of Example 10.
- the physiologically active polypeptide was a glucagon analog, disclosed as SEQ ID NO: 37 in WO 2017/003191 A1.
- the C-terminal amino acid of the glucagon analog was replaced with lysine, to which an azide group was introduced, thereby preparing an azide-introduced glucagon analog, which was designated as glucagon analog-azido.
- glucagon analog-azido was prepared at a concentration of 5 mg/ml such that a molar ratio of glucagon analog-azido:PeAL-PEG 10K-BCN was 1:5, and allowed to react at 4° C. for about 4 hours. At this time, the reaction was allowed in a mixed solvent of 50 mM sodium phosphate buffer (pH 7.5), 60% (v/v) isopropanol, and 20% (v/v) DMSO.
- the reaction solution was purified by applying it to a SP Sepharose High Performance (GE Healthcare, USA) column using a concentration gradient of potassium chloride in sodium citrate (pH 3.0) and 45% (v/v) ethanol.
- SDS-PAGE analysis confirmed that mono-PEGylated glucagon analog-azido-PEG was purified ( FIG. 17 ).
- reaction solution was applied to a Source 15Q (GE Healthcare, USA) column using a concentration gradient of sodium chloride in Tris (pH 7.5), thereby purifying a glucagon analog-azido-PEG-immunoglobulin Fc conjugate.
- FIG. 17 shows a result of non-reducing SDS-PAGE purity analysis of the glucagon analog-azido-PEG-immunoglobulin Fc conjugate.
- M Marker
- 1 glucagon analog
- 2 mono-PEGylated glucagon analog
- 3 immunoglobulin Fc
- 4 glucagon analog-PEG-immunoglobulin Fc conjugate prepared by linking glucagon analog-azido with the immunoglobulin Fc via the PeAL-PEG 10K-BCN linker.
- the linker compound according to Example 10 As shown in FIG. 17 , it was confirmed that when the linker compound according to Example 10 is used, the physiologically active polypeptide conjugate, of which both ends are linked with the physiologically active polypeptide and the immunoglobulin Fc, may be obtained in a high yield.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Indole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Polyethers (AREA)
Abstract
Description
- The present disclosure relates to a non-peptidyl polymeric compound, a conjugate including the compound, and a method of preparing the same. More specifically, the present disclosure relates to a non-peptidyl polymeric compound which may be used as a linker to increase half-life of a physiologically active polypeptide, a conjugate linked with the physiologically active polypeptide via the compound as a linker, and a method of preparing the same.
- Protein drugs have short blood half-lives when administered to the human body. Thus, protein drugs are inconvenient in that they are required to be frequently administered in order to maintain their efficacy. To solve this problem, pegylation which binds polyethylene glycol to a protein drug has been used to increase blood half-life of the protein drug. This pegylation not only increases the blood half-life of the protein drug, but also reduces antigenicity of the protein drug, and thus pegylation is widely employed in protein therapeutic agents.
- The polyethylene glycol has a form of a polyethylene glycol derivative that further includes a functional group binding to an immunoglobulin Fc region which is known to improve the half-life of the protein drug, in addition to a functional group binding to the protein drug. Therefore, the polyethylene glycol may be used as a linker that links the protein drug and the immunoglobulin Fc region. Further, as the linker compound for the protein drug and the immunoglobulin Fc region, various non-peptidyl polymers having biocompatibility have been proposed as a linker capable of forming a conjugate together with the protein drug, in addition to the polyethylene glycol derivative (Patent Document 1).
- The non-peptidyl polymer may have, each independently at both ends thereof, an aldehyde group, a propionaldehyde group, a butyraldehyde group, a maleimide group, a succinimide derivative (succinimidyl propionate, hydroxy succinimidyl, succinimidyl carboxymethyl, or succinimidyl carbonate), etc., as a functional group to bind with the protein drug and immunoglobulin Fc.
- However, the functional groups have a disadvantage in that a conjugate production yield is reduced due to the reason that the entire substances introduced into a reaction may not be converted into conjugates during the reaction targeting a specific amino acid site upon binding with protein drugs, and some reactive groups have reduced stability in the blood.
- (Patent Document 1) Korean Patent Publication No. 2014-0018462
- An aspect of the present disclosure is to provide a non-peptidyl polymeric compound not only capable of stably binding with a physiologically active polypeptide to increase blood half-life of the physiologically active polypeptide but also capable of binding therewith in a high yield.
- Another aspect of the present disclosure is to provide a physiologically active polypeptide linkage, in which a physiologically active polypeptide is linked at one end of the non-peptidyl polymeric compound.
- Still another aspect of the present disclosure is to provide a physiologically active polypeptide conjugate, in which a physiologically active polypeptide and an immunoglobulin Fc region are linked to both ends of the non-peptidyl polymeric compound, respectively.
- Still another aspect of the present disclosure is to provide a method of preparing the non-peptidyl polymeric compound, the physiologically active polypeptide linkage, and the physiologically active polypeptide conjugate.
- An aspect of the present disclosure is to provide a compound, in which a functional group capable of binding with an immunoglobulin Fc region or a physiologically active polypeptide is introduced at one end of a non-peptidyl polymer and a functional group capable of undergoing a click reaction is introduced at the other end thereof.
- The compound may include a compound of the following
Formula 1, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof: -
R1-non-peptidyl polymer-X—R2 [Formula 1] - in Formula 1,
- R1 is an aliphatic hydrocarbon group including a functional group selected from the group consisting of 2,5-dioxopyrrolidinyl, 2,5-dioxopyrrolyl, aldehyde, maleimide, C6-C20 aryl disulfide, C5-C20 heteroaryl disulfide, vinyl sulfone, thiol, halogenated acetamide, succinimide, p-nitrophenyl carbonate, and derivatives thereof;
- the non-peptidyl polymer is selected from the group consisting of polyethylene glycol, polypropylene glycol, a copolymer of ethylene glycol and propylene glycol, polyoxyethylated polyol, polyvinyl alcohol, polysaccharide, dextran, polyvinyl ethyl ether, polylactic acid (PLA), polylactic-glycolic acid (PLGA), lipid polymers, chitins, hyaluronic acid, and polysaccharides;
- X is —(CH2)jNHCO— or —(CH2)jNHCS—, wherein j is an integer of 0 to 6;
- R2 is —(R3)k-(Z)l—(R4)m-(CZ)p—Y—,
- wherein R3 and R4 are each independently C1-C6 alkylene, C6-C20 arylene, or C5-C20 heteroarylene having 1 to 3 heteroatoms selected from N, O, and S,
- Z is O or S,
- Y is C2-C6 alkynyl, cycloalkynyl, arylcycloalkynyl, diarylcycloalkynyl, heterocycloalkynyl, or diarylheterocycloalkynyl (wherein each cycloalkynyl has 3 to 8 carbon atoms, each aryl has 5 to 8 carbon atoms, and each heterocycloalkynyl is a saturated ring including 3 to 8 atoms and having heteroatoms selected from N, O, and S in 1 to 3 of ring atoms),
- k, l, m, and p are each independently an integer of 0 to 3, provided that all of them may not be 0 at the same time, and
- the alkynyl, cycloalkynyl, arylcycloalkynyl, diarylcycloalkynyl, heterocycloalkynyl, or diarylheterocycloalkynyl is substituted or unsubstituted with C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkoxycarbonyl, oxo, or halogen.
- Another aspect of the present disclosure is to provide a method of preparing the compound according to an aspect of the present disclosure, the method including:
- introducing a functional group capable of undergoing a click reaction at one end of the non-peptidyl polymer; and
- introducing a functional group capable of binding with an immunoglobulin Fc region or a physiologically active polypeptide at the other end of the non-peptidyl polymer.
- Still another aspect of the present disclosure is to provide a physiologically active polypeptide linkage in which a physiologically active polypeptide is linked to the functional group capable of undergoing a click reaction at one end of the compound according to an aspect.
- Still another aspect of the present disclosure is to provide an immunoglobulin Fc region linkage in which an immunoglobulin Fc region is linked to the functional group capable of undergoing a click reaction at one end of the compound according to an aspect.
- Still another aspect of the present disclosure is to provide a physiologically active polypeptide conjugate in which a physiologically active polypeptide and an immunoglobulin Fc region are linked to each other via the compound according to an aspect as a linker.
- A compound according to an aspect of the present disclosure may be stably linked to a target site of a physiologically active polypeptide and may form a conjugate with high production yield and stability, as compared with known linker compounds.
-
FIG. 1 shows 1H NMR result of a linker compound 6 (MW=10000) according to an embodiment; -
FIG. 2 shows 1H NMR result of a linker compound 6 (MW=5000) according to an embodiment; -
FIG. 3 shows 1H NMR result of a linker compound 6 (MW=3400) according to an embodiment; -
FIG. 4 shows 1H NMR result of a linker compound 6 (MW=2000) according to an embodiment; -
FIG. 5 shows 1H NMR result of a linker compound 9 (MW=10000) according to an embodiment; -
FIG. 6 shows 1H NMR result of a linker compound 14 (MW=10000) according to an embodiment; -
FIG. 7 shows 1H NMR result of a linker compound 16 (MW=10000) according to an embodiment; -
FIG. 8 shows a result of mass spectrometry of a linker compound ALD-PEG 10K-DBCO; -
FIG. 9 shows a result of mass spectrometry of a linker compound ALD-PEG 5K-DBCO; -
FIG. 10 shows a result of mass spectrometry of a linker compound ALD-PEG 3.4K-DBCO; -
FIG. 11 shows a result of mass spectrometry of a linker compound ALD-PEG 2K-DBCO; -
FIG. 12 shows a result of mass spectrometry of a linker compound PeALD-PEG 10K-BCN; -
FIG. 13 shows a result of mass spectrometry of a linker compound PeALD-PEG 10K-DBCO; -
FIG. 14 shows a result of mass spectrometry of a linker compound ALD-PEG 10K-BCN; -
FIG. 15 shows a result of SDS-PAGE purity analysis of an HMT211-azido-PEG-immunoglobulin Fc conjugate, wherein M: Marker, 1: HMT211-azido peptide, 2: mono-PEGylated HMT211-azido-PEG, 3: immunoglobulin Fc, 4: HMT211-azido-PEG-immunoglobulin FC conjugate prepared by linking HMT211-azido with an immunoglobulin Fc via the ALD-PEG 10K-BCN linker; -
FIG. 16 shows a result of non-reducing SDS-PAGE purity analysis of a GLP-2 analog-azido-PEG-immunoglobulin Fc conjugate, wherein M: Marker, 1: GLP-2 analog, 2: mono-PEGylated GLP-2 analog, 3: immunoglobulin Fc, 4: GLP-2 analog-PEG-immunoglobulin Fc conjugate prepared by linking GLP-2 analog-azido with an immunoglobulin Fc via the ALD-PEG 10K-DBCO linker; and -
FIG. 17 shows a result of non-reducing SDS-PAGE purity analysis of a glucagon analog-azido-PEG-immunoglobulin Fc conjugate, wherein M: Marker, 1: glucagon analog, 2: mono-PEGylated glucagon analog, 3: immunoglobulin Fc, 4: glucagon analog-PEG-immunoglobulin Fc conjugate prepared by linking glucagon analog-azido with an immunoglobulin Fc via a PeAL-PEG 10K-BCN linker. - Hereinafter, the present disclosure will be described in more detail.
- Unless defined otherwise, all technical terms used herein have the same meanings as those generally understood by one of ordinary skill in the art to which the present disclosure belongs. Further, although methods or samples are described herein, those similar or equivalent thereto are also incorporated in the scope of the present disclosure. The numerical values described herein are considered to include the meaning of “about”, unless otherwise specified. The contents of all the publications disclosed as references herein are incorporated in the present disclosure.
- The present inventors have studied to develop a linker compound which may bind with a physiologically active polypeptide to improve in vivo stability of the physiologically active polypeptide, thereby increasing half-life thereof, and as a result, they developed a linker compound capable of more stably binding with a physiologically active polypeptide.
- An aspect of the present disclosure provides a linker compound, in which a functional group capable of binding with an immunoglobulin Fc region or a physiologically active polypeptide is introduced at one end of a non-peptidyl polymer and a functional group capable of undergoing a click reaction is introduced at the other end thereof.
- As used herein, the “functional group capable of binding with an immunoglobulin Fc region or a physiologically active polypeptide” refers to a functional group capable of binding with a functional group of an amino acid at any region of the immunoglobulin Fc region or the physiologically active polypeptide. The “functional group of an amino acid at any region of the immunoglobulin Fc region or the physiologically active polypeptide” may include, for example, an amino group (—NH2) of lysine, an amine group (—NH—) of proline, a thiol group (—SH) of cysteine, etc. In a specific embodiment, the functional group capable of binding with the immunoglobulin Fc region or the physiologically active polypeptide refers to a functional group capable of binding with a functional group (an amine group, an amino group, or a thiol group) of N-terminal amino acid, lysine, or cysteine. The functional group capable of binding with the immunoglobulin Fc region or the physiologically active polypeptide may be, for example, selected from the group consisting of 2,5-dioxopyrrolidinyl, 2,5-dioxopyrrolyl, aldehyde, maleimide, C6-C20 aryl disulfide, C5-C20 heteroaryl disulfide, vinyl sulfone, thiol, halogenated acetamide, succinimide, p-nitrophenyl carbonate, and derivatives thereof, but is not limited thereto.
- As used herein, the term “functional group capable of undergoing a click reaction” refers to a functional group capable of undergoing a so-called click reaction in organic chemistry, and the click reaction may include alkyne-azide or alkyne-nitrone cycloaddition, thiol-ene click reaction (Hoyle, Charles E. et al., 2010, “Thiol-Ene Click Chemistry”. Angewandte Chemie International Edition. 49 (9): 1540-1573), Diels-Alder reaction of dienophiles and dienes (Houk et al, 2013, 135, 15642-15649), cycloaddition of isonitriles and tetrazines (Henning et al., 2011, “Exploring isonitrile-based click chemistry for ligation with biomolecules”, Organic & Biomolecular Chemistry. 9: 7303), etc., but is not limited thereto. The alkyne-azide or alkyne-nitrone cycloaddition may include Copper(I)-Catalyzed Azide-Alkyne Cycloaddition (CuAAC), Strain-promoted Azide-Alkyne Cycloaddition (SPAAC), or Strain-promoted Alkyne-Nitrone Cycloaddition (SPANC). The click reaction is widely known in the organic chemistry field.
- The “functional group capable of undergoing a click reaction” may specifically include alkynyl, dienyl, isonitrile, etc., but is not limited thereto. The alkynyl may include linear or branched alkynyl, cycloalkynyl, arylcycloalkynyl, diarylcycloalkynyl, heterocycloalkynyl, arylheterocycloalkynyl, or diarylheterocycloalkynyl. The functional group capable of undergoing a click reaction which exists at one end of the compound may undergo the click reaction together with a functional group such as azide or nitrone which may be introduced to the physiologically active polypeptide or the immunoglobulin Fc region.
- As used herein, “the functional group is introduced” means that any linkable atomic group containing the corresponding functional group is bound.
- As used herein, the “non-peptidyl polymer” refers to any polymer known in the art which may bind with a physiologically active polypeptide to increase the in vivo half-life of the physiologically active polypeptide while having no peptidyl structure. The non-peptidyl polymer may be, for example, selected from the group consisting of polyethylene glycol, polypropylene glycol, a copolymer of ethylene glycol and propylene glycol, polyoxyethylated polyol, polyvinyl alcohol, polysaccharide, dextran, polyvinyl ethyl ether, polylactic acid (PLA), polylactic-glycolic acid (PLGA), lipid polymers, chitins, hyaluronic acid, and polysaccharides, but is not limited thereto.
- As used herein, the term “halogen” refers to fluoro, chloro, bromo, or iodo.
- The compound according to an aspect may include a compound selected from a compound of the following
Formula 1, a stereoisomer thereof, a solvate thereof, and a pharmaceutically acceptable salt thereof: -
R1-non-peptidyl polymer-X—R2 [Formula 1] - in
Formula 1, - R1 is an aliphatic hydrocarbon group including a functional group selected from the group consisting of 2,5-dioxopyrrolidinyl, 2,5-dioxopyrrolyl, aldehyde, maleimide, C6-C20 aryl disulfide, C5-C20 heteroaryl disulfide, vinyl sulfone, thiol, halogenated acetamide, succinimide, p-nitrophenyl carbonate, and derivatives thereof;
- the non-peptidyl polymer is selected from the group consisting of polyethylene glycol, polypropylene glycol, a copolymer of ethylene glycol and propylene glycol, polyoxyethylated polyol, polyvinyl alcohol, polysaccharide, dextran, polyvinyl ethyl ether, polylactic acid (PLA), polylactic-glycolic acid (PLGA), lipid polymers, chitins, hyaluronic acid, and polysaccharides;
- X is —(CH2)jNHCO— or —(CH2)jNHCS—, wherein j is an integer of 0 to 6;
- R2 is —(R3)k-(Z)l—(R4)m-(CZ)p—Y—,
- wherein R3 and R4 is each independently C1-C6 alkylene, C6-C20 arylene, or C5-C20 heteroarylene having 1 to 3 heteroatoms selected from N, O, and S,
- Z is be O or S,
- Y is C2-C6 alkynyl, cycloalkynyl, bicycloalkynyl, arylcycloalkynyl, diarylcycloalkynyl, heterocycloalkynyl, or diarylheterocycloalkynyl (wherein each cycloalkynyl has 3 to 8 carbon atoms, each aryl has 5 to 8 carbon atoms, and each heterocycloalkynyl is a saturated ring including 3 to 8 atoms and having heteroatoms selected from N, O, and S in 1 to 3 of ring atoms), k, l, m, and p are each independently an integer of 0 to 3, provided that all of them may not be 0 at the same time, and
- the alkynyl, cycloalkynyl, bicycloalkynyl, arylcycloalkynyl, diarylcycloalkynyl, heterocycloalkynyl, or diarylheterocycloalkynyl may be substituted or unsubstituted with C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkoxycarbonyl, oxo, or halogen.
- In R1, the aliphatic hydrocarbon group may include linear or branched alkyl having 1 to 20 carbon atoms, specifically, 1 to 12 carbon atoms, and more specifically 1 to 6 carbon atoms; linear or branched alkenyl containing one or more carbon-carbon double bonds and having 2 to 15 carbon atoms, specifically 2 to 12 carbon atoms, and more specifically 2 to 6 carbon atoms; linear or branched alkynyl containing one or more carbon-carbon triple bonds and having 2 to 15 carbon atoms, specifically 2 to 12 carbon atoms, and more specifically 2 to 6 carbon atoms. The alkyl may be, for example, selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, n-pentyl, heptyl, nonyl, and decyl. The alkenyl may be, for example, selected from the group consisting of ethenyl, propenyl, n-butenyl, 3-methylbut-2-enyl, n-pentenyl, octenyl, and decenyl. The alkynyl may be, for example, selected from the group consisting of ethynyl, propynyl, 2-butynyl, 3-methylbutynyl, n-pentynyl, and decynyl. The alkyl, alkenyl, alkynyl may be substituted or unsubstituted with a group selected from the group consisting of C1-C6 alkyl and halogen.
- R1 may be a C1-C6 aliphatic hydrocarbon group containing an aldehyde group. In a specific embodiment, R1 is C1-C6 alkyl (i.e., HC(O)—C1-6 alkyl) containing an aldehyde group, for example, n-pentaldehyde, n-butyraldehyde, propionaldehyde, or acetaldehyde.
- Y may be selected from the group consisting of bicyclo[6.1.0]nonyne (BCN), dibenzocyclooctyne (DBCO), difluorinated cyclooctyne (DIFO), DIFO2, DIFO3, dibenzoannulated cyclooctyne (DIBO), biarylazacyclooctynone (BARAC), cyclooctyne (OCT), aryl-less cyclooctyne (ALO), monofluorinated cyclooctyne (MOFO), dimethoxyazacyclooctyne (DIMAC), 2,3,6,7-tetramethoxy-DIBO (TMDIBO), carboxymethylmonobenzocyclooctyne (COMBO), pyrrolocyclooctyne (PYRROC), dibenzo-aza-cyclooctyne (DIBAC), 3,3,6,6-tetramethylthiacycloheptyne (TMTH), Sondheimer diyne, and sulfonylated DIBO (S-DIBO), but is not limited thereto.
- In a specific embodiment, the non-peptidyl polymer in Formula 1 may have a structure of the following Formula 1a having a polyethylene glycol structure:
- in Formula 1a,
- n is an integer of 20 to 1000, specifically an integer of 20 to 500, and more specifically an integer of 20 to 250;
- j is an integer of 0 to 6, and specifically, an integer of 0 or 2;
- R1 is an aliphatic hydrocarbon group including a functional group selected from the group consisting of 2,5-dioxopyrrolidinyl, 2,5-dioxopyrrolyl, aldehyde, maleimide, C6-C20 aryl disulfide, C5-C20 heteroaryl disulfide, vinyl sulfone, thiol, halogenated acetamide, succinimide, p-nitrophenyl carbonate, and derivatives thereof;
- R2 is —(R3)k-(Z)l—(R4)m-(CZ)p—Y,
- wherein R3 and R4 are each independently C1-C6 alkylene, C6-C20 arylene, or C5-C20 heteroarylene having 1 to 3 heteroatoms selected from N, O, and S,
- Z is O or S,
- Y is selected from the group consisting of bicyclo[6.1.0]nonyne (BCN), dibenzocyclooctyne (DBCO), difluorinated cyclooctyne (DIFO), DIFO2, DIFO3, dibenzoannulated cyclooctyne (DIBO), biarylazacyclooctynone (BARAC), cyclooctyne (OCT), aryl-less cyclooctyne (ALO), monofluorinated cyclooctyne (MOFO), dimethoxyazacyclooctyne (DIMAC), 2,3,6,7-tetramethoxy-DIBO (TMDIBO), carboxymethylmonobenzocyclooctyne (COMBO), pyrrolocyclooctyne (PYRROC), dibenzo-aza-cyclooctyne (DIBAC), 3,3,6,6-tetramethylthiacycloheptyne (TMTH), Sondheimer diyne, and sulfonylated DIBO (S-DIBO),
- k, l, m, and p are each independently an integer of 0 to 3, provided that all of them may not be 0 at the same time.
- In
Formulae 1 and 1a, - C6-C20 arylene may be, for example, a divalent form of an aromatic group such as benzene, biphenylene, triphenylene, naphthalene, anthracene, binaphthylene, phenanthrene, pyrene, dihydropyrene, chrysene, perylene, tetracene, pentacene, benzopyrene, fluorene, indene, indenofluorene, or spirobifluorene, and more specifically, a divalent form of benzene,
- C5-C20 heteroarylene may be, for example, a divalent form of a heteroaromatic group such as a 5-membered ring (e.g., pyrrole, pyrazole, imidazole, 1,2,3-triazole, 1,2,4-triazole, tetrazole, furan, thiophene, selenophene, oxazole, isoxazole, 1,2-thiazole, 1,3-thiazole, 1,2,3-oxadiazole, 1,2,4-oxadiazole, 1,2,5-oxadiazole, 1,3,4-oxadiazole, 1,2,3-thiadiazole, 1,2,4-thiadiazole, 1,2,5-thiadiazole, and 1,3,4-thiadiazole); a 6-membered ring (e.g., pyridine, pyridazine, pyrimidine, pyrazine, 1,3,5-triazine, 1,2,4-triazine, 1,2,3-triazine, 1,2,4,5-tetrazine, 1,2,3,4-tetrazine, and 1,2,3,5-tetrazine); or a fused group (e.g., carbazole, indole, isoindole, indolizine, indazole, benzimidazole, benzotriazole, purine, naphthimidazole, phenanthrimidazole, pyridimidazole, pyrazineimidazole, quinoxalinimidazole, benzoxazole, naphthoxazole, anthroxazole, phenanthroxazole, isoxazole, benzothiazole, benzofuran, isobenzofuran, dibenzofuran, quinoline, isoquinoline, pteridine, benzo-5,6-quinoline, benzo-6,7-quinoline, benzo-7,8-quinoline, benzoisoquinoline, acridine, phenothiazine, phenoxazine, benzopyridazine, benzopyrimidine, quinoxaline, phenazine, naphthyridine, azacarbazole, benzocarboline, phenanthridine, phenanthroline, thieno[2,3-b]thiophene, thieno[3,2-b]thiophene, dithienothiophene, dithienopyridine, isobenzothiophene, dibenzothiophene, benzothiadiazothiophene, etc).
- In a specific embodiment, Formula 1 a may have any structure of the following Formulae 2a to 2n:
- in Formulae 2a to 2n,
- n may be an integer of 20 to 1000, specifically an integer of 20 to 500, and more specifically an integer of 20 to 250;
- j may be an integer of 0 to 6, and specifically, an integer of 0 or 2;
- R1 may be a C1-C6 aliphatic hydrocarbon group including an aldehyde group.
- The compound according to an aspect may exist in the form of a pharmaceutically acceptable salt. As the salt, an acid addition salt formed by a pharmaceutically acceptable free acid is useful. As used herein, the term “pharmaceutically acceptable salt” refers to any organic or inorganic addition salt of the compound, whose concentration has effective action because it is relatively non-toxic and harmless to patients and whose side effects do not degrade the beneficial efficacy of the compound which is represented by
Formula 1, 1a, or 2a to 2n. The acid addition salt may be prepared by a common method, for example, by dissolving the compound in excessive quantity of an aqueous solution of the acid followed by precipitation of the resultant salt using a water-miscible organic solvent, for example, methanol, ethanol, acetone, or acetonitrile. The compound of the same molar amount and acid or alcohol in water (e.g., glycol monomethyl ether) may be heated, and subsequently, the resultant mixture may be dried by evaporating, or precipitated salts may be filtered by suction. - Further, pharmaceutically acceptable metal salts may be prepared using a base. For example, an alkali metal salt or an alkali earth metal salt may be obtained by dissolving the compound in excessive quantity of an alkali metal hydroxide or alkali earth metal hydroxide solution, filtering an undissolved compound salt, and drying the filtrate by evaporation.
- Further, the present disclosure may include the compound of
Formula 1, 1a, or 2a to 2n and a pharmaceutically acceptable salt thereof as well as a solvate which may be prepared therefrom. - Further, when the compound of
Formula 1, 1a, or 2a to 2n has an asymmetric carbon center (chiral carbon) in its substituent, it may exist in the form of an enantiomer (R or S isomer), a racemate, a diastereomer, or a mixture thereof. Further, when the compound ofFormula 1, 1a, or 2a to 2n includes a bridged ring, it may exist as an exo or endo isomer, and for example, the compound of Formula 2a may exist as an exo or endo isomer. - The compound according to an aspect may have a molecular weight in the range of 0.1 kDa to 100 kDa, specifically 0.1 kDa to 50 kDa, and more specifically 0.3 kDa to 10 kDa, but is not limited thereto.
- Another aspect of the present disclosure provides a method of preparing the compound according to an aspect of the present disclosure, the method including:
- introducing a functional group capable of undergoing a click reaction at one end of the non-peptidyl polymer; and
- introducing a functional group capable of binding with an immunoglobulin Fc region or a physiologically active polypeptide at the other end of the non-peptidyl polymer.
- The above description of the compound according to an aspect of the present disclosure may be applied as it is to the preparation method.
- The preparation method may include 1) introducing an amino group (—NH2) at one end of the non-peptidyl polymer, and then introducing R2 at one end of the non-peptidyl polymer by an amide bond with the amino group; and
- 2) introducing an aliphatic hydrocarbon group including a functional group selected from the group consisting of 2,5-dioxopyrrolidinyl, 2,5-dioxopyrrolyl, aldehyde, maleimide, C6-C20 aryl disulfide, C5-C20 heteroaryl disulfide, vinyl sulfone, thiol, halogenated acetamide, succinimide, p-nitrophenyl carbonate, and derivatives thereof at the other end of the non-peptidyl polymer to which R2 is introduced, wherein R2 is the same as defined in
Formula 1 or 1a. - In a specific embodiment, the non-peptidyl polymer of 1) may be polyethylene glycol.
- In a specific embodiment, the non-peptidyl polymer of 1) may have a molecular weight in the range of 0.1 kDa to 100 kDa, specifically 0.1 kDa to 50 kDa, and more specifically 0.3 kDa to 10 kDa, but is not limited thereto.
- In a specific embodiment, 2) may be introducing a C1-C6 aliphatic hydrocarbon group including an aldehyde group at the other end of the non-peptidyl polymer to which R2 is introduced.
- Specific reaction conditions for a method of introducing the functional group capable of undergoing a click reaction at one end of the non-peptidyl polymer and a method of introducing the functional group capable of binding with the immunoglobulin Fc region or physiologically active polypeptide at the other end of the non-peptidyl polymer may be appropriately determined by those skilled in the organic chemistry field using a known technology.
- The above preparation method is described only for illustrating a method of preparing the compound according to an aspect. The method of preparing the compound according to an aspect is not limited thereto and may be appropriately modified by using a technology known in the art.
- Still another aspect of the present disclosure provides a physiologically active polypeptide linkage in which a physiologically active polypeptide is linked to the functional group capable of undergoing a click reaction at one end of the compound according to an aspect.
- Still another aspect of the present disclosure provides an immunoglobulin Fc region linkage in which an immunoglobulin Fc region is linked to the functional group capable of undergoing a click reaction at one end of the compound according to an aspect.
- As used herein, the term “physiologically active polypeptide linkage” refers to a construct in which the physiologically active polypeptide is linked to the compound according to an aspect, and the term “immunoglobulin Fc region linkage” refers to a construct in which the immunoglobulin Fc region is linked to the compound according to an aspect. The linkage may be a covalent bond, but is not limited thereto. Hereinafter, the physiologically active polypeptide linkage or the immunoglobulin Fc region linkage is also called “physiologically active polypeptide or immunoglobulin Fc region linkage”.
- The physiologically active polypeptide or immunoglobulin Fc region linkage may include a physiologically active polypeptide or immunoglobulin Fc region linkage in which the physiologically active polypeptide or immunoglobulin Fc region is linked to the compound of
Formula 1 or 1a via the functional group Y of the compound ofFormula 1 or 1a. - To link the physiologically active polypeptide or immunoglobulin Fc region to the functional group capable of undergoing the click reaction, specifically, the functional group Y of
Formula 1, the functional group capable of undergoing the click reaction with the functional group Y are introduced to the physiologically active polypeptide, and then the linkage may be formed by the click reaction. The functional group capable of undergoing the click reaction which may be introduced to the physiologically active polypeptide or immunoglobulin Fc region may be, for example, azide, nitrone, etc. To introduce azide or nitrone to the physiologically active polypeptide or immunoglobulin Fc region, an amino acid bound with azide or nitrone may be linked to the physiologically active polypeptide or immunoglobulin Fc region by amide bonds between amino acids. The amino acid bound with azide or nitrone may be directly prepared or purchased from a commercially available source. In a specific embodiment, azidolysine (N3-lysine) may be linked to the physiologically active polypeptide by amide bonds, and the azidolysine may be purchased from a commercially available source (Sigma Aldrich, Fmoc-azidolysine). In a specific embodiment, azidolysine (N3-lysine) may be linked to the C-terminus of the physiologically active polypeptide by amide bonds. - In another specific embodiment, azide or nitrone may be directly linked to an amino acid in the physiologically active polypeptide or immunoglobulin Fc region without separate amino acids. To this end, a functional group which is linkable with an amino acid to be linked with azide or nitrone may be first linked to azide or nitrone. For example, N-hydroxysuccinimidyl azide (e.g., NHS-azide, NHS-PEG4-azide) may be reacted with the physiologically active polypeptide or immunoglobulin Fc region to be directly linked thereto via an amino acid (e.g., lysine, N-terminal amino acid) present in the physiologically active polypeptide or immunoglobulin Fc region.
- In another specific embodiment, azide or nitrone may be linked via an amino acid added or substituted to the physiologically active polypeptide or immunoglobulin Fc region. To this end, an amino acid to be linked with azide or nitrone may be added or substituted to the physiologically active polypeptide or immunoglobulin Fc region, and then a functional group linkable with the added or substituted amino acid may be linked to the azide or nitrone. For example, lysine may be added or substituted to the physiologically active polypeptide or immunoglobulin Fc region, and N-hydroxysuccinimidyl azide (e.g., NHS-azide, NHS-PEG4-azide) may be linked via the added or substituted lysine.
- The physiologically active polypeptide or immunoglobulin Fc region to which azide or nitrone is introduced may be linked with the linker compound by forming triazole (reaction of azide and an ethynylene group —C≡C— of Y) or isoxazolidine (reaction of nitrone and an ethynylene group —C≡C— of Y) together with the functional group capable of undergoing click reaction at one end of the linker compound according to an aspect, for example, the functional group Y of the compound of
Formula 1 or 1a by cycloaddition by a click reaction. Specific conditions for the preparation method may be appropriately determined by those skilled in the art using the common knowledge. - In a specific embodiment, the physiologically active polypeptide linkage may be a physiologically active polypeptide linkage, in which the azide group is introduced to the physiologically active polypeptide and then the azide group and the ethynylene group of the functional group Y of the compound of
Formula 1 or 1a may be bound to each other by forming 1,2,3-triazole by cycloaddition through click reaction. - In a specific embodiment, the physiologically active polypeptide linkage may have any one Formula of the following Formulae 3a to 3l:
- in Formulae 3a to 3l, R1, R3, R4, Z, j, k, l, m, n, and p are the same as defined in Formula 1a; and
- [amino acid] is any one of amino acids constituting the physiologically active polypeptide sequence of a natural form, or an added or substituted amino acid that does not belong thereto.
- In a specific embodiment, [amino acid] of Formulae 3a to 3l is a moiety excluding an epsilon-amino group from a lysine residue of the natural sequence of the physiologically active polypeptide, and triazole nitrogen of Formulae 3a to 3l may be linked to epsilon carbon of the lysine side chain.
- In another specific embodiment, [amino acid] of Formulae 3a to 3l is a moiety excluding the alpha-amino group from the N-terminal amino acid of the natural sequence of the physiologically active polypeptide, and triazole nitrogen of Formulae 3a to 3l may be linked to alpha carbon of the N-terminal amino acid.
- In a specific embodiment, the physiologically active polypeptide linkage may be a physiologically active polypeptide linkage having any one structural formula of the following Formulae 4a to 4n:
- in Formulae 4a to 4n,
- R1, j, and n are the same as defined in Formula 1a, and
- [amino acid] is any one of amino acids constituting the physiologically active polypeptide sequence of the natural form, or an added or substituted amino acid that does not belong thereto.
- In a specific embodiment, [amino acid] of Formulae 4a to 4n is a moiety excluding the epsilon-amino group from the lysine residue of the natural sequence of the physiologically active polypeptide, and triazole nitrogen of Formulae 4a to 4n may be linked to epsilon carbon of the lysine side chain.
- In another specific embodiment, [amino acid] of Formulae 4a to 4n is a moiety excluding the alpha-amino group from the N-terminal amino acid of the natural sequence of the physiologically active polypeptide, and triazole nitrogen of Formulae 4a to 4n may be linked to alpha carbon of the N-terminal amino acid.
- Still another aspect of the present disclosure provides a physiologically active polypeptide linkage in which a physiologically active polypeptide is linked to the functional group R1 at one end of the compound according to an aspect.
- Still another aspect of the present disclosure provides an immunoglobulin Fc region linkage in which an immunoglobulin Fc region is linked to the functional group R1 at one end of the compound according to an aspect.
- Any amino acid of the physiologically active polypeptide or the immunoglobulin Fc region may form a covalent bond with the functional group R1 of the compound of
Formula 1 or 1a. Specifically, R1 which is an aliphatic hydrocarbon group including a functional group selected from the group consisting of 2,5-dioxopyrrolidinyl, 2,5-dioxopyrrolyl, aldehyde, maleimide, C6-C20aryl disulfide, C5-C20heteroaryl disulfide, vinyl sulfone, thiol, halogenated acetamide, succinimide, p-nitrophenyl carbonate, and derivatives thereof may be covalently linked to a functional group (e.g., amino (—NH2) of lysine, amine (—NH—) of proline, thiol (—SH) of cysteine, etc.) of any amino acid of the physiologically active polypeptide or the immunoglobulin Fc region, and more specifically, may be covalently linked to a functional group of the N-terminal amino acid. In a specific embodiment, when the N-terminus of the physiologically active polypeptide has an amine group or an amino group, it may form a covalent bond with R1 including the aldehyde functional group by reductive amination. As used herein, the term “reductive amination” refers to a reaction in which an amine group or an amino group of one reactant reacts with aldehyde (i.e., a functional group capable of undergoing reductive amination) of another reactant to form an imine, and then an amine bond is formed by reduction, and the reductive amination is an organic synthetic reaction widely known in the art. - Still another aspect of the present disclosure provides a physiologically active polypeptide conjugate in which a physiologically active polypeptide and an immunoglobulin Fc region are linked to each other via the compound according to an aspect as a linker.
- As used herein, the term “physiologically active polypeptide conjugate” refers to a construct in which a physiologically active polypeptide and an immunoglobulin Fc region are linked to each other via the compound according to an aspect as a linker to form a single substance. The linkage may be a covalent bond, but is not limited thereto.
- The physiologically active polypeptide conjugate may include a physiologically active polypeptide conjugate in which the physiologically active polypeptide and the immunoglobulin Fc region are linked to each other via the compound of
Formula 1 or 1a as a linker. - In the physiologically active polypeptide conjugate, the physiologically active polypeptide may be linked to any one end of both ends of the linker compound including the compound of
Formula 1 or 1a and the immunoglobulin Fc region may be linked to the other end of the linker compound including the compound ofFormula 1 or 1a. - With regard to the above conjugate, a method of linking the physiologically active polypeptide to any one end of the linker compound including the compound of
Formula 1 or 1a may be performed as in the above description of the physiologically active polypeptide linkage formed via the functional group Y or R1 at one end of the compound according to an aspect. - With regard to the above conjugate, a method of linking the immunoglobulin Fc region to any one end of the linker compound including the compound of
Formula 1 or 1a may be performed as in the above description of the immunoglobulin Fc region linkage formed via the functional group Y or R1 at one end of the compound according to an aspect. - In a specific embodiment, the physiologically active polypeptide conjugate may be a physiologically active polypeptide conjugate, in which an azide group is introduced to the physiologically active polypeptide and then the azide group and the ethynylene group of R2 of
Formula 1 may be bound to each other by forming 1,2,3-triazole by cycloaddition through click reaction, and an amino acid of the immunoglobulin Fc region is linked to R1 of the compound ofFormula 1 via a covalent bond. In another specific embodiment, the physiologically active polypeptide conjugate may be a physiologically active polypeptide conjugate, in which an azide group is introduced to the physiologically active polypeptide and then the azide group and the ethynylene group of R2 ofFormula 1 may be bound to each other by forming 1,2,3-triazole by cycloaddition through click reaction, and N-terminal proline of the immunoglobulin Fc region may form an amine bond with R1 ofFormula 1 by reductive amination. - In a specific embodiment, the physiologically active polypeptide conjugate may be a physiologically active polypeptide conjugate having any one structural formula of the following Formulae 5a to 5l:
- in Formulae 5a to 5l,
- R3, R4, Z, j, k, l, m, n, and p are the same as defined in Formula 1a;
- [amino acid] is any one of amino acids constituting the physiologically active polypeptide sequence of the natural form, or an added or substituted amino acid that does not belong thereto; and
- q is an integer of 1 to 6.
- In a specific embodiment, [amino acid] of Formulae 5a to 5l is a moiety excluding the epsilon-amino group from the lysine residue of the natural sequence of the physiologically active polypeptide, and triazole nitrogen of Formulae 5a to 5l may be linked to epsilon carbon of the lysine side chain.
- In another specific embodiment, [amino acid] of Formulae 5a to 5l is a moiety excluding an alpha-amino group from the N-terminal amino acid of the natural sequence of the physiologically active polypeptide, and triazole nitrogen of Formulae 5a to 5l may be linked to alpha carbon of the N-terminal amino acid.
- In a specific embodiment, the physiologically active polypeptide conjugate may be a physiologically active polypeptide conjugate having any one structural formula of the following Formulae 6a to 6n:
- in Formulae 6a to 6n I,
- j and n are the same as defined in Formula 1a;
- [amino acid] is any one of amino acids constituting the physiologically active polypeptide sequence of the natural form, or an added or substituted amino acid that does not belong thereto; and
- q is an integer of 1 to 6.
- In a specific embodiment, [amino acid] of Formulae 6a to 6n is a moiety excluding the epsilon-amino group from the lysine residue of the natural sequence of the physiologically active polypeptide, and triazole nitrogen of Formulae 6a to 6n may be linked to epsilon carbon of the lysine side chain.
- In another specific embodiment, [amino acid] of Formulae 6a to 6n is a moiety excluding the alpha-amino group from the N-terminal amino acid of the natural sequence of the physiologically active polypeptide, and triazole nitrogen of Formulae 6a to 6n may be linked to alpha carbon of the N-terminal amino acid.
- As used herein, the term “physiologically active polypeptide” refers to any substance having a polypeptide structure exhibiting physiological activity in vivo, in particular, in the human body, and is a concept including precursors, analogs, derivatives, fragments, or variants of a polypeptide having the physiological activity of the corresponding polypeptide.
- The physiologically active polypeptide may be selected from the group consisting of hormones, cytokines, enzymes, antibodies, growth factors, transcription regulatory factors, blood factors, vaccines, insulinotropic peptides, neuropeptides, pituitary hormones, anti-obesity peptides, antiviral peptides, physiologically active non-natural peptide derivatives, structural proteins, and receptors, but is not limited thereto.
- The physiologically active polypeptide may be, for example, selected from the group consisting of glucagon, gastric inhibitory polypeptide (GIP), xenin, insulin, cholecystokinin (CCK), amylin, gastrin, ghrelin, incretins regulating blood glucose and body weight in stomach or intestine (e.g., peptide YY (PYY)), adipokines secreted by adipose (e.g., leptin, adiponectin, adipolin, apelin, cartonectin), neuropeptides (e.g., Kisspeptin, Nesfatin-1), peptides or proteins secreted by muscles (e.g., irisin, myonectin, decorin, follistatin, musclin), vasoactive intestinal peptides, natriuretic peptide, somatostatin, neuropeptide Y (NPY), glucagon-like peptide-1 (GLP-1), glucagon-like peptide-2 (GLP-2), exendin-4, oxyntomodulin, fibroblast growth factor, angiotensin, bradykinin, calcitonin, adrenocorticotropic hormone (corticotropin), eledoisin, oxytocin, vasopressin, luteinizing hormone, luteotrophic hormone, luteinizing hormone releasing hormone, follicle stimulating hormone, parathyroid hormone, secretin, sermorelin, human growth hormone (hGH), growth hormone-releasing peptides, granulocyte colony-stimulating factors (GCSF), interferons (IFN), interferon receptors, interleukins, interleukin receptors, interleukin-binding proteins, prolactin-releasing peptides, orexin, thyroid-releasing peptides, cholecystokinin, gastrin inhibitory peptides, calmodulin, gastric releasing peptides, motilin, vasoactiveintestinal peptide, atrial natriuretic peptide (ANP), B-type natriuretic peptide (BNP), C-type natriuretic peptide (CNP), neurokinin A, neuromedin, renin, endothelin, sarafotoxin peptide, carsomorphin peptide, dermorphin, dynorphin, endorphin, enkepalin, tumor necrosis factors, tumor necrosis factor receptors, urokinase receptors, tumor inhibitory factors, collagenase inhibitors, thymopoietin, thymulin, thymopentin, tymosin, thymichumoral factor, adrenomodullin, allatostatin, amyloid beta-protein fragment, antibacterial peptides, antioxidant peptides, bombesin, osteocalcin, CART peptides, E-selectin, ICAM-1, VCAM-1, leucokine, kringle-5, laminin, inhibin, galanin, fibronectin, pancreastatin, fuzeon, glucagon-like peptides, oxyntomodulin, G protein-coupled receptor, enzymes, cytokine-binding proteins, macrophage-activating factors, macrophage peptides, B cell factor, T cell factor, protein A, allergy inhibitors, cell necrosis glycoprotein, immunotoxin, lymphotoxin, metastasis-inducing factors, alpha-1-antitrypsin, albumin, α-lactalbumin, apolipoprotein-E, erythropoietin, highly glycosylated erythropoietin, angiopoietins, hemoglobin, thrombin, thrombin receptor-activating peptides, thrombomodulin, blood factors VII, VIIa, VIII, IX, and XIII, plasminogen-activating factors, fibrin-binding peptides, urokinase, streptokinase, hirudin, protein C, C-reactive protein, renin inhibitors, superoxide dismutase, platelet-derived growth factors, epidermal growth factors, epithelial cell growth factors, angiostatin,
- osteogenic growth factors, osteogenesis-promoting proteins, atriopeptin, cartilage-inducing factors, elcatonin, connective tissue-activating factors, tissue factor pathway inhibitors, nerve growth factor, relaxin, somatomedin, insulin-like growth factor, adrenocortical hormone, pancreatic polypeptides, gastrin-releasing peptides, corticotropin-releasing factor, thyroid-stimulating hormone, autotaxin, lactoferrin, myostatin, cell surface antigens, virus-derived vaccine antigens, monoclonal antibody, polyclonal antibody, antibody fragments, erythropoietin, leukopoietin, and analogs thereof, but is not limited thereto.
- In a specific embodiment, the type of the physiologically active polypeptide is not limited, and may include, for example, a triple agonist having activities to all of glucagon, GLP-1, and GIP receptors disclosed in International Patent Publication No. WO 2017-116205 A1; glucagon analogs disclosed in International Patent Publication No. WO 2017-003191 A1, etc.
- In a specific embodiment, the physiologically active polypeptide may include GLP-2 analogs. For example, the GLP-2 analogs may include a GLP-2 analog in which a thiol group (e.g., cysteine) is introduced to the C-terminus of natural GLP-2, alanine which is the 2nd amino acid is replaced with glycine, and alpha carbon of a histidine residue which is the 1st amino acid from the N-terminus is removed; a GLP-2 analog in which an amine group (e.g., lysine) is introduced to the C-terminus of natural GLP-2, alanine which is the 2nd amino acid is replaced with glycine, and alpha carbon of a histidine residue which is the 1st amino acid from the N-terminus is removed; a GLP-2 analog in which an amine group (e.g., lysine) is introduced to the C-terminus of natural GLP-2, alanine which is the 2nd amino acid of natural GLP-2 is replaced with glycine, lysine which is the 30th amino acid of natural GLP-2 is replaced with alginine, and alpha carbon of a histidine residue which is the 1st amino acid from the N-terminus is removed; a GLP-2 analog in which an azide group (e.g., azidolysine) is introduced to the C-terminus of natural GLP-2, alanine which is the 2nd amino acid is replaced with glycine, and alpha carbon of a histidine residue which is the 1st amino acid from the N-terminus is removed, etc.
- As used herein, the term “immunoglobulin Fc region” refers to a region having a constant sequence excluding a variable region that binds to an antigen and has many sequence variations in an immunoglobulin, and the corresponding portion is characterized to have effector functions such as activation of complement, ability to cross the placenta, or acting as a ligand for receptors of various immune cells. The immunoglobulin Fc region and “immunoglobulin constant region” may be used with the same meaning.
- Specifically, the immunoglobulin Fc region refers to a protein that contains the heavy chain constant region 2 (CH2) and the heavy chain constant region 3 (CH3) of an immunoglobulin, excluding the heavy chain and light chain variable regions, the heavy chain constant region 1 (CH1) and the light chain constant region 1 (CL1) of an immunoglobulin. The immunoglobulin Fc region may further include a hinge region in the heavy chain constant region. Further, the immunoglobulin Fc region may be an extended Fc region that contains a portion or the whole of the heavy chain constant region 1 (CH1) and/or the light chain constant region 1 (CL1), except for the heavy chain and light chain variable regions, as long as it has effects substantially equal to or better than the native form. Further, the immunoglobulin Fc region may be a fragment having a deletion in a relatively long portion of the amino acid sequence of CH2 and/or CH3. In other words, the immunoglobulin Fc region may include 1) a CH1 domain, a CH2 domain, a CH3 domain, and a CH4 domain, 2) a CH1 domain and a CH2 domain, 3) a CH1 domain and a CH3 domain, 4) a CH2 domain and a CH3 domain, 5) a combination of one or two or more domains and an immunoglobulin hinge region (or a portion of the hinge region), or 6) a dimer of each domain of the heavy chain constant regions and the light chain constant region.
- Further, the immunoglobulin Fc region may include not only a native amino acid sequence, but also a sequence derivative (mutant) thereof. As used herein, the term “amino acid sequence derivative” refers to a sequence that is different from the native amino acid sequence due to a deletion, insertion, non-conservative or conservative substitution or combinations thereof of one or more amino acid residues. For example, in the case of IgG Fc, amino acid residues at positions 214 to 238, 297 to 299, 318 to 322, or 327 to 331, known to be important in binding, may be used as a suitable target for modification.
- In addition, various derivatives of the immunoglobulin Fc region are also possible, including derivatives having a deletion of a region capable of forming a disulfide bond, a deletion of several amino acid residues at the N-terminus of a native Fc, or an addition of methionine residue to the N-terminus of a native Fc. Furthermore, to eliminate effector functions, a complement-binding site, for example, a C1q-binding site, may be removed, and an antibody dependent cell mediated cytotoxicity (ADCC) site may also be removed. Techniques of preparing such sequence derivatives of the immunoglobulin Fc region are disclosed in International Patent Publication Nos. WO 97/34631 and WO 96/32478.
- Amino acid exchanges in proteins and peptides, which do not generally alter the activity of molecules, are known in the art (H. Neurath, R. L. Hill, The Proteins, Academic Press, New York, 1979). The most commonly occurring exchanges are Ala/Ser, Val/Ile, Asp/Glu, Thr/Ser, Ala/Gly, Ala/Thr, Ser/Asn, Ala/Val, Ser/Gly, Thy/Phe, Ala/Pro, Lys/Arg, Asp/Asn, Leu/Ile, Leu/Val, Ala/Glu, Asp/Gly, in both directions. In some case, the immunoglobulin Fc region may also be modified by phosphorylation, sulfation, acrylation, glycosylation, methylation, farnesylation, acetylation, amidation, etc.
- The sequence derivatives of the immunoglobulin Fc region are derivatives that exhibit the same biological activity as that of the immunoglobulin Fc region, but have improved structural stability against heat, pH, etc. The Fc immunoglobulin region may be obtained from native forms isolated from humans and animals including cows, goats, pigs, mice, rabbits, hamsters, rats, guinea pigs, etc., or may be recombinant forms or derivatives thereof, obtained from transformed animal cells or microorganisms. Herein, a method of obtaining the Fc immunoglobulin region from a native form may be a method of isolating a whole immunoglobulin from the living body of humans or animals and then treating it with protease. When the whole immunoglobulin is treated with papain, it is cleaved into Fab and Fc, and when it is treated with pepsin, it is cleaved into pF′c and F(ab)2. These fragments may be subjected to size-exclusion chromatography to isolate Fc or pF′c.
- In a specific embodiment, the immunoglobulin Fc region may be a recombinant immunoglobulin Fc region obtained from a microorganism by using a human Fc region.
- In addition, the immunoglobulin Fc region may be in the form of having native sugar chains, increased sugar chains as compared with a native form, or decreased sugar chains as compared with the native form, or may be in a deglycosylated form. The increase, decrease, or removal of sugar chains of the immunoglobulin Fc region may be performed using common methods, such as a chemical method, an enzymatic method, and a genetic engineering method using a microorganism. Here, the deglycosylated immunoglobulin Fc region may exhibit a sharp decrease in binding affinity for the complement (c1q) and a decrease or loss in antibody-dependent cell-mediated cytotoxicity or complement-dependent cytotoxicity, and thus does not induce unnecessary immune responses in vivo. In this regard, an immunoglobulin Fc region in a deglycosylated or aglycosylated form may be more suitable for use as a drug carrier.
- As used herein, the term “deglycosylation” means an immunoglobulin Fc region from which sugar moieties are removed using an enzyme, and the term “aglycosylation” means an unglycosylated immunoglobulin Fc region that is produced in a prokaryote, specifically E. coli.
- The immunoglobulin Fc region may originate from humans or animals such as cattle, goats, pigs, mice, rabbits, hamsters, rats, guinea pigs, etc. Specifically, it is of human origin.
- In addition, the immunoglobulin Fc region may be an Fc region that is derived from IgG, IgA, IgD, IgE, IgM, or combinations thereof, or hybrids thereof. Specifically, it is derived from IgG or IgM, which is the most abundant proteins in the human blood, and most specifically, it is derived from IgG known to enhance the half-life of binding proteins.
- As used herein, the term “combination” means that polypeptides encoding single-chain immunoglobulin Fc regions of the same origin are linked to a single-chain polypeptide of a different origin to form a dimer or multimer. In other words, a dimer or multimer may be formed from two or more fragments selected from the group consisting of IgG Fc, IgA Fc, IgM Fc, IgD Fc and IgE Fc fragments.
- As used herein, the term “hybrid” means that sequences encoding two or more immunoglobulin Fc fragments of different origins are present in a single-chain immunoglobulin Fc region. Various types of hybrids are possible. In other words, domain hybrids may be composed of one to four domains selected from the group consisting of CH1, CH2, CH3 and CH4 of IgG Fc, IgM Fc, IgA Fc, IgE Fc, and IgD Fc, and optionally, may include a hinge region.
- IgG may be divided into IgG1, IgG2, IgG3, and IgG4 subclasses, and combinations or hybrids thereof may be used as the immunoglobulin Fc region. The immunoglobulin Fc region is specifically IgG2 and IgG4 subclasses, and most specifically, the Fc fragment of IgG4 rarely having effector functions such as complement dependent cytotoxicity (CDC).
- In a specific embodiment, the immunoglobulin Fc region may be a human IgG4-derived aglycosylated Fc region. The human-derived Fc region is suitable, as compared with a non-human Fc region which may act as an antigen in the human body and cause undesirable immune responses such as the production of a new antibody against the antigen.
- Still another aspect of the present disclosure provides a method of preparing the physiologically active polypeptide conjugate in which the physiologically active polypeptide and the immunoglobulin Fc region are linked to each other via the compound of
Formula 1 as a linker, the method including: - introducing the azide group to the physiologically active polypeptide;
- forming 1,2,3-triazole by cycloaddition through click reaction of the azide group and the ethynylene group (—C≡C—) of R2 of the compound of the following
Formula 1; and - covalently linking an amino acid of the immunoglobulin Fc region with R1 of the compound of
Formula 1. -
R1-non-peptidyl polymer-X—R2 [Formula 1] - in
Formula 1, - R1 is an aliphatic hydrocarbon group including a functional group selected from the group consisting of 2,5-dioxopyrrolidinyl, 2,5-dioxopyrrolyl, aldehyde, maleimide, C6-C20 aryl disulfide, C5-C20 heteroaryl disulfide, vinyl sulfone, thiol, halogenated acetamide, succinimide, p-nitrophenyl carbonate, and derivatives thereof;
- X is —(CH2)jNHCO— or —(CH2)jNHCS—, wherein j is an integer of 0 to 6;
- R2 is —(R3)k-(Z)l—(R4)m-(CZ)p—Y, wherein R3 and R4 are each independently C1-C6 alkylene, C6-C20 arylene, or C5-C20 heteroarylene having 1 to 3 heteroatoms selected from N, O, and S, Z is O or S,
- Y is C2-C6 alkynyl, cycloalkynyl, bicycloalkynyl, arylcycloalkynyl, diarylcycloalkynyl, heterocycloalkynyl, or diarylheterocycloalkynyl (wherein each cycloalkynyl has 3 to 8 carbon atoms, each aryl has 5 to 8 carbon atoms, and each heterocycloalkynyl is a saturated ring including 3 to 8 atoms and having heteroatoms selected from N, O, and S in 1 to 3 of ring atoms),
- k, l, m, and p are each independently an integer of 0 to 3, provided that all of them may not be 0 at the same time, and
- the alkynyl, cycloalkynyl, bicycloalkynyl, arylcycloalkynyl, diarylcycloalkynyl, heterocycloalkynyl, or diarylheterocycloalkynyl may be substituted or unsubstituted with C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkoxycarbonyl, oxo, or halogen.
- The above description of the physiologically active polypeptide conjugate according to an aspect of the present disclosure may be applied as it is to the preparation method.
- A method of introducing the azide group to the physiologically active polypeptide may be performed according to a method known in the organic chemistry field.
- In a specific embodiment, the amino acid at the C-terminus of the physiologically active polypeptide may be replaced with lysine, and the azide group may be introduced to the replaced lysine position.
- In a specific embodiment, azidolysine (N3-lysine) may be linked to the C-terminus of the physiologically active polypeptide.
- The cycloaddition through click reaction of the azide group and the ethynylene group of R2 of the compound of the following
Formula 1 may be performed according to Copper(I)-Catalyzed Azide-Alkyne Cycloaddition (CuAAC) or Strain-promoted Azide-Alkyne Cycloaddition (SPAAC) widely known in the organic chemistry field, depending on the structure of R2. When Y of R2 is C2-C6 alkynyl, click reaction may be carried out according to CuAAC in the presence of a monovalent copper catalyst, and when Y of R2 has a ring structure such as cycloalkynyl, arylcycloalkynyl, heterocycloalkynyl, arylheterocycloalkynyl, diarylcycloalkynyl, diarylheterocycloalkynyl, etc., cycloaddition may be performed according to SPAAC in the absence of a monovalent copper catalyst. - In the click reaction of the azide group of the physiologically active polypeptide and the ethynylene group of R2 of the compound of
Formula 1, a reaction molar ratio of the physiologically active polypeptide and the compound ofFormula 1 may be selected from the range of 1:1 to 1:20, but is not limited thereto. In a specific embodiment, the reaction molar ratio of the physiologically active polypeptide and the compound ofFormula 1 may be 1:2 to 1:20. - In the covalent linking of the amino acid of the immunoglobulin Fc region with R1 of the compound of
Formula 1, R1 which is an aliphatic hydrocarbon group including a functional group selected from the group consisting of 2,5-dioxopyrrolidinyl, 2,5-dioxopyrrolyl, aldehyde, maleimide, C6-C20 aryl disulfide, C5-C20heteroaryl disulfide, vinyl sulfone, thiol, halogenated acetamide, succinimide, p-nitrophenyl carbonate, and derivatives thereof may be covalently linked to a functional group such as an amine group, an amino group, or a thiol group of the N-terminal amino acid of the immunoglobulin Fc region. In a specific embodiment, the amine group or amino group of the amino acid of the immunoglobulin Fc region may be covalently linked to R1 including an aldehyde functional group by reductive amination. In a specific embodiment, the N-terminal amino acid of the immunoglobulin Fc region may be covalently linked to R1 of the compound ofFormula 1. - In the covalent linking of the amino acid of the immunoglobulin Fc region with R1 of the compound of
Formula 1, a reaction molar ratio of the compound ofFormula 1 linked with the physiologically active polypeptide and the immunoglobulin Fc may be selected from the range of 1:1 to 1:20, but is not limited thereto. In a specific embodiment, the reaction molar ratio of the compound ofFormula 1 linked with the physiologically active polypeptide and the immunoglobulin Fc may be 1:2 to 1:20. - Still another aspect of the present disclosure provides a method of using a compound selected from the compound of
Formula 1, a stereoisomer thereof, a solvate thereof, and a pharmaceutically acceptable salt thereof in the preparation of the physiologically active polypeptide linkage. In other words, provided is use of the compound ofFormula 1, etc. in the preparation of physiologically active polypeptide linkage. - Still another aspect of the present disclosure provides a method of using a compound selected from the compound of
Formula 1, a stereoisomer thereof, a solvate thereof, and a pharmaceutically acceptable salt thereof in the preparation of the physiologically active polypeptide conjugate. In other words, provided is use of the compound ofFormula 1, etc. as a linker in the preparation of physiologically active polypeptide conjugate. - Hereinafter, the present disclosure will be described in more detail with reference to exemplary embodiments. However, these exemplary embodiments are for illustrative purposes only, and the scope of the present disclosure is not limited to these exemplary embodiments.
-
- 1-1: Preparation of Compound 2 (MW=10000)
- 20 g of compound 1 (MW=10000) and 60 mL of dichloromethane were introduced into a reactor. 1.11 g of triethylamine and 1.15 g of methanesulfonyl chloride were added thereto while maintaining a reaction temperature at 10° C. or less, followed by stirring at room temperature for 3 hours. After completing the reaction, 100 mL of water and 40 mL of dichloromethane were introduced, followed by stirring for 5 minutes. The obtained organic layer was separated, and then 100 mL of dichloromethane was added to an aqueous layer for further extraction. The organic layer was collected and washed with 100 mL of water, and dried over magnesium sulfate. Filtration was performed, and a remaining filtrate was distilled under reduced pressure. 20 mL of dichloromethane was added to the concentrate, which was then dissolved, and 300 mL of methyl t-butyl ether was added dropwise for 20 minutes. Resulting crystals were filtered and washed with methyl t-butyl ether, and then dried at room temperature under nitrogen to obtain 17.2 g of a compound (2) (MW=10000) which is a title compound.
- 1-2: Preparation of Compound 3 (MW=10000)
- 200 mL of an ammonia aqueous solution and 20 g of ammonium chloride were introduced into a reactor. 10 g of the compound 2 (MW=10000) was added, followed by stirring at room temperature for 4 days. After completing the reaction, 200 mL of dichloromethane was introduced, followed by stirring for 5 minutes. The obtained organic layer was separated, and then 200 mL of dichloromethane was added to an aqueous layer for further extraction. The organic layer was collected and washed with 200 mL of water, and dried over magnesium sulfate. Filtration was performed, and a remaining filtrate was distilled under reduced pressure. 10 mL of dichloromethane was added to the concentrate, which was then dissolved, and 150 mL of methyl t-butyl ether was added dropwise for 20 minutes. Resulting crystals were filtered and washed with methyl t-butyl ether, and then dried at room temperature under nitrogen to obtain 8.5 g of a compound (3) (MW=10000) which is a title compound.
- 1-3: Preparation of Compound 5 (MW=10000)
- 1.66 g of the compound 3 (MW=10000) and 17 mL of dichloromethane were introduced into a reactor. 200 mg of
compound - 1-4: Preparation of Compound 6 (MW=10000)
- 0.8 g of compound 5 (MW=10000) and 14.4 mL of distilled water were introduced into a reactor. 1.6 mL of 0.1 N HCl was added thereto and stirred at room temperature for 2 hours. Then, completion of the reaction was confirmed by NMR. The reaction solution was neutralized with a 5% (w/v) sodium bicarbonate aqueous solution, and extraction was performed twice using 20 mL of dichloromethane. The resultant was dried over magnesium sulfate, and filtered and distilled under reduced pressure. 1 mL of dichloromethane was added to the concentrate, which was then dissolved, and 15 mL of methyl t-butyl ether was added dropwise for 20 minutes. Resulting crystals were filtered and washed with methyl t-butyl ether, and then dried under nitrogen to obtain 498 mg of a compound (6) (MW=10000) which is a title compound. The compound 6 (MW=10000) was designated as ALD-PEG 10K-DBCO.
FIG. 1 shows 1H NMR result of the linker compound 6 (MW=10000). 1H NMR (CDCl3, 400 MHz) δ 9.78 (s, 1H), 7.65 (d, 1H), 7.51 (d, 1H), 7.38-7.25 (m, 6H), 6.11 (br s, 1H), 5.14 (d, 1H), 3.85-3.43 (m, 915H), 3.31 (m, 2H), 2.80 (m, 1H), 2.67 (t, 2H), 2.45 (m, 1H), 2.15 (m, 1H), 1.93 (m, 1H). - 2-1: Preparation of Compound 2 (MW=5000)
- 20 g of the compound 1 (MW=5000) and 60 mL of dichloromethane were introduced into a reactor. 2.23 g of triethylamine and 2.29 g of methanesulfonyl chloride were added thereto while maintaining a reaction temperature at 10° C. or less, followed by stirring at room temperature for 3 hours. After completing the reaction, 100 mL of water and 40 mL of dichloromethane were introduced, followed by stirring for 5 minutes. The obtained organic layer was separated, and then 100 mL of dichloromethane was added to an aqueous layer for further extraction. The organic layer was collected and washed with 100 mL of water, and dried over magnesium sulfate. Filtration was performed, and a remaining filtrate was distilled under reduced pressure. 20 mL of dichloromethane was added to the concentrate, which was then dissolved, and 300 mL of methyl t-butyl ether was added dropwise for 20 minutes. Resulting crystals were filtered and washed with methyl t-butyl ether, and then dried at room temperature under nitrogen to obtain 16.2 g of a compound (2) (MW=5000) which is a title compound.
- 2-2: Preparation of Compound 3 (MW=5000)
- 200 mL of an ammonia aqueous solution and 20 g of ammonium chloride were introduced into a reactor. 10 g of compound 2 (MW=5000) was added, followed by stirring at room temperature for 4 days. After completing the reaction, 200 mL of dichloromethane was introduced, followed by stirring for 5 minutes. The obtained organic layer was separated, and then 200 mL of dichloromethane was added to an aqueous layer for further extraction. The organic layer was collected and washed with 200 mL of water, and dried over magnesium sulfate. Filtration was performed, and a remaining filtrate was distilled under reduced pressure. 10 mL of dichloromethane was added to the concentrate, which was then dissolved, and 150 mL of methyl t-butyl ether was added dropwise for 20 minutes. Resulting crystals were filtered and washed with methyl t-butyl ether, and then dried at room temperature under nitrogen to obtain 8.1 g of a compound (3) (MW=5000) which is a title compound.
- 2-3: Preparation of Compound 5 (MW=5000)
- 2 g of the compound 3 (MW=5000) and 20 mL of dichloromethane were introduced into a reactor. 483 mg of the
compound 4 and 122 mg of triethylamine were added, followed by stirring at room temperature for 3 hours. After completing the reaction, the solvent was distilled under reduced pressure and 30 mL of water was introduced to dissolve the product. Ethyl acetate (35 mL×3) was introduced and stirred for 5 minutes, and then an aqueous layer was separated and extracted twice using 30 mL of dichloromethane. The obtained organic layer was dried over magnesium sulfate. Filtration was performed, followed by distillation under reduced pressure. 2 mL of dichloromethane was added to the concentrate, which was then dissolved, and 30 mL of methyl t-butyl ether was added dropwise for 20 minutes. Resulting crystals were filtered and washed with methyl t-butyl ether, and then dried under nitrogen to obtain 1.2 g of a compound (5) (MW=5000) which is a title compound. - 2-4: Preparation of Compound 6 (MW=5000)
- 0.8 g of the compound 5 (MW=10000) and 14.4 mL of distilled water were introduced into a reactor. 1.6 mL of 0.1 N HCl was added thereto and stirred at room temperature for 2 hours. Then, completion of the reaction was confirmed by NMR. The reaction solution was neutralized with a 5% (w/v) sodium bicarbonate aqueous solution, and extraction was performed twice using 20 mL of dichloromethane. The resultant was dried over magnesium sulfate, and filtered and distilled under reduced pressure. 1 mL of dichloromethane was added to the concentrate, which was then dissolved, and 15 mL of methyl t-butyl ether was added dropwise for 20 minutes. Resulting crystals were filtered and washed with methyl t-butyl ether, and then dried under nitrogen to obtain 500 mg of a compound (6) (MW=5000) which is a title compound. The compound 6 (MW=5000) was designated as ALD-PEG 5K-DBCO.
FIG. 2 shows 1H NMR result of the linker compound 6 (MW=5000). 1H NMR (CDCl3, 400 MHz) δ 9.78 (s, 1H), 7.66 (d, 1H), 7.50 (d, 1H), 7.40-7.25 (m, 6H), 6.10 (br s, 1 H), 5.13 (d, 1 H), 3.82-3.41 (m, 459H), 3.32 (m, 2H), 2.80 (m, 1H), 2.67 (t, 2H), 2.45 (m, 1H), 2.16 (m, 1H), 1.92 (m, 1H). - 3-1: Preparation of Compound 2 (MW=3400)
- 20 g of compound 1 (MW=3400) and 60 mL of dichloromethane were introduced into a reactor. 3.27 g of triethylamine and 3.37 g of methanesulfonyl chloride were added thereto while maintaining a reaction temperature at 10° C. or less, followed by stirring at room temperature for 3 hours. After completing the reaction, 100 mL of water and 40 mL of dichloromethane were introduced, followed by stirring for 5 minutes. The obtained organic layer was separated, and then 100 mL of dichloromethane was added to an aqueous layer for further extraction. The organic layer was collected and washed with 100 mL of water, and dried over magnesium sulfate. Filtration was performed, and a remaining filtrate was distilled under reduced pressure. 40 mL of dichloromethane was added to the concentrate, which was then dissolved, and 400 mL of methyl t-butyl ether was added dropwise for 20 minutes. Resulting crystals were filtered and washed with methyl t-butyl ether, and then dried at room temperature under nitrogen to obtain 17.1 g of a compound (2) (MW=3400) which is a title compound.
- 3-2: Preparation of Compound 3 (MW=3400)
- 200 mL of an ammonia aqueous solution and 20 g of ammonium chloride were introduced into a reactor. 10 g of the compound 2 (MW=3400) was added, followed by stirring at room temperature for 4 days. After completing the reaction, 200 mL of dichloromethane was introduced, followed by stirring for 5 minutes. The obtained organic layer was separated, and then 200 mL of dichloromethane was added to an aqueous layer for further extraction. The organic layer was collected and washed with 200 mL of water, and dried over magnesium sulfate. Filtration was performed, and a remaining filtrate was distilled under reduced pressure. 20 mL of dichloromethane was added to the concentrate, which was then dissolved, and 200 mL of methyl t-butyl ether was added dropwise for 20 minutes. Resulting crystals were filtered and washed with methyl t-butyl ether, and then dried at room temperature under nitrogen to obtain 8.7 g of a compound (3) (MW=3400) which is a title compound.
- 3-3: Preparation of Compound 5 (MW=3400)
- 1.7 g of the compound 3 (MW=3400) and 17 mL of dichloromethane were introduced into a reactor. 604 mg of
compound 4 and 152 mg of triethylamine were added, followed by stirring at room temperature for 3 hours. After completing the reaction, the solvent was distilled under reduced pressure and 35 mL of water was introduced to dissolve the product. Ethyl acetate (35 mL×3) was introduced and stirred for 5 minutes, and then an aqueous layer was separated and extracted twice using 35 mL of dichloromethane. The obtained organic layer was dried over magnesium sulfate. Filtration was performed, followed by distillation under reduced pressure. 3.5 mL of dichloromethane was added to the concentrate, which was then dissolved, and 35 mL of methyl t-butyl ether was added dropwise for 20 minutes. Resulting crystals were filtered and washed with methyl t-butyl ether, and then dried under nitrogen to obtain 1.1 g of a compound (5) (MW=3400) which is a title compound. - 3-4: Preparation of Compound 6 (MW=3400)
- 0.9 g of the compound 5 (MW=10000) and 16.2 mL of distilled water were introduced into a reactor. 1.8 mL of 0.1 N HCl was added thereto and stirred at room temperature for 2 hours. Then, completion of the reaction was confirmed by NMR. The reaction solution was neutralized with a 5% (w/v) sodium bicarbonate aqueous solution, and extraction was performed twice using 20 mL of dichloromethane. The resultant was dried over magnesium sulfate, and filtered and distilled under reduced pressure. 2 mL of dichloromethane was added to the concentrate, which was then dissolved, and 20 mL of methyl t-butyl ether was added dropwise for 20 minutes. Resulting crystals were filtered and washed with methyl t-butyl ether, and then dried under nitrogen to obtain 590 mg of a compound (6) (MW=3400) which is a title compound. The compound 6 (MW=5000) was designated as ALD-PEG 3.4K-DBCO.
FIG. 3 shows 1H NMR result of the linker compound 6 (MW=3400). 1H NMR (CDCl3, 400 MHz) δ 9.77 (s, 1H), 7.65 (d, 1H), 7.50 (d, 1H), 7.38-7.24 (m, 6H), 6.11 (br s, 1 H), 5.13 (d, 1 H), 3.80-3.39 (m, 315H), 3.32 (m, 2H), 2.80 (m, 1H), 2.66 (t, 2H), 2.44 (m, 1H), 2.15 (m, 1H), 1.92 (m, 1H). - 4-1: Preparation of Compound 2 (MW=2000)
- 29.3 g of the compound 1 (MW=2000) and 90 mL of dichloromethane were introduced into a reactor. 8.2 g of triethylamine and 8.4 g of methanesulfonyl chloride were added thereto while maintaining a reaction temperature at 10° C. or less, followed by stirring at room temperature for 3 hours. After completing the reaction, 150 mL of water and 60 mL of dichloromethane were introduced, followed by stirring for 5 minutes. The obtained organic layer was separated, and then 150 mL of dichloromethane was added to an aqueous layer for further extraction. The organic layer was collected and washed with 150 mL of water, and dried over magnesium sulfate. Filtration was performed, and a remaining filtrate was distilled under reduced pressure. 30 mL of dichloromethane was added to the concentrate, which was then dissolved, and 900 mL of methyl t-butyl ether was added dropwise for 20 minutes. Resulting crystals were filtered and washed with methyl t-butyl ether, and then dried at room temperature under nitrogen to obtain 23.0 g of a compound (2) (MW=2000) which is a title compound.
- 4-2: Preparation of Compound 3 (MW=2000)
- 200 mL of an ammonia aqueous solution and 20 g of ammonium chloride were introduced into a reactor. 10 g of the compound 2 (MW=2000) was added, followed by stirring at room temperature for 4 days. After completing the reaction, 200 mL of dichloromethane was introduced, followed by stirring for 5 minutes. The obtained organic layer was separated, and then 200 mL of dichloromethane was added to an aqueous layer for further extraction. The organic layer was collected and washed with 200 mL of distilled water, and dried over magnesium sulfate. Filtration was performed, and a remaining filtrate was distilled under reduced pressure. 10 mL of dichloromethane was added to the concentrate, which was then dissolved, and 300 mL of methyl t-butyl ether was added dropwise for 20 minutes. Resulting crystals were filtered and washed with methyl t-butyl ether, and then dried at room temperature under nitrogen to obtain 8.1 g of a compound (3) (MW=2000) which is a title compound.
- 4-3: Preparation of Compound 5 (MW=2000)
- 1.5 g of the compound 3 (MW=2000) and 15 mL of dichloromethane were introduced into a reactor. 905 mg of the
compound 4 and 228 mg of triethylamine were added, followed by stirring at room temperature for 3 hours. After completing the reaction, the solvent was distilled under reduced pressure and 30 mL of water was introduced to dissolve the product. Ethyl acetate (30 mL×3) was introduced and stirred for 5 minutes, and then an aqueous layer was separated and extracted twice using 30 mL of dichloromethane. The obtained organic layer was dried over magnesium sulfate. Filtration was performed, followed by distillation under reduced pressure. 2 mL of dichloromethane was added to the concentrate, which was then dissolved, and 60 mL of methyl t-butyl ether was added dropwise for 20 minutes. Resulting crystals were filtered and washed with methyl t-butyl ether, and then dried under nitrogen to obtain 1.0 g of a compound (5) (MW=2000) which is a title compound. - 4-4: Preparation of Compound 6 (MW=2000)
- 0.65 g of the compound 5 (MW=10000) and 12.6 mL of distilled water were introduced into a reactor. 1.6 mL of 0.1 N HCl was added thereto and stirred at room temperature for 2 hours. Then, completion of the reaction was confirmed by NMR. The reaction solution was neutralized with a 5% (w/v) sodium bicarbonate aqueous solution, and extraction was performed twice using 20 mL of dichloromethane. The resultant was dried over magnesium sulfate, and filtered and distilled under reduced pressure. 1 mL of dichloromethane was added to the concentrate, which was then dissolved, and 30 mL of methyl t-butyl ether was added dropwise for 20 minutes. Resulting crystals were filtered and washed with methyl t-butyl ether, and then dried under nitrogen to obtain 140 mg of a compound (6) (MW=2000) which is a title compound. The compound 6 (MW=2000) was designated as ALD-PEG 2K-DBCO.
FIG. 4 shows 1H NMR result of the linker compound 6 (MW=2000). 1H NMR (CDCl3, 400 MHz) δ 9.78 (s, 1H), 7.65 (d, 1H), 7.51 (d, 1H), 7.38-7.24 (m, 6H), 6.11 (br s, 1 H), 5.13 (d, 1 H), 3.82-3.37 (m, 187H), 3.32 (m, 2H), 2.67 (m, 1H), 2.67 (t, 2H), 2.45 (m, 1H), 2.15 (m, 1H), 1.93 (m, 1H). -
- 5-1: Preparation of Compound 2 (MW=10000)
- A compound 2 (MW=10000) was obtained in the same manner as in Example 1-1.
- 5-2: Preparation of Compound 3 (MW=10000)
- A compound 3 (MW=10000) was obtained in the same manner as in Example 1-2.
- 5-3: Preparation of Compound 8 (MW=10000)
- 1.76 g of the compound 3 (MW=10000) and 17 mL of dichloromethane were introduced into a reactor. 154 mg of the compound 7 and 54 mg of triethylamine were added, followed by stirring at room temperature for 3 hours. After completing the reaction, the solvent was distilled under reduced pressure and 35 mL of distilled water was introduced to dissolve the product. Ethyl acetate (35 mL×3) was introduced and stirred for 5 minutes, and then an aqueous layer was separated and extracted twice using 35 mL of dichloromethane. The obtained organic layer was dried over magnesium sulfate. Filtration was performed, followed by distillation under reduced pressure. 2 mL of dichloromethane was added to the concentrate, which was then dissolved, and 30 mL of methyl t-butyl ether was added dropwise for 20 minutes. Resulting crystals were filtered and washed with methyl t-butyl ether, and then dried under nitrogen to obtain 1.0 g of a compound (8) (MW=10000) which is a title compound.
- 5-4: Preparation of Compound 9 (MW=10000)
- 0.4 g of the compound 5 (MW=10000) and 7.2 mL of distilled water were introduced into a reactor. 0.8 mL of 0.1 N HCl was added thereto and stirred at room temperature for 2 hours. Then, completion of the reaction was confirmed by NMR. The reaction solution was neutralized with a 5% (w/v) sodium bicarbonate aqueous solution, and extraction was performed twice using 10 mL of dichloromethane. The resultant was dried over magnesium sulfate, and filtered and distilled under reduced pressure. 1 mL of dichloromethane was added to the concentrate, which was then dissolved, and 15 mL of methyl t-butyl ether was added dropwise for 20 minutes. Resulting crystals were filtered and washed with methyl t-butyl ether, and then dried under nitrogen to obtain 260 mg of a compound (9) (MW=10000) which is a title compound. The compound 9 (MW=10000) was designated as ALD-PEG 10K-BCN.
FIG. 5 shows 1H NMR result of the linker compound 9 (MW=10000). 1H NMR (CDCl3, 400 MHz) δ 9.78 (s, 1H), 5.23 (br s, 1H), 4.13 (d, 2H), 3.81-3.41 (m, 914H), 3.36 (m, 2H), 2.67 (t, 2H), 2.26-2.18 (m, 6H), 1.57 (m, 2H), 1.35 (m, 1H), 0.93 (m, 2H). - 6-1: Preparation of Compound 2 (MW=5000)
- A compound 2 (MW=5000) was obtained in the same manner as in Example 2-1.
- 6-2: Preparation of Compound 3 (MW=5000)
- A compound 3 (MW=5000) was obtained in the same manner as in Example 2-2.
- 6-3: Preparation of Compound 8 (MW=5000)
- 3 g of the compound 3 (MW=5000) and 30 mL of dichloromethane were introduced into a reactor. 524 mg of the compound 7 and 182 mg of triethylamine were added, followed by stirring at room temperature for 3 hours. After completing the reaction, the solvent was distilled under reduced pressure and 30 mL of water was introduced to dissolve the product. Ethyl acetate (30 mL×3) was introduced and stirred for 5 minutes, and then an aqueous layer was separated and extracted twice using 30 mL of dichloromethane. The obtained organic layer was dried over magnesium sulfate. Filtration was performed, followed by distillation under reduced pressure. 3 mL of dichloromethane was added to the concentrate, which was then dissolved, and 45 mL of methyl t-butyl ether was added dropwise for 20 minutes. Resulting crystals were filtered and washed with methyl t-butyl ether, and then dried under nitrogen to obtain 2.0 g of a compound (8) (MW=5000) which is a title compound.
- 6-4: Preparation of Compound 9 (MW=5000)
- 1.7 g of the compound 5 (MW=5000) and 30.6 mL of distilled water were introduced into a reactor. 3.4 mL of 0.1 N HCl was added thereto and stirred at room temperature for 2 hours. Then, completion of the reaction was confirmed by NMR. The reaction solution was neutralized with a 5% (w/v) sodium bicarbonate aqueous solution, and extraction was performed twice using 34 mL of dichloromethane. The resultant was dried over magnesium sulfate, and filtered and distilled under reduced pressure. 2 mL of dichloromethane was added to the concentrate, which was then dissolved, and 30 mL of methyl t-butyl ether was added dropwise for 20 minutes. Resulting crystals were filtered and washed with methyl t-butyl ether, and then dried under nitrogen to obtain 1.25 g of a compound (9) (MW=5000) which is a title compound. The compound 9 (MW=5000) was designated as ALD-PEG 5K-BCN. 1H NMR (CDCl3, 400 MHz) δ 9.78 (s, 1H), 5.26 (br s, 1H), 4.15 (d, 2H), 3.81-3.41 (m, 458H), 3.36 (m, 2H), 2.68 (t, 2H), 2.26-2.18 (m, 6H), 1.57 (m, 2H), 1.37 (m, 1 H), 0.93 (m, 2H).
- 7-1: Preparation of Compound 2 (MW=3400)
- A compound 2 (MW=3400) was obtained in the same manner as in Example 3-1.
- 7-2: Preparation of Compound 3 (MW=3400)
- A compound 3 (MW=3400) was obtained in the same manner as in Example 3-2.
- 7-3: Preparation of Compound 8 (MW=3400)
- 2.5 g of the compound 3 (MW=3400) and 50 mL of dichloromethane were introduced into a reactor. 643 mg of the compound 7 and 223 mg of triethylamine were added, followed by stirring at room temperature for 3 hours. After completing the reaction, the solvent was distilled under reduced pressure and 50 mL of water was introduced to dissolve the product. Ethyl acetate (50 mL×3) was introduced and stirred for 5 minutes, and then an aqueous layer was separated and extracted twice using 50 mL of dichloromethane. The obtained organic layer was dried over magnesium sulfate. Filtration was performed, followed by distillation under reduced pressure. 5 mL of dichloromethane was added to the concentrate, which was then dissolved, and 50 mL of methyl t-butyl ether was added dropwise for 20 minutes. Resulting crystals were filtered and washed with methyl t-butyl ether, and then dried under nitrogen to obtain 1.4 g of a compound (8) (MW=3400) which is a title compound.
- 7-4: Preparation of Compound 9 (MW=3400)
- 1 g of the compound 5 (MW=3400) and 18 mL of distilled water were introduced into a reactor. 2 mL of 0.1 N HCl was added thereto and stirred at room temperature for 2 hours. Then, completion of the reaction was confirmed by NMR. The reaction solution was neutralized with a 5% (w/v) sodium bicarbonate aqueous solution, and extraction was performed twice using 20 mL of dichloromethane. The resultant was dried over magnesium sulfate, and filtered and distilled under reduced pressure. 2 mL of dichloromethane was added to the concentrate, which was then dissolved, and 20 mL of methyl t-butyl ether was added dropwise for 20 minutes. Resulting crystals were filtered and washed with methyl t-butyl ether, and then dried under nitrogen to obtain 630 mg of a compound (9) (MW=3400) which is a title compound. The compound 9 (MW=3400) was designated as ALD-PEG 3.4K-BCN. 1H NMR (CDCl3, 400 MHz) δ 9.78 (s, 1 H), 5.26 (br s, 1H), 4.15 (d, 2H), 3.81-3.41 (m, 314H), 3.36 (m, 2H), 2.68 (t, 2H), 2.26-2.18 (m, 6H), 1.57 (m, 2H), 1.37 (m, 1 H), 0.93 (m, 2H).
- 8-1: Preparation of Compound 2 (MW=2000)
- A compound 2 (MW=2000) was obtained in the same manner as in Example 4-1.
- 8-2: Preparation of Compound 3 (MW=2000)
- A compound 3 (MW=2000) was obtained in the same manner as in Example 4-2.
- 8-3: Preparation of Compound 8 (MW=2000)
- 1.5 g of the compound 3 (MW=2000) and 30 mL of dichloromethane were introduced into a reactor. 655 mg of the compound 7 and 230 mg of triethylamine were added, followed by stirring at room temperature for 3 hours. After completing the reaction, the solvent was distilled under reduced pressure and 30 mL of water was introduced to dissolve the product. Ethyl acetate (30 mL×3) was introduced and stirred for 5 minutes, and then an aqueous layer was separated and extracted twice using 30 mL of dichloromethane. The obtained organic layer was dried over magnesium sulfate. Filtration was performed, followed by distillation under reduced pressure. 3 mL of dichloromethane was added to the concentrate, which was then dissolved, and 90 mL of methyl t-butyl ether was added dropwise for 20 minutes. Resulting crystals were filtered and washed with methyl t-butyl ether, and then dried under nitrogen to obtain 900 mg of a compound (8) (MW=2000) which is a title compound.
- 8-4: Preparation of Compound 9 (MW=2000)
- 0.8 g of the compound 5 (MW=2000) and 14.4 mL of distilled water were introduced into a reactor. 1.6 mL of 0.1 N HCl was added thereto and stirred at room temperature for 2 hours. Then, completion of the reaction was confirmed by NMR. The reaction solution was neutralized with a 5% (w/v) sodium bicarbonate aqueous solution, and extraction was performed twice using 20 mL of dichloromethane. The resultant was dried over magnesium sulfate, and filtered and distilled under reduced pressure. 2 mL of dichloromethane was added to the concentrate, which was then dissolved, and 60 mL of methyl t-butyl ether was added dropwise for 20 minutes. Resulting crystals were filtered and washed with methyl t-butyl ether, and then dried under nitrogen to obtain 549 mg of a compound (9) (MW=2000) which is a title compound. The compound 9 (MW=2000) was designated as ALD-PEG 2K-BCN. 1H NMR (CDCl3, 400 MHz) δ 9.78 (s, 1H), 5.26 (br s, 1H), 4.15 (d, 2H), 3.81-3.41 (m, 186H), 3.36 (m, 2H), 2.68 (t, 2H), 2.26-2.18 (m, 6H), 1.57 (m, 2H), 1.37 (m, 1 H), 0.93 (m, 2H).
-
- 9-1: Preparation of Compound 11 (MW=10000)
- 27.7 g of the compound 10 (MW=10000) and 83 mL of dichloromethane were introduced into a reactor. 1.54 g of triethylamine and 1.59 g of methanesulfonyl chloride were added thereto while maintaining a reaction temperature at 10° C. or less, followed by stirring at room temperature for 3 hours. After completing the reaction, 140 mL of water and 57 mL of dichloromethane were introduced, followed by stirring for 5 minutes. The obtained organic layer was separated, and then 140 mL of dichloromethane was added to an aqueous layer for further extraction. The organic layer was collected and washed with 140 mL of water, and dried over magnesium sulfate. Filtration was performed, and a remaining filtrate was distilled under reduced pressure. 30 mL of dichloromethane was added to the concentrate, which was then dissolved, and 450 mL of methyl t-butyl ether was added dropwise for 20 minutes. Resulting crystals were filtered and washed with methyl t-butyl ether, and then dried at room temperature under nitrogen to obtain 25.5 g of a compound (11) (MW=10000) which is a title compound.
- 9-2: Preparation of Compound 12 (MW=10000)
- 200 mL of an ammonia aqueous solution and 20 g of ammonium chloride were introduced into a reactor. 10 g of compound 11 (MW=10000) was added, followed by stirring at room temperature for 4 days. After completing the reaction, 200 mL of dichloromethane was introduced, followed by stirring for 5 minutes. The obtained organic layer was separated, and then 200 mL of dichloromethane was added to an aqueous layer for further extraction. The organic layer was collected and washed with 200 mL of distilled water, and dried over magnesium sulfate. Filtration was performed, and a remaining filtrate was distilled under reduced pressure. 10 mL of dichloromethane was added to the concentrate, which was then dissolved, and 150 mL of methyl t-butyl ether was added dropwise for 20 minutes. Resulting crystals were filtered and washed with methyl t-butyl ether, and then dried at room temperature under nitrogen to obtain 8.1 g of a compound (12) (MW=10000) which is a title compound.
- 9-3: Preparation of Compound 13 (MW=10000)
- 3 g of the compound 12 (MW=10000) and 30 mL of dichloromethane were introduced into a reactor. 362 mg of the
compound 4 and 91 mg of triethylamine were added, followed by stirring at room temperature for 3 hours. After completing the reaction, the solvent was distilled under reduced pressure and 30 mL of water was introduced to dissolve the product. Ethyl acetate (30 mL×3) was introduced and stirred for 5 minutes, and then an aqueous layer was separated and extracted twice using 30 mL of dichloromethane. The obtained organic layer was dried over magnesium sulfate. Filtration was performed, followed by distillation under reduced pressure. 3 mL of dichloromethane was added to the concentrate, which was then dissolved, and 45 mL of methyl t-butyl ether was added dropwise for 20 minutes. Resulting crystals were filtered and washed with methyl t-butyl ether, and then dried under nitrogen to obtain 1.7 g of a compound (13) (MW=10000) which is a title compound. - 9-4: Preparation of Compound 14 (MW=10000)
- 1.6 g of the compound 5 (MW=10000) and 28.8 mL of distilled water were introduced into a reactor. 3.2 mL of 0.1 N HCl was added thereto and stirred at room temperature for 2 hours. Then, completion of the reaction was confirmed by NMR. The reaction solution was neutralized with a 5% (w/v) sodium bicarbonate aqueous solution, and extraction was performed twice using 32 mL of dichloromethane. The resultant was dried over magnesium sulfate, and filtered and distilled under reduced pressure. 2 mL of dichloromethane was added to the concentrate, which was then dissolved, and 30 mL of methyl t-butyl ether was added dropwise for 20 minutes. Resulting crystals were filtered and washed with methyl t-butyl ether, and then dried under nitrogen to obtain 1.2 g of a compound (14) (MW=10000) which is a title compound. The compound 14 (MW=10000) was designated as PeAL-PEG 10K-DBCO.
FIG. 6 shows 1H NMR result of the linker compound 14 (MW=10000). 1H NMR (CDCl3, 400 MHz) δ 9.75 (s, 1H), 7.65 (d, 1H), 7.51 (d, 1 H), 7.37-7.19 (m, 6H), 6.11 (br s, 1 H), 5.12 (d, 1 H), 3.85-3.42 (m, 915H), 3.32 (m, 2H), 2.80 (m, 1H), 2.47-2.41 (m, 3H), 2.16 (m, 1H), 1.92 (m, 1H), 1.70 (m, 2H), 1.61 (m, 2H). -
- 10-1: Preparation of Compound 11 (MW=10000)
- A compound 11 (MW=10000) was obtained in the same manner as in Example 9-1.
- 10-2: Preparation of Compound 12 (MW=10000)
- A compound 12 (MW=10000) was obtained in the same manner as in Example 9-2.
- 10-3: Preparation of Compound 15 (MW=10000)
- 3 g of the compound 12 (MW=10000) and 30 mL of dichloromethane were introduced into a reactor. 262 mg of the compound 7 and 91 mg of triethylamine were added, followed by stirring at room temperature for 3 hours. After completing the reaction, the solvent was distilled under reduced pressure and 30 mL of water was introduced to dissolve the product. Ethyl acetate (30 mL×3) was introduced and stirred for 5 minutes, and then an aqueous layer was separated and extracted twice using 30 mL of dichloromethane. The obtained organic layer was dried over magnesium sulfate. Filtration was performed, followed by distillation under reduced pressure. 3 mL of dichloromethane was added to the concentrate, which was then dissolved, and 45 mL of methyl t-butyl ether was added dropwise for 20 minutes. Resulting crystals were filtered and washed with methyl t-butyl ether, and then dried under nitrogen to obtain 1.6 g of a compound (15) (MW=10000) which is a title compound.
- 10-4: Preparation of Compound 16 (MW=10000)
- 1.5 g of the compound 5 (MW=10000) and 27 mL of distilled water were introduced into a reactor. 3 mL of 0.1 N HCl was added thereto and stirred at room temperature for 2 hours. Then, completion of the reaction was confirmed by NMR. The reaction solution was neutralized with a 5% (w/v) sodium bicarbonate aqueous solution, and extraction was performed twice using 30 mL of dichloromethane. The resultant was dried over magnesium sulfate, and filtered and distilled under reduced pressure. 2 mL of dichloromethane was added to the concentrate, which was then dissolved, and 30 mL of methyl t-butyl ether was added dropwise for 20 minutes. Resulting crystals were filtered and washed with methyl t-butyl ether, and then dried under nitrogen to obtain 1.1 g of a compound (16) (MW=10000) which is a title compound. The compound 16 (MW=10000) was designated as PeAL-PEG 10K-BCN.
FIG. 7 shows 1H NMR result of the linker compound 16 (MW=10000). 1H NMR (CDCl3, 400 MHz) δ 9.75 (s, 1 H), 5.20 (br s, 1 H), 4.12 (d, 2H), 3.85-3.44 (m, 914H), 3.36 (m, 2H), 2.45 (t, 2H), 2.28-2.16 (m, 6H), 1.70 (m, 2H), 1.62-1.59 (m, 4H), 1.18 (m, 1H), 0.93 (m, 2H). - Mass spectrometry of the linker compounds prepared in Examples was performed using a MALDI-TOF mass spectrometer. Results were analyzed using a Polytool software.
-
FIG. 8 shows a result of mass spectrometry of the linker compound ALD-PEG 10K-DBCO. -
FIG. 9 shows a result of mass spectrometry of the linker compound ALD-PEG 5K-DBCO. -
FIG. 10 shows a result of mass spectrometry of the linker compound ALD-PEG 3.4K-DBCO. -
FIG. 11 shows a result of mass spectrometry of the linker compound ALD-PEG 2K-DBCO. -
FIG. 12 shows a result of mass spectrometry of the linker compound PeALD-PEG 10K-BCN. -
FIG. 13 shows a result of mass spectrometry of the linker compound PeALD-PEG 10K-DBCO. -
FIG. 14 shows a result of mass spectrometry of the linker compound ALD-PEG 10K-BCN. - A physiologically active polypeptide linkage was prepared by linking a physiologically active polypeptide to the ALD-PEG 10K-BCN linker of Example 5.
- In detail, the physiologically active polypeptide was a triple agonist having activities to all of glucagon, GLP-1, and GIP receptors, disclosed as SEQ ID NO: 42 in WO 2017/116205 A1. The C-terminal amino acid of the triple agonist was replaced with lysine, to which an azide group was introduced, thereby preparing an azide-introduced triple agonist, which was designated as HMT211-azido.
- The prepared HMT211-azido powder was dissolved in 10% (v/v) 10 mM HCl, and then HMT211-azido was prepared at a final concentration of 5 mg/ml such that a molar ratio of the HMT211-azido and the ALD-PEG 10K-BCN linker of Example 5 was 1:5, and allowed to react at 4° C. for about 2 hours. At this time, the reaction was allowed in a mixed solvent of 50 mM sodium citrate buffer (pH 7.5) and 60% (v/v) isopropanol.
- The reaction solution was purified using a SP-HP (GE Healthcare) column with a concentration gradient of KCl in a buffer containing sodium citrate (pH 3.0) and 45% (v/v) EtOH. As a result, mono-PEGylated HMT211-azido-PEG was obtained.
- Next, mono-PEGylated HMT211-azido-PEG purified in Example 11 and an immunoglobulin Fc were reacted at a molar ratio of 1:4 at a final concentration of 10 mg/ml at 25° C. for about 15 hours. At this time, to the reaction solution, 10 mM potassium phosphate (pH 6.0) and 20 mM sodium cyanoborohydride as a reducing agent were added.
- After completing the reaction, the reaction solution was applied to a S.15Q (GE, USA) column using a concentration gradient of NaCl in Tris-HCl (pH 7.5) buffer, thereby purifying a HMT211-azido-PEG-immunoglobulin Fc conjugate.
- Purity of the eluted HMT211-azido-PEG-immunoglobulin Fc conjugate was analyzed by SDS-PAGE.
-
FIG. 15 shows a result of SDS-PAGE purity analysis of the HMT211-azido-PEG-immunoglobulin Fc conjugate. M: Marker, 1: HMT211-azido peptide, 2: mono-PEGylated HMT211-azido-PEG, 3: immunoglobulin Fc, 4: HMT211-azido-PEG-immunoglobulin FC conjugate prepared by linking HMT211-azido with an immunoglobulin Fc via the ALD-PEG 10K-BCN linker. - As shown in
FIG. 15 , it was confirmed that when the linker compound according to Example 5 is used, the physiologically active polypeptide conjugate, of which both ends are linked with the physiologically active polypeptide and the immunoglobulin Fc, may be obtained in a high yield. - A physiologically active polypeptide linkage was prepared by linking a physiologically active polypeptide to the ALD-PEG 10K-DBCO linker of Example 1.
- In detail, the physiologically active polypeptide was GLP-2 derivative-azido, in which azido-lysine was introduced to the C-terminus of GLP-2. For example, GLP-2 derivative-azido in this Example was prepared by introducing azido-lysine to the C-terminus of natural GLP-2, substituting glycine for alanine which is the second amino acid, and removing alpha carbon of a histidine residue which is the first amino acid from the N-terminus.
- To PEGylate the ALD-PEG 10K-DBCO (10 kDa) of Example 1 to the GLP-2 derivative-azido, GLP-2 derivative-azido was prepared at a concentration of 5 mg/ml such that a molar ratio of GLP-2 derivative-azido powder:ALD-PEG 10K-DBCO was 1:5, and allowed to react at 4° C. for about 4 hours. At this time, the reaction was allowed in a mixed solvent of 50 mM sodium phosphate buffer (pH 7.5) and 60% (v/v) isopropanol.
- The reaction solution was purified by applying it to a Q Sepharose High Performance (GE Healthcare, USA) column using a concentration gradient of sodium chloride in Bis-Tris (pH 6.2). As a result, SDS-PAGE analysis confirmed that mono-PEGylated GLP-2 derivative-azido-PEG was purified (
FIG. 16 ). - Next, mono-PEGylated GLP-2 analog-azido-PEG purified in Example 13 and an immunoglobulin Fc were reacted at a molar ratio of 1:4 at a final concentration of 10 mg/ml at 2° C. to 8° C. for about 12 hours to 18 hours. At this time, to the reaction solution, 10 mM potassium phosphate and 20% (v/v) isopropanol (pH 6.0), 20 mM sodium cyanoborohydride as a reducing agent were added, and under this environment, the reaction was allowed.
- After completing the reaction, the reaction solution was applied to a
Butyl Sepharose 4 Fast Flow (GE Healthcare, USA) column using a concentration gradient of sodium chloride in Tris (pH 7.5) and isopropanol buffer, thereby purifying a GLP-2 analog-azido-PEG-immunoglobulin Fc conjugate. - Purity of the eluted GLP-2 analog-azido-PEG-immunoglobulin Fc conjugate was analyzed by SDS-PAGE.
-
FIG. 16 shows a result of non-reducing SDS-PAGE purity analysis of the GLP-2 analog-azido-PEG-immunoglobulin Fc conjugate. M: Marker, 1: GLP-2 analog, 2: mono-PEGylated GLP-2 analog, 3: immunoglobulin Fc, 4: GLP-2 analog-PEG-immunoglobulin Fc conjugate prepared by linking GLP-2 analog-azido with the immunoglobulin Fc via the ALD-PEG 10K-DBCO linker. - As shown in
FIG. 16 , it was confirmed that when the linker compound according to Example 1 is used, the physiologically active polypeptide conjugate, of which both ends are linked with the physiologically active polypeptide and the immunoglobulin Fc, may be obtained in a high yield. - A physiologically active polypeptide linkage was prepared by linking a physiologically active polypeptide to the PeAL-PEG 10K-BCN linker of Example 10.
- In detail, the physiologically active polypeptide was a glucagon analog, disclosed as SEQ ID NO: 37 in WO 2017/003191 A1. The C-terminal amino acid of the glucagon analog was replaced with lysine, to which an azide group was introduced, thereby preparing an azide-introduced glucagon analog, which was designated as glucagon analog-azido.
- To PEGylate the PeAL-PEG 10K-BCN (10 kDa) of Example 10 to the glucagon analog-azido, glucagon analog-azido was prepared at a concentration of 5 mg/ml such that a molar ratio of glucagon analog-azido:PeAL-PEG 10K-BCN was 1:5, and allowed to react at 4° C. for about 4 hours. At this time, the reaction was allowed in a mixed solvent of 50 mM sodium phosphate buffer (pH 7.5), 60% (v/v) isopropanol, and 20% (v/v) DMSO.
- The reaction solution was purified by applying it to a SP Sepharose High Performance (GE Healthcare, USA) column using a concentration gradient of potassium chloride in sodium citrate (pH 3.0) and 45% (v/v) ethanol. As a result, SDS-PAGE analysis confirmed that mono-PEGylated glucagon analog-azido-PEG was purified (
FIG. 17 ). - Next, mono-PEGylated glucagon analog-azido-PEG purified in Example 15 and an immunoglobulin Fc were reacted at a molar ratio of 1:4 at a final concentration of 10 mg/ml at 2° C. to 8° C. for about 12 hours to 18 hours. At this time, to the reaction solution, 100 mM potassium phosphate and 20% (v/v) isopropanol (pH 6.0), 20 mM sodium cyanoborohydride (NaCNBH3) as a reducing agent were added, and under this environment, the reaction was allowed.
- After completing the reaction, the reaction solution was applied to a Source 15Q (GE Healthcare, USA) column using a concentration gradient of sodium chloride in Tris (pH 7.5), thereby purifying a glucagon analog-azido-PEG-immunoglobulin Fc conjugate.
- Purity of the eluted glucagon analog-azido-PEG-immunoglobulin Fc conjugate was analyzed by SDS-PAGE.
-
FIG. 17 shows a result of non-reducing SDS-PAGE purity analysis of the glucagon analog-azido-PEG-immunoglobulin Fc conjugate. M: Marker, 1: glucagon analog, 2: mono-PEGylated glucagon analog, 3: immunoglobulin Fc, 4: glucagon analog-PEG-immunoglobulin Fc conjugate prepared by linking glucagon analog-azido with the immunoglobulin Fc via the PeAL-PEG 10K-BCN linker. - As shown in
FIG. 17 , it was confirmed that when the linker compound according to Example 10 is used, the physiologically active polypeptide conjugate, of which both ends are linked with the physiologically active polypeptide and the immunoglobulin Fc, may be obtained in a high yield. - The present disclosure has been shown and described with reference to exemplary embodiments. It will be understood by those skilled in the art that various modifications may be made without departing from the fundamental characteristics of the present disclosure. Therefore, it should be understood that embodiments described herein should be considered in a descriptive sense only and not for purposes of limitation. The scope of the present disclosure is defined by the appended claims rather than by the foregoing description, and all differences within the scope of equivalents thereof should be construed as being included in the present disclosure.
Claims (30)
R1-non-peptidyl polymer-X—R2 [Formula 1]
A-R1-non-peptidyl polymer-X—R2-B Formula 2a
B-R1-non-peptidyl polymer-X—R2-A Formula 2b
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20170016916 | 2017-02-07 | ||
KR10-2017-0016916 | 2017-02-07 | ||
PCT/KR2018/001660 WO2018147641A1 (en) | 2017-02-07 | 2018-02-07 | Non-peptidic polymeric linker compound, conjugate comprising same linker compound, and methods for preparing same linker compound and conjugate |
Publications (2)
Publication Number | Publication Date |
---|---|
US20230139745A1 true US20230139745A1 (en) | 2023-05-04 |
US11925691B2 US11925691B2 (en) | 2024-03-12 |
Family
ID=63107687
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/484,290 Active 2041-07-14 US11925691B2 (en) | 2017-02-07 | 2018-02-07 | Non-peptidic polymeric linker compound, conjugate comprising same linker compound, and methods for preparing same linker compound and conjugate |
Country Status (6)
Country | Link |
---|---|
US (1) | US11925691B2 (en) |
EP (1) | EP3581208A4 (en) |
JP (1) | JP7121024B2 (en) |
KR (2) | KR20180091773A (en) |
CN (1) | CN110545852B (en) |
WO (1) | WO2018147641A1 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11951165B2 (en) | 2016-12-30 | 2024-04-09 | Vaxcyte, Inc. | Conjugated vaccine carrier proteins |
CN109234281A (en) * | 2018-09-19 | 2019-01-18 | 北京环球科联高新科技发展有限公司 | The method for improving cellular anti-oxidant capacity using human lactoferrin gene rice is turned |
CN114945587A (en) | 2019-07-18 | 2022-08-26 | 韩美药品株式会社 | Novel process for preparing long-acting drug conjugates by preparing intermediates |
CN111534475B (en) * | 2019-11-28 | 2022-03-15 | 厦门诺康得生物科技有限公司 | Method for coupling antibody on cell surface and application thereof |
KR20210125880A (en) * | 2020-04-08 | 2021-10-19 | 주식회사 프로앱텍 | GLP-1 with albumin linked to a specific site |
CN115636876A (en) * | 2021-07-20 | 2023-01-24 | 重庆派金生物科技有限公司 | Directional chemical conjugate of glucagon-like peptide-2 mutant and application thereof |
WO2024026099A1 (en) * | 2022-07-29 | 2024-02-01 | The Trustees Of The University Of Pennsylvania | Lymphatic targeted anti-coagulant for the prevention of lymphatic thrombosis |
CN116655906B (en) * | 2023-04-13 | 2024-03-29 | 大连理工大学 | Sulfated glycopeptide, preparation method and antiviral application |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
DE69731289D1 (en) | 1996-03-18 | 2004-11-25 | Univ Texas | IMMUNGLOBULIN-LIKE DOMAIN WITH INCREASED HALF-VALUE TIMES |
KR101968344B1 (en) | 2012-07-25 | 2019-04-12 | 한미약품 주식회사 | A composition for treating hyperlipidemia comprising oxyntomodulin analog |
WO2014078734A2 (en) * | 2012-11-15 | 2014-05-22 | Apellis Pharmaceuticals, Inc. | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods |
CA2901873C (en) | 2013-02-26 | 2022-05-03 | Hanmi Pharm. Co., Ltd. | Novel insulin analog and use thereof |
AR096891A1 (en) | 2013-07-12 | 2016-02-03 | Hanmi Pharm Ind Co Ltd | CONJUGATE OF BIOMOLOGICALLY ACTIVE POLYPEPTIDE MONOMER AND CONJUGATE OF FRAGMENTO FC OF IMMUNOGLOBULINA, THAT SHOWS CLEARING THROUGH REDUCED RECEPTOR, AND THE METHOD FOR PREPARING THE SAME |
SI3701971T1 (en) | 2014-03-14 | 2023-01-31 | Biomolecular Holdings LLC, | Compounds useful in preparing hybrid immunoglobulin containing non-peptidyl linkage |
JP6863888B2 (en) | 2014-10-01 | 2021-04-21 | メディミューン,エルエルシー | How to conjugate a polypeptide |
NZ739250A (en) | 2015-06-30 | 2024-02-23 | Hanmi Pharmaceutical Co Ltd | Glucagon derivative and a composition comprising a long acting conjugate of the same |
JP6638970B2 (en) | 2015-06-30 | 2020-02-05 | 株式会社 東北テクノアーチ | Method for producing hetero-type monodisperse polyethylene glycol and intermediate for producing hetero-type monodisperse polyethylene glycol |
BR112018013530A2 (en) | 2015-12-31 | 2018-12-04 | Hanmi Pharm. Co., Ltd. | " isolated peptide, polynucleotide and pharmaceutical composition " |
US11613607B2 (en) * | 2016-10-07 | 2023-03-28 | Tokyo Institute Of Technology | Branched type hetero monodispersed polyethylene glycol, production method thereof, and conjugate thereof |
-
2018
- 2018-02-07 CN CN201880023818.1A patent/CN110545852B/en active Active
- 2018-02-07 WO PCT/KR2018/001660 patent/WO2018147641A1/en unknown
- 2018-02-07 KR KR1020180015184A patent/KR20180091773A/en not_active IP Right Cessation
- 2018-02-07 JP JP2019542628A patent/JP7121024B2/en active Active
- 2018-02-07 US US16/484,290 patent/US11925691B2/en active Active
- 2018-02-07 EP EP18750900.5A patent/EP3581208A4/en active Pending
-
2020
- 2020-11-19 KR KR1020200155786A patent/KR102271863B1/en active IP Right Grant
Non-Patent Citations (3)
Title |
---|
BROADPHARM, "endo-BCN-PEG4-NHS-ester", BP-22851, dated October 10, 2016, Retrieved from the Internet: URL: https://broadpharm.com/web/product.php?catalog=BP-22851 (Year: 2016) * |
Colombo et al., Angew. Chem. Int. Ed. 2012, 51, 496-499 (Year: 2012) * |
DATABASE CAPLUS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; Registry No. 1817769-38-2, 03 Nov 2015 (Year: 2015) * |
Also Published As
Publication number | Publication date |
---|---|
KR20200135905A (en) | 2020-12-04 |
CN110545852A (en) | 2019-12-06 |
WO2018147641A1 (en) | 2018-08-16 |
JP7121024B2 (en) | 2022-08-17 |
KR102271863B1 (en) | 2021-07-01 |
US11925691B2 (en) | 2024-03-12 |
EP3581208A4 (en) | 2020-12-30 |
KR20180091773A (en) | 2018-08-16 |
CN110545852B (en) | 2023-05-26 |
JP2020508366A (en) | 2020-03-19 |
EP3581208A1 (en) | 2019-12-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11925691B2 (en) | Non-peptidic polymeric linker compound, conjugate comprising same linker compound, and methods for preparing same linker compound and conjugate | |
KR102182701B1 (en) | Conjugate of biologically active polypeptide monomer and immunoglobulin Fc fragment with reduced receptor-mediated clearance, and the method for preparing the same | |
TWI784914B (en) | Composition for treating diabetes comprising long-acting insulin analogue conjugate and long-acting insulinotropic peptide conjugate | |
JP6320293B2 (en) | Composition for treatment of diabetes comprising sustained insulin conjugate and sustained insulin secretory peptide conjugate | |
CA2674538C (en) | An insulinotropic complex using an immunoglobulin fragment | |
CA2795291C (en) | An insulin conjugate using an immunoglobulin fragment | |
RU2752671C2 (en) | Linker links and molecular structures containing them | |
RU2639256C2 (en) | Improved method for physiologically active polypeptide conjugate production | |
EP3428147A1 (en) | Polyethylene glycol derivative and use thereof | |
US10660940B2 (en) | Preparation method for high-yield production of physiologically active polypeptide conjugate | |
US11926678B2 (en) | Composite polypeptide having a metal binding motif and molecular construct comprising the same | |
CN114599402A (en) | anti-CD 37 antibody-maytansine conjugates and methods of use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: HANMI PHARM. CO., LTD., KOREA, REPUBLIC OF Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PARK, SU YEON;KIM, DAE JIN;JUNG, YONG GYU;REEL/FRAME:049993/0303 Effective date: 20190806 |
|
FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |